MX2008006776A - Heteroaryl substituted piperidine derivatives as l-cpt1 inhibitors - Google Patents

Abstract

The invention is concerned with novel substituted piperidine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, R7and X are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L- CPT1 and can be used as medicaments.

Description

DERIVATIVES OF PIPERIDINE SUBSTITUTED BY HETEROARYL SUBSTITUTED AS INHIBITORS OF L-PALMITOYLTRANSFERASE DEPENDENT OF CARNITINE 1 Description of the invention The present invention relates to novel substituted piperidine derivatives of the formula (I) wherein X is C (R8R9), NR10, O, S, S (O), S (02); R1 is phenyl optionally substituted by 1 to 3 substituents selected from the group consisting of halogen, hydroxy, lower alkyl, hydroxyalkyl, fluoralkyl, lower alkoxy and CN; R is hydrogen or lower alkyl; R3 and R4 independently of each other are hydrogen, halogen, lower alkyl or lower alkoxy, or R3 and R4 together are = 0 to form a carbonyl group together with the carbon atom to which they are attached; R5 and R6 independently of each other are hydrogen, halogen, lower alkyl or lower alkoxy, or R5 and R6 together Ref: 193225 are = 0 to form a carbonyl group together with the carbon atom to which they are attached; R7 is an oxadiazolyl or triazolyl, the oxadiazolyl or triazolyl are substituted by R11 and optionally substituted by R12; R8 and R9 independently of each other are hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy; or R8 and R9 are linked together and -R8-R9- is - (CH2) 2.7-to form a ring together with the carbon atom to which they are attached; R10 is hydrogen, lower alkyl, (lower alkyl) -carbonyl or lower alkylsulfonyl; R11 is aryl or heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl, pyridinyl-2-one, oxadiazolyl, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one , benzotriazolyl, imidazopyridinyl, triazolopyridinyl, tetrazolpyridinyl, benzimidazolyl, 2-oxo-2,3-dihydro-lH-indol-5-yl, pyrimidin-4-one, furanyl, thiadiazolyl, pyrazolyl, isoxazolyl, pyrimidine-2,4-dione , benzooxazin-3-one, 1,4-dihydro-benzooxazin-2-one, indolyl, thiophenyl, oxazolyl, benzooxazin-2-one, 3,4-dihydro-quinazolin-2-one, pyridazinyl, quinoxalinyl, benzothiazolyl, benzothiadiazolyl , naphthyridinyl, cinolinyl, 1,4-dihydro-quinoxaline-2,3-dione and 1,2-dihydro-indazol-3-one, aryl or heteroaryl is optionally substituted by 1 to 3 substituents selected from the group consisting of lower alkyl, hydroxy, B (OH) 2, carboxy-lower alkoxy, carbamoyl-lower alkoxy, cyano, lower hydroxyalkyl, lower fluoroalkyl, lower alkoxy, halogen, S (02) R13, C (0) R14, N02, NR15R16, imidazolyl, pyrazolyl, tetrazolyl, pyrrolyl, phenyl-lower alkoxy, [1, 3, 4] oxadiazol-2-one, oxadiazolyl, triazolyl and isoxazolyl, imidazolyl is optionally substituted by lower alkyl and the phenyl-lower alkoxy is optionally substituted by hydroxy, halogen, lower alkyl, lower alkoxy or fluoroalkyl lower and the pyrazolyl is optionally substituted by lower alkyl and the isoxazolyl is optionally substituted by lower alkyl; R 12 is hydrogen or lower alkyl; R 13 is lower alkyl, NR 17 R 18 or lower fluoroalkyl; R14 is OH, NR19R20, lower alkoxy, lower alkenyloxy or lower alkyl; R15 and Rld independently of each other are hydrogen, lower alkyl, (lower alkyl) -carbonyl, lower alkyl-S02, (lower alkenyloxy) -carbonyl, NH2-carbonyl, (lower alkyl) -NH-carbonyl, (lower alkyl) 2N -carbonyl or phenyl-lower alkyl, phenyl-lower alkyl is optionally substituted by hydroxy, halogen, alkyl lower, lower alkoxy or lower fluoroalkyl; or NR15R16 is a heterocyclyl selected from the group consisting of morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, 8-oxa-3-aza-bicyclo [3.2.1] ] octyl, piperazinyl, pyrrolidinyl, 1,1-dioxo-isothiazolidinyl, pyrrolidin-2-one, imidazolidine-2, -dione, 2,4-dihydro [l, 2,4] triazol-3-one, pyrrolidine-2, 5-dione, azetidin-2-one and 1,3-dihydro-imidazol-2-one, the heterocyclyl is optionally substituted by lower hydroxyalkyl or (lower alkyl) -carbonyl; R17 and R18 independently of each other are hydrogen, lower alkyl, lower hydroxyalkyl, lower alkoxy-lower alkyl; or NR17R18 is morpholinyl; R19 and R20 independently of each other are hydrogen, lower alkyl, cycloalkyl, lower hydroxyalkyl, lower alkoxy-lower alkyl, (lower alkyl) 2N-lower alkyl, pyridinyl-lower alkyl or cyano-lower alkyl; or NR19R20 is a heterocyclyl selected from the group consisting of morpholinyl, pyrrolidinyl, 8-oxa-3-aza-bicyclo [3.2.1] octyl, piperidinyl, piperazinyl, piperazin-2-one, thiazolidinyl, thiomorpholinyl, 1, 3, 8 -triaza-spiro [4, 5] decane-2,4-dione and spiro (1-phthalane) -piperidin-4-yl, the heterocyclyl is optionally substituted by hydroxy, (lower alkyl) -S (02), lower alkyl, (lower alkyl) -carbonyl, carboxy, carbamoyl, lower alkoxycarbonyl, cyano, phenyl, pyridinyl or lower alkoxy; and the pharmaceutically acceptable salts and esters thereof. The invention also relates to a process for obtaining the above compounds, to pharmaceutical preparations containing these compounds as was to the use of these compounds for the manufacture of pharmaceutical preparations. Elevated levels of free fatty acids (FFA) lead to mitochondrial ß-oxidation in the liver, which is crucial for efficient gluconeogenesis. Mitochondrial oxidation of long-chain FFA requires the intervention of two palmitoyltransferases dependent on carnitine (CPT) membrane-bound. CPT1, the enzyme of the outer mitochondrial membrane, catalyzes the formation of long chain acylcarnitines. The isoforms of the CPT1 of the liver (L-CPT1) and the muscle (M-CPT1) are encoded by two different genes and are inhibited by malonyl-CoA. The N-ter domain of L-CPTl confers its low sensitivity to malonyl-CoA. CPT2, the enzyme of the inner mitochondrial membrane, converts long-chain acylcarnitines into long-chain acyl-CoA-esters. Then, the long chain acyl-CoA is ß-oxidized to acetyl-CoA, which activates the pyruvate-carboxylase and gluconeogenesis. According to the mechanism of action just described, pharmaceutically active substances that inhibit L-CPTl reduce ß-oxidation in the liver, therefore, they inhibit gluconeogenesis and, in this way, counteract hypergiukaemia. The present invention relates to new compounds that inhibit the activity of carnitine palmitoyl transferase of liver 1 (L-CPTl). The compounds of the present invention can be used as pharmaceutically active agents, which are useful for the prevention and / or treatment of diseases modulated by inhibitors of L-CPTl, in particular diseases related to hypergiukaemia and / or glucose tolerance disorders. Such diseases include, for example, diabetes and associated pathologies, diabetes mtus not dependent on insulin (also called type II diabetes), obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, liver disease. fatty tissue, atherosclerosis, congestive heart failure and renal failure. Unless otherwise indicated, the following definitions are established to illustrate and define the meaning and scope of the various terms used to describe the present invention.

In this description, the term "lower" is used to indicate a group containing one to seven carbon atoms, preferably one to four. The term "halogen" refers to fluorine, chlorine, bromine or iodine, with fluorine, chlorine and bromine being preferred. The term "alkyl", alone or in combination with other groups, refers to a straight or branched chain saturated aliphatic hydrocarbon group, of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably from one to ten carbon atoms. The lower alkyl groups described below are also preferred alkyl groups. The term "lower alkyl", alone or in combination with other groups, refers to a monovalent, straight or branched chain alkyl group of one to seven carbon atoms, preferably one to four carbon atoms. This term is also illustrated with a group of the methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl type and the like. The term "hydroxy-lower alkyl" refers to a lower alkyl group that is substituted with hydroxy. The term "fluoro-lower alkyl" refers to lower alkyl groups that are mono- or multi-substituted by fluorine. Examples of fluoro-lower alkyl groups are CFH2, CF2H, CF3, CF3CH2, CF3 (CH2) 2, (CF3) 2CH and CF2H-CF2. The term "alkoxy" refers to the group R'-O-, wherein R 'is an alkyl. The term "lower alkoxy" refers to the group R'-O-, wherein R 'is a lower alkyl. The term "fluoro-lower alkoxy" refers to the group R "-0-, wherein R" is fluoro-lower alkyl. Examples of fluoro-lower alkoxy are CFH2-0, CF2H-0, CF3-0, CF3CH2-0, CF3 (CH2) 2-0, (CF3) 2CH-0 and CF2H-CF2-0. The term "alkenyl", alone or in combination with other groups, means a straight or branched chain hydrocarbon group containing an olefinic bond and up to 20 carbon atoms, preferably up to 16. The term "lower alkenyl" means a hydrocarbon group straight or branched chain containing an olefinic bond and up to 7 carbon atoms, preferably up to 4, eg 2-propenyl. The term "alkynyl", alone or in combination with other groups, means a straight or branched chain hydrocarbon group containing a triple bond and up to 20 carbon atoms, preferably up to 16. The term "lower alkenyl" means a hydrocarbon group straight or branched chain containing a triple bond and up to 7 carbon atoms, preferably up to 4, eg 2-propynyl. The term "alkylene" means a divalent, straight-chain or branched saturated aliphatic hydrocarbon group having 1 to 20 carbon atoms, preferably 1 to 16 carbon atoms, more preferably up to 10 carbon atoms. The lower alkylene groups just described are also preferred alkylene groups. The term "lower alkylene" denotes a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 7 carbon atoms, preferably 1 to 6 or 3 to 6 carbon atoms. Preferred are straight chain alkylene groups and lower alkylene groups. The term "cycloalkyl" means a monovalent carbocyclic group of 3 to 10 carbon atoms, preferably 3 to 6 carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. The term "aryl", alone or in combination, denotes a phenyl or naphthyl group, preferably the phenyl group, which may be optionally substituted by from 1 to 5 substituents, preferably from 1 to 3, independently chosen from each other. group consisting of halogen, hydroxy, amino, N02, lower alkyl, lower hydroxyalkyl, lower alkoxy, carboxy, carboxy-lower alkyl, lower alkoxycarbonyl, lower alkoxy-carbonyl-lower alkyl, (lower alkyl) carbonyl, (lower alkyl) carbonyloxy, (lower alkyl) carbonyl-NH, H2NC (0), (H, lower alkyl) NC (0), (lower alkyl) 2NC (O), H2NC (0) -lower alkyl, (H, lower alkyl) NC (O) -lower alkyl, (lower alkyl) 2NC (O) -lower alkyl, lower fluoralkyl, fluoro-lower alkoxy, H2N-lower alkyl, (H, lower alkyl) -lower alkyl, (alkyl) lower) 2N-lower alkyl, lower alkyl-S02, lower alkyl-S020, lower alkyl-S02-NH, lower alkyl-S02-N (lower alkyl), H2NS02, (H, lower alkyl) NS02, (lower alkyl) 2NS02 , dioxo-lower alkylene (forming, for example, a benzodioxyl group), cyano, heteroaryl, cycloalkyl, lower alkoxy-lower alkyl, lower alkenyl, lower alkynyl, phenyl and phenyloxy. Among the above-mentioned substituents, halogen, lower alkyl, fluoro-lower alkyl, lower alkoxy and fluoro-lower alkoxy are preferred. In addition and more preferably, the aryl groups may be substituted in the manner indicated below in the description. The term "heteroaryl" denotes a 5- or 6-membered monocyclic aromatic ring, which may contain 1, 2 or 3 atoms selected from nitrogen, oxygen and / or sulfur, for example furyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1, 2, 3-thiadiazolyl, benzimidazolyl, indolyl, indazolyl, benzisothiazolyl, benzoxazolyl, benzoisoxazolyl, pyridinyl-2-one, oxadiazolyl, 1, 3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one, benzotriazolyl, imidazopyridinyl, triazolopyridinyl and tetrazolpyridinyl. Other possible heteroaryls are 2-oxo-2,3-dihydro-lH-indol-5-yl, pyrimidin-4-one, furanyl, thiadiazolyl, pyrazolyl, isoxazolyl, pyrimidine-2,4-dione, benzooxazin-3-one, 1,4-dihydro-benzooxazin-2-one, indolyl, thiophenyl, oxazolyl, benzooxazin-2-one, 3,4-dihydro-quinazolin- 2-one, pyridazinyl, quinoxalinyl, benzothiazolyl, benzothiadiazolyl, naphthyridinyl, cinolinyl, 1,4-dihydro-quinoxaline-2,3-dione and 1,2-dihydro-indazol-3-one. A heteroaryl group can have a substitution pattern similar to that described above on the occasion of the term "aryl". In addition, the heteroaryl groups may be preferably substituted in the manner indicated below in the description. The term "heterocyclyl" means a monocyclic ring of 5 or 6 links or a bi- or tricyclic ring of 8 to 14 links, preferably from 8 to 10, which may contain 1, 2 or 3 atoms selected from nitrogen, oxygen and / or or sulfur, for example morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, 8-oxa-3-aza-bicyclo [3.2.1] octyl, piperazinyl and pyrrolidinyl. Other possible heterocyclyls are 1,1-dioxo-isothiazolidinyl, pyrrolidin-2-one, imidazolidine-2,4-dione, 2,4-dihydro [l, 2,4] triazol-3-one, pyrrolidine-2, 5 -dione, azetidin-2-one, 1,3-dihydro-imidazol-2-one, thiazolidinyl, 1, 3, 8-triaza-spiro [4, 5] decane-2,4-dione and spiro (1-phthalane) ) -piperidin-4-yl. A heterocyclyl group can optionally have the model of substitution described earlier on the occasion of the term "aryl". In addition, the heterocyclyl groups may be preferably substituted in the manner indicated below in the description. The compounds of the formula (I) which carry an amino group can form pharmaceutically acceptable acid addition salts. Examples of the pharmaceutically acceptable salts are the salts of compounds of the formula (I) with physiologically compatible inorganic acids, such as hydrochloric acid, sulfuric acid, sulfurous acid or phosphoric acid; or with organic acids, such as methanesulfonic acid, p-toluenesulfonic acid, acetic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid. The term "pharmaceutically acceptable salts" denotes this type of salts. The compounds of the formula (I) which carry a COOH group can also form salts with bases. Examples of the salts are the alkali metal, alkaline earth metal and ammonium salts, for example the Na, K, Ca and trimethylammonium salt. The term "pharmaceutically acceptable salts" also indicates this type of salt. The salts obtained by the addition of an acid are preferred. The term "pharmaceutically acceptable esters" encompasses the derivatives of the compounds of the formula (I), in the that a carboxy group has been converted into an ester group. Examples of suitable esters are the esters of lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, amino-lower alkyl, mono- or di-lower alkyl-amino-lower alkyl, morpholino-lower alkyl, pyrrolidino-lower alkyl, piperidino-lower alkyl, piperazino-lower alkyl, lower alkyl-piperazino-lower alkyl and aralkyl. Preferred esters are methyl, ethyl, propyl, butyl and benzyl esters. The term "pharmaceutically acceptable esters" further encompasses the compounds of the formula (I), in which the hydroxy groups have been converted into the corresponding ester groups by reaction with inorganic or organic acids, such as nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulfonic acid, p-toluenesulfonic acid and the like, which are not toxic to living organisms. The present invention relates in particular to the compounds of the formula (I) wherein X is C (R8R9), NR10, O, S, S (O), S (02); R1 is phenyl optionally substituted by 1 to 3 substituents selected from the group consisting of halogen, hydroxy, lower alkyl, hydroxyalkyl lower, fluoralkyl lower, lower alkoxy and CN; R2 is hydrogen or lower alkyl; R3 and R4 independently of each other are hydrogen, halogen, lower alkyl or lower alkoxy, or R3 and R4 together are = 0 to form a carbonyl group together with the carbon atom to which they are attached; R5 and R6 independently of each other are hydrogen, halogen, lower alkyl or lower alkoxy, or R5 and R6 together are = 0 to form a carbonyl group together with the carbon atom to which they are attached; R7 is an oxadiazolyl or triazolyl, oxadiazolyl or triazolyl is substituted by R11 and optionally substituted by R12; R8 and R9 independently of each other are hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy; or R8 and R9 are linked together and -R8-R9- is - (CH2) 2_- to form a ring together with the carbon atom to which they are attached; R10 is hydrogen, lower alkyl, (lower alkyl) -carbonyl or lower alkylsulfonyl; R11 is aryl or heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl, pyridinyl-2-one, oxadiazolyl, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one , benzotriazolyl, imidazopyridinyl, triazolopyridinyl, tetrazolipyridinyl, benzimidazolyl, 2-oxo-2,3-dihydro-lH-indol-5-yl, pyrimidin-4-one, furanyl, thiadiazolyl, pyrazolyl, isoxazolyl, pyrimidine-2,4-dione , benzooxazin-3-one, 1,4-dihydro-benzooxazin-2-one, indolyl, thiophenyl, oxazolyl, benzooxazin-2-one, 3,4-dihydro-quinazolin-2-one, pyridazinyl, quinoxalinyl, benzothiazolyl, benzothiadiazolyl , naphthyridinyl, cinolinyl, 1,4-dihydro-quinoxaline-2,3-dione and 1,2-dihydro-indazol-3-one, the aryl or heteroaryl is optionally substituted by 1 to 3 substituents selected from the group consisting of lower alkyl, hydroxy, B (OH) 2, carboxy-lower alkoxy, carbamoyl-lower alkoxy, cyano, lower hydroxyalkyl, lower fluoroalkyl, lower alkoxy, halogen, S (02 ) R13, C (0) R14, N02, NR15R16, imidazolyl, pyrazolyl, tetrazolyl, pyrrolyl, phenyl-lower alkoxy, [1, 3, 4] oxadiazol-2-one, oxadiazolyl, triazolyl and isoxazolyl, the imidazolyl is optionally substituted with lower alkyl and phenyl-lower alkoxy is optionally substituted with hydroxy, halogen, lower alkyl, lower alkoxy or fluoroalkyl lower and the pyrazolyl is optionally substituted with - lower alkyl and the isoxazolyl is optionally substituted with lower alkyl; R 12 is hydrogen or lower alkyl; R 13 is lower alkyl, NR 17 R 18 or lower fluoroalkyl; R14 is OH, NR19R20, lower alkoxy, lower alkenyloxy or lower alkyl; R15 and R16 independently of each other are hydrogen, lower alkyl, (lower alkyl) -carbonyl, lower alkyl-S02, (lower alkenyloxy) -carbonyl, NH-carbonyl, (lower alkyl) -NH-carbonyl, (lower alkyl) 2N -carbonyl or phenyl-lower alkyl, the phenyl-lower alkyl is optionally substituted with hydroxy, halogen, lower alkyl, lower alkoxy or fluoralkyl lower; or NR15R16 is a heterocyclyl selected from the group consisting of morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, 8-oxa-3-aza-bicyclo [3.2.1] ] octyl, piperazinyl, pyrrolidinyl, 1,1-dioxo-isothiazolidinyl, pyrrolidin-2-one, imidazolidine-2,4-dione, 2,4-dihydro [1, 2, 4] triazol-3-one, pyrrolidine-2 , 5-dione, azetidin-2-one and 1,3-dihydro-imidazol-2-one, the heterocyclyl is optionally substituted with lower hydroxyalkyl or (lower alkyl) -carbonyl; R17 and R18 independently of each other are hydrogen, lower alkyl, lower hydroxyalkyl, lower alkoxy- - lower alkyl; or NR17R18 is morpholinyl; R19 and R20 independently of each other are hydrogen, lower alkyl, cycloalkyl, lower hydroxyalkyl, lower alkoxy-lower alkyl, (lower alkyl) N-lower alkyl, pyridinyl-lower alkyl or cyano-lower alkyl; or NR19R20 is a heterocyclyl selected from the group consisting of morpholinyl, pyrrolidinyl, 8-oxa-3-aza-bicyclo [3.2.1] octyl, piperidinyl, piperazinyl, piperazin-2-one, thiazolidinyl, thiomorpholinyl, 1, 3, 8 -triaza-spiro [4, 5] decane-2,4-dione and spiro (1-phthalane) -piperidin-4-yl, the heterocyclyl is optionally substituted with hydroxy, (lower alkyl) -S (02), lower alkyl , (lower alkyl) -carbonyl, carboxy, carbamoyl, lower alkoxycarbonyl, cyano, phenyl, pyridinyl or lower alkoxy; and the pharmaceutically acceptable salts and esters thereof. The compounds of the formula (I) are preferred on an individual basis and the physiologically acceptable salts thereof are preferred on an individual basis and the pharmaceutically acceptable esters thereof are preferred on an individual basis, with the compounds of the formula (I) being especially preferred. ). The compounds of the formula (I) may have one or more - - asymmetric C atoms and, therefore, may exist in the form of a mixture of enantiomers, a mixture of stereoisomers or in the form of optically pure compounds. Preferred compounds of the formula (I) described above are those in which X is C (R8R9), NR10, 0, S, S (0), S (02); R1 is phenyl optionally substituted with from 1 to 3 substituents selected from the group consisting of halogen, hydroxy, lower alkyl, hydroxyalkyl, lower fluoroalkyl, lower alkoxy and CN; R2 is hydrogen or lower alkyl; R3 and R4 independently of each other are hydrogen, halogen, lower alkyl or lower alkoxy, or R3 and R4 together are = 0 to form a carbonyl group together with the carbon atom to which they are attached; R5 and R6 independently of each other are hydrogen, halogen, lower alkyl or lower alkoxy, or R5 and R6 together are = 0 to form a carbonyl group together with the carbon atom to which they are attached; R7 is an oxadiazolyl or triazolyl, the oxadiazolyl or triazolyl is substituted with R11 and optionally substituted with R12; R8 and R9 independently of each other are hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy; or R8 and R9 are joined together and -R8-R9- is - (CH2) 2_7- - to form a ring together with the carbon atom to which they are attached; R10 is hydrogen, lower alkyl, (lower alkyl) -carbonyl or lower alkylsulfonyl; R11 is aryl or heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl, pyridinyl-2-one, oxadiazolyl, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one , benzotriazolyl, imidazopyridinyl, triazolopyridinyl, tetrazolpyridinyl and benzimidazolyl, the aryl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of lower alkyl, lower hydroxyalkyl, lower fluoroalkyl, lower alkoxy, halogen, S (02) R13, C (0) R14, N02, NR15R16, imidazolyl, pyrazolyl, tetrazolyl, pyrrolyl and phenyl-lower alkoxy, the imidazolyl is optionally substituted with lower alkyl and the phenyl-lower alkoxy is optionally substituted with hydroxy, halogen, lower alkyl, lower alkoxy or lower fluoroalkyl; R 12 is hydrogen or lower alkyl; R 13 is lower alkyl, NR 1 R 18 or lower fluoroalkyl; R 14 is OH, NR 19 R 20, lower alkoxy or lower alkenyloxy; R15 and R16 independently of each other are hydrogen, - lower alkyl, (lower alkyl) -carbonyl, lower alkyl-S02, (lower alkenyloxy) -carbonyl, NH2-carbonyl, (lower alkyl) -NH-carbonyl, (lower alkyl) 2N-carbonyl or phenyl-lower alkyl, phenyl-lower alkyl is optionally substituted with hydroxy, halogen, lower alkyl, lower alkoxy or fluoralkyl lower; or NR15R16 is a heterocyclyl selected from the group consisting of morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, 8-oxa-3-aza-bicyclo [3.2.1] ] octyl, piperazinyl and pyrrolidinyl, the heterocyclyl is optionally substituted with lower hydroxyalkyl or (lower alkyl) -carbonyl; R17 and R18 independently of each other are hydrogen, lower alkyl, lower hydroxyalkyl, lower alkoxy-lower alkyl; or NR17R18 is morpholinyl; R19 and R20 independently of each other are hydrogen, lower alkyl, cycloalkyl, hydroxy-lower alkyl or lower alkoxy-lower alkyl; or NR19R20 is a heterocyclyl selected from the group consisting of morpholinyl, pyrrolidinyl and 8-oxa-3-aza-bicyclo [3.2.1] octyl, the heterocyclyl is optionally substituted by hydroxy or (lower alkyl) -S (02); and the pharmaceutically acceptable salts and esters thereof. They are preferred compounds of the formula (I), already described above, those in which R 1 is phenyl optionally substituted with halogen, hydroxy, hydroxyalkyl or CN, more preferably those, wherein R 1 is phenyl. Other preferred compounds are those, wherein R2 is hydrogen. Also preferred are those compounds, wherein R3 is hydrogen. Other preferred compounds are those, wherein R 4 is hydrogen. Other preferred compounds are those, wherein R5 is hydrogen. Also preferred are compounds, wherein R6 is hydrogen. Preferably, when R7 is an oxadiazolyl it will not be substituted with R12. In a preferred embodiment of the present invention, R7 is wherein R11 and R12 have the meanings defined above. Preferably, R7 is - in which R > ? and R > 12"have the meanings defined in claim 1. It is preferred in addition that R7 is wherein R11 has the meaning defined above. Preferred compounds of formula (I) described above are those, wherein X is C (R8R9), NR10, O or S, wherein R8, R9 and R10 have the meanings defined above. Preferably, X is C (R8R9) or NR10, wherein R8, R9 and R10 have the meanings defined above. In the compounds defined above it is preferred that R8 is hydrogen. Preferably, R9 is hydrogen. It is further preferred that R10 is hydrogen. Another preferred embodiment of the present invention relates to the compounds already defined above, wherein R 11 is phenyl or a heteroaryl group selected from the group consisting of pyridyl, pyrazyl, p? Pd? N? L-2-one, mdazolyl, 1,3-d? -hydrobenz? Dazol-2-one, 1,3-d? -hydro-mdol-2-one, benzothipazolyl and benzimidazolyl, the phenyl or heteroaryl is optionally substituted with 1 or 2 substituents chosen from the group consisting of lower alkyl, lower hydroxyalkyl, lower fluoroalkyl, lower alkoxy, halogen, S (02) R13, C (0) R14, N02, NR15R16, imidazolyl, pyrazolyl, tetrazolyl, pyrrolyl and phenyl-lower alkoxy, the imidazolyl is optionally substituted with lower alkyl, in that R13, R14, R15 and R16 have the meanings defined above. Preferably, R 11 is phenyl or a heteroaryl selected from the group consisting of pyridinyl, pyridinyl-2-one, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one, benzotriazolyl and benzimidazolyl, the phenyl or heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of lower fluoroalkyl, halogen, C (0) R14 and NR15R16, wherein R14, R15 and R16 have the meanings defined above. More preferably, R11 is lH-indazol-5-yl, 1H-indazol-6-yl, 1,3-dihydro-indol-2-on-6-yl, 1,3-dihydro-benzoimidazol-2-onyl. 5-yl, 1,3-dihydro-indol-2-on-5-yl, 1H-benzotriazol-5-yl, lH-benzoimidazol-5-yl, lH-pyridin-2-on-4-yl, 4- fluor-phenyl, 3-trifluoromethyl-phenyl, 1H-benzoimidazol-5-yl, 3-benzamide, 5-nicotinamide, 3- (N-acetamide) -phenyl or 3- (N-methanesulfonamide) -phenyl. Another preferred embodiment of the present invention relates to the compounds defined above, wherein R 11 is phenyl or a heteroaryl selected from the group consisting of 2-oxo-2,3-dihydro-lH-indol-5-yl, pyrimidin- 4-one, furanyl, thiadiazolyl, pyrazolyl, isoxazolyl, pyrimidine-2,4-dione, benzooxazin-3-one, 1,4-dihydro-benzooxazin-2-one, indolyl, thiophenyl, oxazolyl, benzooxazin-2-one, 3,4- dihydro-quinazolin-2-one, pyridazinyl, quinoxalinyl, benzothiazolyl, benzothiadiazolyl, naphthyridinyl, cinolinyl, 1,4-dihydro-quinoxaline-2,3-dione and 1,2-dihydro-indazol-3-one, phenyl or heteroaryl is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, B (OH) 2, carboxy-lower alkoxy, carbamoyl-lower alkoxy, cyano, [1, 3, 4] oxadiazol-2-one, oxadiazolyl, triazolyl and isoxazolyl, the pyrazolyl is optionally substituted with lower alkyl and the isoxazolyl is optionally substituted with lower alkyl. Preferably, R11 is phenyl or a heteroaryl selected from the group consisting of pyridinyl, 1,3-dihydro-indol-2-one, lH-benzimidazolyl, 3H-pyrimidin-4-one, lH-pyrazolyl, isoxazolyl and 4H-benzo [1,4] oxazin-3-one, the phenyl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of lower alkyl, hydroxy, halogen and NR15R16, wherein R14 and R15 have the meanings defined in claim 1. More preferably, R11 is 2-methyl-3H-pyrimidin-4-one, 5-methyl-isoxazol-3-yl, lH-pyrazol-3-yl, 6-amino-pyridin-3-yl, 1,3-dihydro-indol-2-one, 2-amino-pyridin-4-yl, 4H-benzo [1,] oxazin-3-one, lH-benzimidazol-5-yl, 3- (N-) - - acetamide) -4-fluoro-phenyl or 2-hydroxy-pyridin-4-yl. Preferably, R12 is hydrogen. Also preferred are the compounds defined above, wherein R 13 is lower alkyl. Other preferred compounds are those, wherein R14 is NR19R20, wherein R19 and R20 have the meanings defined above. Other preferred compounds are those, wherein R 14 is lower alkyl. Another preferred embodiment of the present invention relates to compounds already defined above, wherein R15 and R16 independently of each other are hydrogen, lower alkyl, (lower alkyl) -carbonyl, lower alkyl-S02, (lower alkenyloxy) -carbonyl or (lower alkyl) -NH-carbonyl; or NR15R16 is a heterocyclyl selected from the group consisting of morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, piperazinyl and pyrrolidinyl, the heterocyclyl is optionally substituted with lower hydroxyalkyl or (lower alkyl) -carbonyl. More preferably, R15 and R16 independently of each other are hydrogen, (lower alkyl) -carbonyl or lower alkyl-S02. Other preferred compounds are those, wherein NR15R16 is a heterocyclyl selected from the group consisting of 1,1-dioxo-isothiazolidinyl, pyrrolidin-2-one, imidazolidine-2,4-dione, 2,4-dihydro [1, 2 , 4] triazol-3-one, pyrrolidine-2, 5-dione, azetidin-2-one and 1,3-dihydro-imidazol-2-one, heterocyclyl is optionally substituted with lower hydroxyalkyl or (lower alkyl) -carbonyl. Other preferred compounds are those, wherein R17 and R18 independently of each other are hydrogen or lower alkyl; or NR17R18 is morpholinyl. Also preferred are the compounds defined above, wherein R19 and R20 independently of each other are hydrogen, lower alkyl, cycloalkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl; or NR19R20 is a heterocyclyl selected from the group consisting of morpholinyl or pyrrolidinyl, the heterocyclyl is optionally substituted with hydroxy or (lower alkyl) -S (02). More preferably, R19 and R20 are hydrogen. Other preferred compounds are those, in which R19 and R20 independently of each other are (lower alkyl) 2N-lower alkyl, pyridinyl-lower alkyl or cyano-lower alkyl; or NR19R20 is a heterocyclyl selected from the group consisting of piperidinyl, piperazinyl, piperazin-2-one, thiazolidinyl, thiomorpholinyl, 1, 3, 8-triaza-spiro [4, 5] decane-2, -dione and spiro (1- phthalane) -piperidin-4-yl, the heterocyclyl is optionally substituted with hydroxy, (lower alkyl) -S (02), lower alkyl, (lower alkyl) -carbonyl, carboxy, carbamoyl, lower alkoxycarbonyl, cyano, phenyl, pyridinyl or lower alkoxy. Preferred compounds of the formula (I) defined - - above are those, which are R isomers and which are characterized by the formula (la) wherein R1, R2, R3, R4, R5, R5, R7 and X have the meanings defined above. In particular, the preferred compounds are the compounds of the formula (I) described in the examples as individual compounds as well as the pharmaceutically acceptable salts and the pharmaceutically acceptable esters thereof. The preferred compounds of the formula (I) are those selected from the group consisting of: (R) -l-. { 2- [3- (4-methoxy-phenyl) - [1,4,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -3- (2- { 2- [3- (4-methoxy-phenyl) [1, 2, 4] oxadiazol-5-yl] -piperidin-l-yl .} -2-oxo-ethoxy) benzonitrile, (R) -l-. { 2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-propan-1-one, (R) -l-. { 2- [3- (4-bromo-phenyl) [1, 2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, - - (R) -2- (4-Hydroxy-phenoxy) -l-. { 2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -etanone, (R) -2- (4-chloro-phenoxy) -l-. { 2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -etanone, (R) -2- (4-hydroxymethyl-phenoxy) -l-. { 2- [3- (-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -etanone, (R) -2- (3-chloro-phenoxy) -1-. { 2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -etanone, (R) -2- (4-fluoro-phenoxy) -l-. { 2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -etanone, (R) -l-. { 2- [3- (4-Fluoro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-methano-suifoni-1-phenyl) - [1, 2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzenesulfonamide, (R) -2- (4-fluoro-phenoxy) -1- [2- (3-pyridin-4-yl- [1, 2,4] oxadiazol-5-yl) -piperidin-1-yl ] -etanone, (R) -3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -methylbenzoate, (R) -l-. { 2- [3- (3-nitro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-Nitro-phenyl) - [1,2-] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -3-. { 5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzenesulfonamide, (R) -2-phenoxy-l- [2- (3-pyrazin-2-yl- [1, 2, 4] oxadiazol-5-yl) -piperidin-1-yl] -ethanone, (R ) -1- (2- { 3- [4- (morpholine-4-sulfonyl) -phenyl] - [1,2,4] oxadiazol-5-yl}. -piperidin-1-yl) -2 -phenoxy-ethanone, (R) -l-. { 2- [3- (6-methoxy-pyridin-3-yl) - [1, 2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (3-hydroxymethyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -6-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -allylnicnicinate, (R) -l-. { 2- [3- (4-imidazol-1-yl-phenyl) - [1, 2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -N-meth1-4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzenesulfonamide, (R) -l-. { 2- [3- (6-morpholin-4-yl-pyridin-3-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -2-phenoxy-1-. { 2- [3- (4-trifluoromethanesulfonyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -etanone, (R) -2-phenoxy-1-. { 2- [3- (4-trifluoromethyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -etanone, (R) -l-. { 2- [3- (4-chloro-phenyl) - [1, 2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -N- (4-. {5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazole-3 il.} -2-trifluoromethyl-phenyl) -acetamide, (R) -l-. { 2- [3- (3-methanesulfonyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-Methyl-3-nitro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-methoxy-3-nitro-phenyl) - [1,2,] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -N- (2-hydroxy-ethyl) -4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzenesulfonamide, (R) -N- (2-methoxy-ethyl) -N-methyl-4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -benzenesulfonamide, (R) -N, N-dimethyl-4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzenesulfonamide, (R) -N, N-diethyl-4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-y1} -benzenesulfonamide, (R) -l-. { 2- [3- (2-morpholin-4-yl-pyridin-4-yl) - [1,2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -2-phenoxy-1-. { 2- [3- (3, 4, 5, 6-tetrahydro-2H- [1, 2 '] bipyridinyl-4'-yl) - [1, 2,4] oxadiazol-5-yl] -piperidin-1- il} -etanone, (R) -2-phenoxy-1-. { 2- [3- (2-thiomorpholin-4-yl-pyridin-4-yl) - [1,2, 4] oxadiazol-5-yl] -piperidin-1-yl} -etanone, (R) -l-. { 2- [3- (2-diethylamino-pyridin-4-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -4-. { 5- [L- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -ethyl pyridine-2-carboxylate, (R) -l- (2- {3- [6- (4-acetyl-piperazin-1-yl) -pyridin-3-yl] [1,2,4] oxadiazol-5-yl}. -piperidin-1-yl) -2-phenoxy-ethanone, (R) -l-. { 2- [3- (2-imidazol-1-yl-pyridin-4-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l- (3-. {5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazole-3 il.}. phenyl) -piperidin-2-one, (R) -l- (2- { 3- [4- (3H-imidazol-4-yl) -phenyl] - [1,2,4 ] oxadiazol-5-yl.} - piperidin-1-yl) -2-phenoxy-ethanone, (R) -l- (2- { 3- [4- (2-methyl-imidazol-1-yl) ) -phenyl] - [l, 2,4] oxadiazol-5-yl.} - piperidin-1-yl) -2-phenoxy-ethanone, (R) -2-phenoxy-1 -. { 2- [3- (2-pyrazol-l-yl-pyridin-4-yl) - [1,2, 4] oxadiazol-5-yl] -piperidin-1-yl) -ethanone, (R) -4- (5- { 5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2, 4] oxadiazol-3-yl.} - pyridin-2-yl) -piperazine -2-one, (R) -2-phenoxy-1- (2- { 3- [4- (lH-tetrazol-5-yl) -phenyl] - [1,2,4] oxadiazole-5- il.}. -piperidin-1-yl) -ethanone, (R) -l-. { 2- [3- (1H-indazol-5-yl) - [1, 2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (1H-indazol-6-yl) - [1, 2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-Fluoro-3-trifluoromethyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -6-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-y1} -l, 3-dihydro-indol-2-one, (R) -5-. { 5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - - - [1,2,4] oxadiazol-3-i1} -l, 3-dihydro-benzoimidazol-2-one, (R) -5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -l, 3-dihydro-indol-2-one, (R) -l-. { 2- [3- (1H-benzotriazol-5-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (1H-benzoimidazol-5-yl) - [1,2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l- (2- { 3- [6- (l, l-dioxo-thiomorpholin-4-yl) -pyridin-3-yl] - [1, 2, 4] oxadiazol-5-yl.} - piperidin-l-yl) -2-phenoxy-ethanone, (R) -N- (4-. {5- [l- (2-phenoxy-acetyl) -piperidine] -2-yl] - [1,2,4] oxadiazol-3-yl.} - pyridin-2-yl) -acetamide, (R) -1-. { 2- [3- (6-benzyloxy-pyridin-3-yl) - [1, 2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -nicotinate of ethyl, (R) -4-. { 5- [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1,2,4] oxadiazol-3-yl} -lH-pyridin-2-one, (R) -5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-y1} -lH-pyridin-2-one, (R) -2-phenoxy-l- [2- (5-phenyl-2H- [1, 2,4] triazol-3-yl) -piperidin-1-yl] - ethanone, (R) -l-. { 2- [5- (4-methanesulfonyl-phenyl) -2H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [5- (3, 4-dimethoxy-phenyl) -2 H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [5- (3,4-dichloro-phenyl) -2H- [1, 2,4] triazol-3-yl] piperidin-1-yl} -2-phenoxyethanone, (R) -l-. { 2- [5- (4-Fluoro-phenyl) -2H- [1,2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -2-phenoxy-1-. { 2- [5- (3-trifluoromethyl-phenyl) -2H- [l, 2,4] triazol-3-yl] -piperidin-1-yl} -etanone, (R) -l-. { 2- [5- (4-methoxy-phenyl) -2H- [1,2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [5- (3-Nitro-phenyl) -2 H- [1, 2,] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1 H- [1, 2, 4] triazol-3-yl} -methylbenzoate, (R) -l-. { 2- [5- (4-Fluoro-3-trifluoromethyl-phenyl) -2H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -6-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2,4] triazol-3-yl} -l, 3-dihydro-indol-2-one, 1-. { 3- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -morpholin-4-yl} -2-phenoxy-ethanone, 1-. { 3- [3- (4-methanesulfonyl-phenyl) - [1,2,4] oxadiazol-5-id morpholin-4-yl} -2-phenoxy-ethanone, 4-. { 5- [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1,2, 4] oxadiazol-3-yl} -benzenesulfonamide, 1- (3. {3- [6- (1, 1-dioxo-thiomorpholin-4-yl) -pyridin-3-yl] - [1,2, 4] oxadiazol-5-yl} -morpholin-4-yl) -2-phenoxy-ethanone, N- (4-. {5- [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1,2,4] oxadiazol-3-yl} -pyridin-2-yl) -acetamide, l-. { 3- [5- (4-methanesulfonyl-phenyl) -2H- [1,2, 4] triazol-3-yl] -morpholin-4-yl} -2-phenoxy-ethanone, 2-phenoxy-1-. { 3- [5- (3-trifluoromethyl-phenyl) -2H- [l, 2,4] triazol-3-yl] -morpholin-4-yl} -etanone, (R) -4-. { 5- [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1,2,4] oxadiazol-3-yl} -lH-pyridin-2-one, l-. { 3- [3- (4-methoxy-phenyl) - [1, 2, 4] oxadiazol-5-yl] -thiomorpholin-4 -i1} -2-phenoxy-ethanone, 1-. { 3- [3- (4-methanesulfonyl-phenyl) - [1,2,4] oxadiazol-5-yl] -thiomorpholin-4-i1} -2-phenoxy-ethanone, 4-. { 5- [4- (2-phenoxy-acetyl) -thiomorpholin-3-yl] - [1,2, 4] oxadiazol-3-yl} -benzenesulfonamide, 2-phenoxy-l- [3- (3-pyridin-4-yl- [1, 2,4] oxadiazol-5-yl) -thiomorpholin-4-yl] -ethanone, l-. { 2- [3- (4-methoxy-phenyl) - [1,4,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, N- (5-. {5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl}. -pyridin-2-yl) -acetamide, l-. { 2- [3- (2-imidazol-1-yl-pyridin-4-yl) - [1,4,2] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, N, N-diethyl-4-. { 5- [1- (2-phenoxy-acetyl) -piperazin-2-y1] - [1,2,4] oxadiazol-3-yl} -benzenesulfonamide, N, N-dimethyl-4-. { 5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-y1} -benzenesulfonamide, 4- . { 5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzenesulfonamide, 1-. { 2- [3- (4-methanesulfonyl-phenyl) - [1,4,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1- [2- (3-pyridin-4-yl- [1, 2,4] oxadiazol-5-yl) -piperazin-1-yl] -ethanone, l- . { 2- [3- (2,4-Dichloro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-l- [2- (3-pyridin-2-yl- [1, 2,4] oxadiazol-5-yl) -piperazin-1-yl] -ethanone, 2- phenoxy-l- [2- (3-pyridin-2-yl- [1,2,4] oxadiazol-5-yl) -piperazin-2-yl] -ethanone, l-. { 2- [3- (4-Nitro-phenyl) - [1,4,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 1-. { 2- [3- (6-methoxy-pyridin-3-yl) - [1,4,2] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 1-. { 2- [3- (6-morpholin-4-yl-pyridin-3-yl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, l-. { 2- [3- (6-morpholin-4-yl-pyridin-3-yl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 1-. { 2- [3- (3-hydroxymethyl-phenyl) - [1,4,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 1-. { 2- [3- (4-diethylamino-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, l- (2- (3- [4- (morpholine-4-sulfonyl) -phenyl] - [1,2,4] oxadiazol-5-yl} -piperazin-1-yl) -2-phenoxy-ethanone, N-methy1-4- (5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazole- 3-yl.} - benzenesulfonamide, N- (2-methoxy-ethyl) -N-methyl-1-4 -. {5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1 , 2,4] oxadiazol-3-yl.} - benzenesulfonamide, l-. {2- [3- (4-chloro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazine- l-il.} -2-phenoxy-ethanoneN- (4- { 5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [l, 2,4] oxadiazol-3-yl.} -2-trifluoromethyl-phenyl ) -acetamide, allyl 4- (5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1, 2, 4] oxadiazol-3-yl.} - benzoate, l- ( 2- [3- (4-methyl-3-nitro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 1-. { 2- [3- (4-methoxy-3-nitro-phenyl) - [1,2-] oxadiazol-5-yl 'piperazin-1-yl} -2-phenoxy-ethanone, 1- (2- [3- (4-chloro-3-nitro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl.} -2-phenoxy-ethanone, 3-fluoro-4- { 5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,4,2-oxadiazol-3-yl} -benzoic acid methyl ester, 4 -. [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1, 2, 4] oxadiazol-3-yl.} - pyridine-2-carboxylic acid ethyl ester, 2-phenoxy-1- { 2- [3- (4-piperidin-1-yl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -ethanone, 1- (2). [3- (4-morpholin-4-yl-phenyl) - [1, 2, 4] oxadiazol-5-yl] -piperazin-1-yl.} -2-phenoxy-ethanone, 1- (2- { 3- [4- (2-methyl-imidazol-1-yl) -phenyl] - [1,2,4] oxadiazol-5-yl}. -piperazin-1-yl) -2-phenoxy-ethanone, 1- (2 { 3- [4- (3H-imidazol-4-yl) -phenyl] - [1,2, 4] oxadiazol-5-yl}. -piperazin -l-yl) -2-phenoxy-ethanone, 4- (5-. {5- [l- (2-phenoxy-acetyl) -piperazin-2-y1] - [1,2,4] oxadiazole-3 -yl.}. -pyridin-2-yl) -piperazin-2-one, 1-. { 2- [3- (6-imidazol-1-yl-pyridin-3-yl) - [1, 2,] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 1- (2- (3- [6- (4-acetyl-piperazin-1-yl) -pyridin-3-yl] - [1,2,4] oxadiazol-5-yl} -piperazin-l-yl) -2-phenoxy-ethanone, 2-phenoxy-l-. {2- [3- (4-pyrrol-l-yl-phenyl) - [1,4,4] oxadiazole -5-yl] -piperazin-1-yl.}. -etanone, 2-phenoxy-1- (2- [3- (4-trifluoromethanesulfonyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl.}. -etanone, l- { 2- [3- (2-morpholin-4-yl-pyridin-4-yl) - [1,2,4] oxadiazol-5-yl. ] -piperazin-l-yl.} -2-phenoxy-ethanone, 2-phenoxy-1- { 2- [3- (2-thiomorpholin-4-yl-pyridin-4-yl) - [1, 2,4] oxadiazol-5-yl] -piperazin-1-yl}. -etanone, l- (2- { 3- [6- (3-hydroxymethyl-pyrrolidin-1-yl) -pyridin-3 -yl] - [1, 2,4] oxadiazol-5-yl.} - piperazin-1-yl) -2-phenoxy-ethanone, (R) -1-. { 2- [3- (6-methoxy-pyridin-3-yl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (6-morpholin-4-yl-pyridin-3-yl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -N- (4-. {5- [l- (2-phenoxy-acetyl) -piperazin-2-yl] - - 3í [1, 2,4] oxadiazol-3-yl} -2-trifluoromethyl-phenyl) -acetamide, (R) -l-. { 2- [3- (-methyl-3-nitro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-methyl-3-nitro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-morpholin-4-yl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l- (2- { 3- [4- (3H-imidazol-4-yl) -phenyl] - [1,2,4] oxadiazol-5-yl} -piperazin-1-yl) -2-phenoxy-ethanone, (R) -1- (2. {3- [6- (3-hydroxymethyl-pyrrolidin-1-yl) -pyridin-3-yl} ] - [1, 2, 4] oxadiazol-5-yl.} - piperazin-1-yl) -2-phenoxy-ethanone, (R) -1- (2- { 3- [6- (4 -acetyl-piperazin-1-yl) -pyridin-3-yl] - [1,2,4-oxadiazol-5-yl]. -piperazin-1-yl) -2-phenoxy-ethanone, (R) - N- (3- {5- (l- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,] oxadiazol-3-yl} -phenyl) -acetamide, hydrochloride, (R) -l-. { 2- [3- (1H-benzoimidazol-5-yl) - [1,2, 4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (1H-Benzotriazol-5-yl) - [1, 2, 4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (lH-indazol-5-yl) - [1,2, 4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, hydrochloride, (R) -5-. { 5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2, 4] oxadiazol-3-yl} -l, 3-dihydro-benzoimidazol-2-one, (R) -1- (2-. {3- [6- (1,1-dioxo-thiomorpholin-4-yl) -pyridin-3-) - il] - [1, 2, 4] oxadiazol-5-yl} -piperazin-1-yl) -2-phenoxy-ethanone, hydrochloride, (R) -l-. { 2- [3- (3-nitro-phenyl) - [1,4,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-Fluoro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -4-. { 5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl} -lH-pyridin-2-one, l-. { 4-Acetyl-2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, l-. { 4-Acetyl-2- [3- (4-methanesulfonyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 4-. { 5- [4-acetyl-l- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2, 4] oxadiazol-3-yl} -benzenesulfonamide, l- [4-acetyl-2- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-yl) -piperazin-1-yl] -2-phenoxy-ethanone, 1- . { 4-methanesulfonyl-2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [5- (4-Fluoro-phenyl) -2H- [1,2,4] triazol-3-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -2-phenoxy-1-. { 2- [5- (3-trifluoromethyl-phenyl) -2H- [1,2, 4] triazol-3-yl] -piperazin-1-yl} -etanona, l-. { 2- [5- (4-Fluoro-3-trifluoromethyl-phenyl) -2H- [1, 2,4] triazol-3-yl] -piperazin-1-yl} -2-phenoxy-ethanone, l-. { 2- [5- (4-methanesulfonyl-phenyl) -2 H- [1, 2, 4] triazole-3- il] -piperazin-l-il} -2-phenoxy-ethanone, 2-phenoxy-1-. { 2- [5- (3-trifluoromethyl-phenyl) -2H- [l, 2,4] triazol-3-yl] -piperazin-1-yl} -etanone, 2-phenoxy-1- [2- (5-p-tolyl-2H- [1, 2,] triazol-3-yl) -piperazin-1-yl] -ethanone, 2-phenoxy-1-. { 2- [5- (4-trifluoromethyl-phenyl) -2H- [1, 2,4] triazol-3-yl] -piperazin-1-yl} -etanona, l-. { 2- [5- (4-methoxy-phenyl) -2H- [1, 2,4] triazol-3-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 1- (2- [5- (4-fluoro-phenyl) -2H- [1, 2,4] triazol-3-yl] -piperazin-1-yl.} -2- phenoxy-ethanone, l- { 2- [5- (4-fluoro-phenyl) -2H- [1, 2,4] triazol-3-yl] -piperazin-1-yl.} -2-phenoxy -etanone, l- { 2- [5- (3,4-dimethoxy-phenyl) -2H- [1,2,4] triazol-3-yl] -piperazin-1-yl.} -2- phenoxy-ethanone, l- { 2- [5- (3,4-dichloro-phenyl) -2H- [1,2,4] triazol-3-yl] -piperazin-1-yl} -2 -phenoxy-ethanone, l- { 2- [5- (2-fluoro-phenyl) -2H- [1,2, 4] triazol-3-yl] -piperazin-1-yl.} -2- phenoxy-ethanone, l- { 2- [5- (2-fluoro-phenyl) -2H- [1, 2,4] triazol-3-yl] -piperazin-1-yl} -2-phenoxy -etanone, 4- {5- [4-methyl-1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzamide, (R) -l-. {2- [3- (lH-indazol-5-yl) - [1,2,4] oxadiazol-5-yl] -4-methyl-piperazin-1-yl} -2 -phenoxy-ethanone, (R) -l-. { 2- [3- (4-Fluoro-phenyl) - [1,2,4] oxadiazol-5-yl] -4-methyl-piperazin-1-yl} -2-phenoxy-ethanone, (R) -5-. { 5- [4-methi1-1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-y1} -1, 3-dihydro-indol-2-one, (R) -5-. { 5- [4-methi1-1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl} -l, 3-dihydro-benzoimidazol-2-one, (R) -l-. { 2- [3- (lH-benzoimidazol-5-yl) - [1,2, 4] oxadiazol-5-yl] -4-methyl-piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (1H-benzotriazol-5-yl) - [1, 2, 4] oxadiazol-5-yl] -4-methyl-piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 4-methyl-2- [5- (3-trifluoromethyl-1-phenyl) -2H- [1, 2,4] triazol-3-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [5- (4-methoxy-phenyl) -2H- [1,2, 4] triazol-3-yl] -4-methyl-piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [5- (4-Fluoro-phenyl) -2H- [1, 2,4] triazol-3-yl] -4-methyl-piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [5- (4-methanesulfonyl-phenyl) -2H- [1,2,4] triazol-3-yl] -4-methyl-piperazin-1-yl} -2-phenoxy-ethanone, (R) -4- (5- [4-methyl-1- (2-phenoxy-acetyl) -piperazin-2-yl] -1H- [1, 2, 4] triazole-3 methyl .benzoate, (R) -N- (3- { 5- [- methi1-1- (2-phenoxy-acetyl) -piperazin-2-yl] -lH- [l, 2,4] triazol-3-yl.} - phenyl) -acetamide, (R) -N- (3-. {5- [4-methyl-1- (2-phenoxy-acetyl) -piperazin-2) -yl] -lH- [1, 2,4] triazol-3-yl.} - phenyl) -methanesulfonamide, (R) -4- (5- [4-methyl-1- (2-phenoxy-acetyl) -piperazin-2-yl] - - - 1 H- [1, 2, 4] triazol-3-yl} -benzamide, acid (R) -4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzoic, acid (R) -3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzoic acid (R) -6-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -nicotinic, acid (R) -2-fluor-4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-y1} -benzoic acid (R) -5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -pyridine-2-carboxylic acid, (R) -4- acid. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -pyridine-2-carboxylic acid, (R) -3- acid. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1,2, 4] triazol-3-yl} -benzoic, acid 3-. { 5- [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1, 2, 4] oxadiazol-3-yl} -benzoic, acid 3-. { 5- [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1, 2, 4] oxadiazol-3-yl} -benzoic, 4-. { 5- [4- (2-phenoxy-acetyl) -thiomorpholin-3-yl] - [1,2, 4] oxadiazol-3-yl} -benzamide, 4-. { 5- [4- (2-phenoxy-acetyl) -thiomorpholin-3-yl] - [1,2, 4] oxadiazol-4-yl} -benzamide, acid 3-. { 5- [4-acetyl-l- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzoic, 4- acid. { 5- [4-acetyl-l- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,4,4] oxadiazol-3-y1} -benzoic, acid (R) -4-. { 5- [4-methi1-1- (2-phenoxy-acetyl) -piperazin-2-yl] -lH- [l, 2,4] triazol-3-yl} -benzoic acid (R) -5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -nicotinic, l- (2- { 3- [4- (morpholine-4 -carbonyl) -phenyl] - [1,2,4] oxadiazol-5-yl}. -piperidin-1-yl) - 2-phenoxy-ethanone, (R) -l- (2- (3- [4- (3-hydroxy-pyrrolidine-1-carbonyl) -phenyl] - [1,2,4] oxadiazol-5-yl}. . -piperidin-1-yl) -2-phenoxy-ethanone, (R) -N, N-diethyl-4- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2,4] oxadiazol-3-yl.}. -benzamide, (R) -N-methyl-4-. {5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2,4] oxadiazol-3-yl.}. -benzamide, (R) -N, N-dimethyl-4- { 5- [1- (2-phenoxy-acetyl) -piperidin-2 -yl] - [l, 2,4] oxadiazol-3-yl.}. -benzamide, (R) -N-ethyl-4-. {5- [1- (2-phenoxy-acetyl) -piperidine- 2-yl] - [l, 2,4] oxadiazol-3-yl.}. -benzamide, (R) -N-cyclopropyl-4-. {5- [l- (2-phenoxy-acetyl) -piperidine] -2-yl] - [1, 2,4] oxadiazol-3-yl.}. -benzamide, (R) -N- (2-hydroxy-ethyl) -4- { 5- [1- (2 -phenoxy-acetyl) -piperidin-2-yl] - [l, 2,4] oxadiazol-3-yl.}. -benzamide, (R) -N- (2-methoxy-ethyl) -N-methyl-1-4 - { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazole-3-i 1 } -benzamide, (R) -N-methyl-3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -benzamide, (R) -N, N-dimethyl-3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2, 4] oxadiazol-3-yl} -benzamide, (R) -N-ethyl-3-. { 5- [L- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -benzamide, (R) -N-cyclopropyl-3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -benzamide, (R) -N- (2-hydroxy-ethyl) -3- (5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [l, 2,4] oxadiazole-3 -yl.}. -benzamide, (R) -N- (2-methoxy-ethyl) -N-methy1-3-. {5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl.}. -benzamide, (R) -l- (2- { 3- [3- (morpholine-4 -carbonyl) -phenyl] - [l, 2,4] oxadiazol-5-yl.}. -piperidin-1-yl) -2-phenoxy-ethanone, (R) -l- (2- (3- [3- (3-hydroxy-pyrrolidine-1- carbonyl) -phenyl] - [1,2,4] oxadiazol-5-yl.} - piperidin-1-yl) -2-phenoxy-ethanone, (R) -N, N-diethyl-3-. 5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl}. -benzamide, methylamide of (R) -4-. 5- [1- (2-phenoxy-acetyl) piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.} - pyridine-2-carboxylic acid, dimethylamide of (R) -4- {. 5- [1- (2-phenoxy-acetyl) piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.} - pyridine-2-carboxylic acid, 4 ethylamide of (R) -4- acid. { 5- [1- (2-phenoxy-acetyl-piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.} - pyridine-2-carboxylic acid, diethylamide of (R) -4- {. 5- [1- (2-phenoxy-acetyl] piperidin-2-yl] - [1,2,4] oxadiazol-3-yl}. -pyridine-2-carboxylic acid, (R) -1- (2- { 3- [2- (morpholine-4-carbonyl) -pyridin-4-yl] - [1,2, 4] oxadiazol-5-yl.}. -piperidin-1-yl) -2 -phenoxy-ethanone, (R) -l- (2- { 3- [2- (3-methanesulfonyl-pyrrolidine-1-carbonyl) -pyridin-4-yl] - [1,2, 4] oxadiazole- 5-yl.}. -piperidin-l-yl) -2-phenoxy-ethanone, (R) -5-. {5- [1- (2-phenoxy-acetyl [piperidin-2-yl]] methylamide - [1, 2, 4] oxadiazol-3-yl.} - pyridine-2-carboxylic acid, (R) -N-methy1-3- { 5- [1- (2-phenoxy-acetyl) -piperidine -2-yl] -lH- [l, 2,4] triazol-3-yl.}. -benzamide, lN, N-diethyl-4-. {5- [1- (2-phenoxy-acetyl) - piperazin-2-yl] - [1,2, 4] oxadiazol-3-yl.}. -benzamide, 1- (2 { 3- [4- (morpholine-4-carbonyl) -phenyl] - [ 1,2,4-oxadiazol-5-yl.} - piperazin-1-yl) -2-phenoxy-ethanone, N-methy1-4- { 5- [1- (2-phenoxy-a cetyl) -piperazin-2-yl] - [1,2, 4] oxadiazol-3-yl} -benzamide, (R) -N-meti1-5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -nicotinamide, (R) -N-ethyl-5-. { 5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2,4] oxadiazol-3-yl} -nicotinamide, (R) -N-diethyl-5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -nicotinamide, (R) -N-diethyl-5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -nicotinamide, (R) -N- (2-hydroxy-ethyl) -5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -nicotinamide, (R) -N- (2-methoxy-ethyl) -N-methyl-5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -nicotinamide, (R) -N-cyclopropyl-5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -nicotinamide, (R) -1- (2- { 3- [5- (3-hydroxy-pyrrolidine-1-carbonyl) -pyridin-3-yl] - [1,2,] oxadiazol-5-yl .}. -piperidin-1-yl) -2-phenoxy-ethanone, (R) -4-. { 5- [L- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -benzamide, (R) -3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzamide, amide of (R) -4- acid. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -pyridine-2-carboxylic, (R) -3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2,4] triazol-3-yl} -benzamide, 4-. { 5- [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1,2,4] oxadiazol-3-yl} -benzamide, 4-. { 5- [4- (2-phenoxy-acetyl) -thiomorpholine-3-yl] - 4 [1, 2, 4] oxadiazol-3yl} -benzamide, 4-. { 5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -benzamide, 5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -nicotinamide, (R) -l-. { 2- [3- (3-Amino-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-Amino-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [5- (3-Amino-phenyl) -2 H- [1,2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -N- (3- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2, 4] oxadiazole-3- il.}.-phenyl) -acetamide, (R) -N- (4-. {5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazole -3-yl.}.-Phenyl) -acetamide, (R) -N- (5- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2, 4] oxadiazol-3-yl.} - pyridin-2-yl) -acetamide, (R) -N- (3- {5- (1- (2-phenoxy-acetyl) -piperidin-2-yl} ] -1 H- [1, 2,4] triazol-3-yl.} - phenyl) -acetamide, (R) -N- (3-. {5- [l- (2-phenoxy-acetyl) - piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.} - phenyl) -methanesulfonamide, (R) -N- (4-. {5- [1- (2-phenoxy) acetyl) -piperidin-2-yl] - [l, 2,4] oxadiazol-3-yl.} - phenyl) -methane-sulfonamide, (R) - (3-. {5- [1- (2 allyl-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl.} - phenyl) -carbamate, - 4! (R) - (4- (5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2,4] oxadiazol-3-yl.} - phenyl) -alicyl ester , (R) -N- (3- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl}. phenyl) -metanesulfonamide, (R) -l-ethyl-3- (3-. {5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2, 4 ] tria zol-3-yl.}.-phenyl) -urea, (R) -3- (5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl} -benzonitrile and (R) -5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -nicotinonitrile, and pharmaceutically acceptable salts and esters thereof. Especially preferred compounds of the formula (I) are those selected from the group consisting of: (R) -l- (2- [3- (IH-indazol-5-yl) - [1,2,] oxadiazole-5- il] -piperidin-1-yl.} -2-phenoxy-ethanone, (R) -l- { 2- [3- (lH-indazol-6-yl) - [1,2, 4] oxadiazole -5-yl] -piperidin-1-yl.} -2-phenoxy-ethanone, (R) -6-. {5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl.} - l, 3-dihydro-indol-2-one, (R) -5- { 5- [1- (2-phenoxy-acetyl) - piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.} -1, 3-dihydro-benzoimidazol-2-one, (R) -5-. {5- [l- ( 2-phenoxy-acetyl) -piperidin-2-yl] - [l, 2,4] oxadiazol-3-yl.} - l, 3-dihydro-indol-2-one, (R) -l-. { 2- [3- (lH-benzotriazol-5-yl) - [1,2,4] oxadiazole-5- il] -piperidin-l-il} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (1H-benzoimidazol-5-yl) - [1,2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -4-. { 5- [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1,2,4] oxadiazol-3-yl} -lH-pyridin-2-one, (R) -l-. { 2- [5- (4-Fluoro-phenyl) -2H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -2-phenoxy-1-. { 2- [5- (3-trifluoromethyl-phenyl) -2H- [l, 2,4] triazol-3-yl] -piperidin-1-yl} -etanone, (R) -l-. { 2- [3- (1H-Benzoimidazol-5-yl) - [1, 2, 4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzamide, 5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -nicotinamide, (R) -N- (3- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2,4] triazol-3-yl}-phenyl) -acetamide and (R) -N- (3- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazole -3-yl.}.-Phenyl) -methanesulfonamide, and the pharmaceutically acceptable salts and esters thereof. Other preferred compounds of formula (I) are those selected from the group consisting of: l-. { (R) -2- [3- (2-Methyl-lH-benzoimidazol-5-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [3- (2-Amino-pyridin-4-yl) - [1, 2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [3- (3-hydroxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 4-. { 5 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -lH-pyridin-2-one, l-. { (R) -2- [3- (4-hydroxy-phenyl) - [1,2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 3- acid. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] [1,2,4] oxadiazol-3-yl} phenylboronic, 4- (2-oxo-2- { (R) -2- [3- (2-oxo-2,3-dihydro-lH-indol-5-yl) - [1,2,4 ] oxadiazol-5-yl] -piperidin-1-yl.}. -ethoxy) -benzonitrile, 4- (2- { (R) -2- [3- (4-methoxy-phenyl) - [1, 2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-oxo-ethoxy) -benzonitrile, 2-methyl-5. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -3H-pyrimidin-4-one, l- [(R) -2- (3-furan-2-yl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -2- phenoxy-ethanone, 1- [(R) -2- (3-imidazo [l, 2-a] pyridin-2-yl- [l, 2,4] oxadiazol-5-yl) -piperidin-1-yl] -2-phenoxy-ethanone, l-. { (R) -2- [3- (4-methyl- [1,2,3] thiadiazol-5-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [3- (2, 5-dimethyl-2H-pyrazol-3-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1-. { (R) -2- [3- (1H-pyrazol-4-yl) - [1, 2, 4] oxadiazole- -yl] -piperidin-1-yl} -etanona, l-. { (R) -2- [3- (5-Methyl-isoxazol-3-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1-. { (R) -2- [3- (1H-pyrazol-3-yl) - [1,2, 4] oxadiazol-5-yl] -piperidin-1-yl} -etanona, 5-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2, 4] oxadiazol-3-yl} -lH-pyrimidine-2,4-dione, 1-. { (R) -2- [3- (6-Amino-pyridin-3-yl) - [1,4,2] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l- [(R) -2- (3-imidazo [l, 2-a] pyridin-6-yl- [1,2,4] oxadiazol-5-yl) -piperidin-1 -yl] -2-phenoxy-ethanone, 6-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -4H-benzo [1,4] oxazin-3-one, 6-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -l, 4-dihydro-benzo [d] [l, 3] oxazin-2-one, 1- ((R) -2-. {3- [3- (l, l-dioxo-l6- isothiazolidin-2-yl) -phenyl] - [1,2,4] oxadiazol-5-yl}. -piperidin-l-yl) -2-phenoxy-ethanone, 1- (3- {5- [5- (R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.} - phenyl) -pyrrolidin-2-one, 1- (3 - { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.} - phenyl) -imidazolidine-2 , 4-dione, 4- (3- { 5 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2, 4] oxadiazol-3-yl}-phenyl) -2,4-dihydro- [1, 2, 4] triazol-3-one, 1- (3-Fluoro-5- { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,4,2] oxadiazol-3-yl.} .-phenyl) -pyrrolidine-2,5-dione, 5-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl} -l, 3-dihydro-indol-2-one, l-. { (R) -2- [5- (lH-indazol-5-yl) -2H- [l, 2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (1H-indol-5-yl) -2 H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (3 H -benzotriazol-5-yl) -2 H- [1, 2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 5-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1 H- [1, 2, 4] triazol-3-yl} -l, 3-dihydro-benzoimidazol-2-one, l-. { (R) -2- [5- (2-Methyl-lH-benzoimidazol-5-yl) -2H- [l, 2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (2-Amino-pyridin-4-yl) -2 H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 5- (3. {5 - [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2,4] triazole- 3-yl.}.-Phenyl) -3H- [l, 3,4] oxadiazol-2-one, l- ((R) -2- [5- (3- [l, 3,4] oxadiazole-2 -yl-phenyl) -2H- [l, 2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 3-. {5- [l- (2 -phenoxy-acetyl) -piperidin-2-yl] -lH- [1, 2, 4] triazol-3-yl.} - phenylboronic, 6-. {5 - [(R) -l- (2- phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl.} -4 H -benzo [1,4] oxazin-3-one, l- [(R) -2- (5-imidazo [1,2- a] pyridin-6-yl-2H- [1, 2,4] triazol-3-yl) -piperidin-1-yl] -2-phenoxy-ethanone, 1-. { (R) -2- [5- (6-Amino-pyridin-3-yl) -2 H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l- ((R) -2- [5- (lH-benzoimidazol-5-yl) -2H- [1, 2, 4] triazol-3-yl] -piperidin-l-yl .} -2-phenoxy-ethanone, 2-phenoxy-1 - [(R) -2- (5-pyridin-3-yl-2H- [1, 2, 4] triazol-3-yl) -piperidine- 1-yl] -ethanone, l- { (R) -2- [5- (3,5-dimethyl-isoxazol-4-yl) -2H- [l, 2,4] triazol-3-yl] -piperidin-1-yl.} -2-phenoxy-ethanone, 2-phenoxy-l- [(R) -2- (5-thiophen-2-yl-2H- [1, 2, 4] triazole-3 -yl) -piperidin-1-yl] -ethanone, 2-phenoxy-l- [(R) -2- (5-pyrimidin-2-yl-2H- [l, 2,4] triazol-3-yl) -piperidin-1-yl] -ethanone, l- { (R) -2- [5- (4-methyl-oxazol-5-yl) -2H- [1,2, 4] triazol-3-yl ] -piperidin-1-yl.} -2-phenoxy-ethanone, 2-phenoxy-1 - [(R) -2- (5-pyrazin-2-yl-2H- [1,2,4] triazole- 3-yl) -piperidin-1-yl] -ethanone, l- { (R) -2- [5- (2-fluoro-phenyl) -2H- [1,2, 4] triazol-3-yl ] -piperidin-1-yl.} -2-phenoxy-ethanone, l- { (R) -2- [5- (3,5-difluor-phenyl) -2H- [1,2,4] triazol-3-yl] -piperidin-l-yl.} -2-phenoxy-ethanone, l- { (R) -2- [5- (2-methyl-pyridin-4-yl) -2H- [1,2, 4] t riazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l- ((R) -2- [5- (3-fluoro-phenyl) -2H- [1,2, 4] triazol-3-yl] -piperidin-1-yl}. -2-phenoxy-ethanone, - l-. { (R) -2- [5- (3, 4-difluorophenyl) -2 H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 6-. { 5- [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl} -l, 4-dihydro-benzo [d] [l, 3] oxazin-2-one, 7-. { 5- [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -lH- [l, 2,4] triazol-3-yl} -3, -dihydro-lH-quinazolin-2-one, 1- (3 { 5- [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l , 2,4] triazol-3-yl.} - phenyl) -imidazolidine-2,4-dione, 1-. { (R) -3- [3- (2-Amino-pyridin-4-yl) - [1,2, 4] oxadiazol-5-yl] -morpholin-4-yl} -2-phenoxy-ethanone, l-. { (R) -3- [3- (lH-benzoimidazol-5-yl) - [1,2, 4] oxadiazol-5-yl] -morpholin-4-yl} -2-phenoxy-ethanone, l-. { (R) -2- [3- (1H-Benzoimidazol-5-yl) - [1,2, 4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 5-. { 5- [(R) -l- (2-phenoxy-acetyl) -piperazin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -1, 3-dihydro-indol-2-one, l-. { (R) -2- [3- (2-Amino-pyridin-4-yl) - [1,2, 4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (3- {5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] [1,2,4] oxadiazol-3-yl} acid}-phenoxy) -acetic, 2-phenoxy-1- ((R) -2- { 5- [3- (piperidine-1-carbonyl) -phenyl] -2H- [l, 2,4] triazole -3-yl.}. -piperidin-1-yl) -ethanone, 1- ((R) -2- { 5- [3- (morpholine -carbonyl) -phenyl] -2H- [l, 2 , 4] triazol-3-yl.} - piperidin-1-yl) -2-phenoxy-ethanone, l - ((R) -2- { 5- [3- (4-methy1-piperazine-1 -carbonyl) -phenyl] - 2H- [1,2,4] tr? Azol-3? L} -p? per? dm-l-? l) -2-phenoxy? -ethanone, 4- (3- { 5 - [(R) -l- (2-phenox? -acet? l) -p? per? dm-2-? l] -1H- [l, 2,4] tr? azol-3?.]. -benzoyl) -p? perazm-2-one, N- (2-methox) ? -et? l) -N-met? l-3-. { 5- [(R) -1- (2-phenoxy-acetyl) -p? Per? D? N-2-? L] -1H- [1, 2, 4] tr? Azol-3? L} -benzamide, l - ((R) -2- { 5- [3- (4-acet? lp? peraz? na-l-carbon? l) -phenyl] -2H- [l, 2,4] tr? azole-3-? l.). -p? per? dm-l-? l) -2-phenoxy? -ethanone, acid 1- (3- { 5- [(R) -l- ( 2-phenoxy? -acet? L) -p? Per? D? N-2-? L] -lH- [l, 2,4] tr? Azol-3?.]. -benzoyl) - p? per? ama-4-carboxylic acid amide 1- (3 { 5- [(R) -1- (2-f enoxy-acetyl) -p? per? dm-2 -? l] -1H- [1,2, 4] tpazol-3?,.]. -benzoyl) -piperidma-4-carboxylic acid, 2-f enoxyl-1 - ((R ) -2- { 5- [3- (t? Azol? Dma-3-carbon? L) -phenyl] -2H- [l, 2,4] tr? Azole-3? L. p? per? dm-l-? l) -ethanone, N- (2-d? met? lammo-et? l) -N-met? l-3-. { 5- [(R) -1- (2-phenoxy? -acetyl) -p? Per? D? N-2-? L] -lH- [l, 2,4] tr? Azole-3? L} -benzamide, 2-phenoxy? -l- ((R) -2-. {5- [3- (thiomorpholma-4-carbonyl) -phenyl] -2H- [l, 2,4] tr? -3-? L.}. -p? Pepd? N-1-? L) -ethanone, 4- (3- { 5- [(R) -1- (2-phenox? -acet? L) -p? per? dm-2-? l] -1H- [1, 2, 4] tr? azole-3?.}. -benzoyl) -p? peraz? na-1-carbox? lato of ethyl, N- (2-h? drox? -et? l) -3-. { 5 - [(R) -l- (2-f-enoxy-acetyl) -p? Per? Dm-2-? L] -lH- [l, 2,4] tr? Azole-3? L} -benz amide, N -me ti 1-3- (5- [(R) -1- (2-phenoxy? -acet? l) -p? per? dm-2-? l] -1H- [1, 2,4] tpazol-3-yl.} - N- (2-p? Pdm-2-? L-et? L) -benzamide, N- (2-cyano-ethyl) -N-cyclopropyl-3-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2,4] triazol-3-yl} -benzamide, 1- (3- { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1,2, 4] triazol-3-yl} -benzoyl) -4-phenyl-piperidine-4-carbonitrile, 1- ((R) -2- { 5- [3- (4-hydroxy-piperidine-1-carbonyl) -phenyl] -2H- [1,2,4] triazol-3-yl.}. -piperidin-1-yl) -2-phenoxy-ethanone, 8- (3. {5 - [(R) -1- (2-phenoxy) -acetyl) -piperidin-2-yl] -1H- [1,2,] triazol-3-yl.} - benzoyl) -1, 3, 8-triaza-spiro [4, 5] decane-2,4 -dione, 1- (2- { 5- [3- (spiro (1-phthalano) -piperidine-4-carbonyl) -phenyl] -2H- [l, 2,4] triazol-3-yl.} . -piperidin-1-yl) -2-phenoxy-ethanone, 2-phenoxy-l- ((R) -2- { 5- [3- (3-pyridin-4-yl-pyrrolidine-l-carbonyl ) -phenyl] -2H- [l, 2,4] triazol-3-yl.}. -piperidin-1-yl) -ethanone, l - ((R) -2- { 5- [3- ( 3-methanesulfonyl-pyrrolidine-1-carbonyl) -phenyl] -2H- [1,2,4] triazol-3-yl}. -piperidin-1-yl) -2-phenoxy-ethanone, l - ((R ) -2- { 5- [3 - ((S) -3-ethoxy-pyrrolidine-1-carbonyl) -phenyl] -2H- [l, 2,4] triazol-3-yl}. -piperidine -1-yl) -2-phenoxy-ethanone, l - ((R) -2- { 5- [3 - ((S) -3-hydroxy-pyrrolidine-1-carbonyl) -phenyl] -2H- [1, 2,] triazol-3-yl} -piperidin-1-yl) -2-phenoxy-ethanone, - . { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2,] triazol-3-yl} -nicotinamide, 2- (3- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4-oxadiazol-3-yl}. -phenoxy) - acetamide, N- (3-fluoro-5- { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,4,2] oxadiazol-3-yl .}.-phenyl) -acetamide, N- (2-fluoro-5- { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl.} - phenyl) -acetamide, N- (3- (5- [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l , 2,4] triazol-3-yl.} - phenyl) -propionamide, N- (3-. {5- (R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2,4] triazol-3-yl.}. Phenyl) -isobutyramide, N- (4-fluoro-3. {5 - [(R) -1- (2-phenoxy) acetyl) -piperidin-2-yl] -lH- [l, 2,4] triazol-3-yl.} - phenyl) -acetamide, N- (3-fluoro-5-. {5- [(R ) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1,2, 4] triazol-3-yl.} - phenyl) -acetamide, N- (2-fluor-5) - { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -lH- [l, 2,4] triazol-3-yl.} - phenyl) -acetamide , N- (4- { 5 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] t riazol-3-il} -pyridin-2-yl) -acetamide, 1- (3. {5 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2.4 ] triazol-3-yl.} - phenyl) -azetidin-2-one, 1- (3. {5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [ 1,2,4] triazol-3-yl.}. Phenyl) -pyrrolidine-2, 5-dione, 2-phenoxy-l- [(R) -2- (5-pyridazin-4-yl- [1 , 2,4] oxadiazol-3 il) -piperidin-1-yl] -ethanone, 4-. { 3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl} -benzonitrile, 1-. { (R) -2- [5- (3-Amino-pyrazin-2-yl) - [1, 2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 3- (3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl.} - benzonitrile, l- { (R) -2- [5- (2-hydroxy-pyridin-3-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1-yl}. -2-phenoxy-ethanone, l- { (R) -2- [5- (5-amino-pyridin-3-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1 -yl.} -2-phenoxy-ethanone, l- { (R) -2- [5- (2-hydroxy-pyridin-4-yl) - [1,2,4] oxadiazol-3-yl ] -piperidin-l-yl.} -2-phenoxy-ethanone, l- { (R) -2- [5- (2-hydroxy-6-methyl-pyridin-4-yl) - [l, 2,4] oxadiazol-3-yl] -piperidin-1-yl.} -2-phenoxy-ethanone, l- { (R) -2- [5- (4-hydroxy-pyridin-2-yl) ) - [1,2,] oxadiazol-3-yl] -piperidin-1-yl.} -2-phenoxy-ethanone, l- { (R) -2- [5- (2-amino-5 -chloro-pyrimidin-4-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl.} -2-phenoxy-ethanone, 2-phenoxy-1 - [(R) - 2- (5-pyrazin-2-yl- [1,2,4] oxadiazol-3-yl) -piperidin-1-yl] -ethanone, 2-phenoxy-1 -. (R) -2- [ 5- (4- [1, 2,4] triazol-1-yl-phenyl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl}. -etanone, 2-phenoxy-1-. { (R) -2- [5- (4-tetrazol-1-yl-phenyl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -etanone, - - l- { (R) -2- [5- (lH-benzoimidazol-4-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (4-Acetyl-phenyl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (6-hydroxy-pyridin-2-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (5-Methyl-pyrazin-2-yl) - [1,2,] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1- [(R) -2- (5-quinoxalin-2-yl- [1,2,4] oxadiazol-3-yl) -piperidin-1-yl] - Etanona, 1-. { (R) -2- [5- (3-methanesulfonyl-phenyl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (6-chloro-pyridin-3-yl) - [1, 2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l- [(R) -2- (5-benzothiazol-6-yl- [1, 2, 4] oxadiazol-3-yl) -piperidin-l-yl] -2-phenoxy- ethanone, 2-phenoxy-1-. { (R) -2- [5- (2,4,5-Trifluorophenyl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -etanone, 2-phenoxy-1-. { (R) -2- [5- (6-trifluoromethyl-pyridin-3-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1-yl} -etanone, 1- [(R) -2- (5-benzo [1, 2, 3] thiadiazol-5-yl- [1,2, 4] oxadiazol-3-yl) -piperidin-1-yl] - 2-phenoxy-ethanone, l- [(R) -2- (5- [1, 8] naphthyridin-2-yl- [1,2,4] oxadiazol-3-yl) -piperidin-1-yl] - 2-phenoxy-ethanone, l - [(R) -2- (5- [1, 6] naphthyridin-2-yl- [1, 2,4] oxadiazol-3-yl) - piperidin-l-yl] -2-phenoxy-ethanone, l- [(R) -2- (5-cinolin-4-yl- [1,2,4] oxadiazol-3-yl) -piperidin-l-yl ] -2-phenoxy-ethanone, l-. { (R) -2- [5- (1H-Benzotriazol-5-yl) - [1, 2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (1H-benzoimidazol-5-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (3,6-dichloro-pyridazin-4-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 6-. { 3 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl} -4H-benzo [1,] oxazin-3-one, l-. { (R) -2- [5- (3H-imidazo [4, 5-b] pyridin-6-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, N- (4- { 3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,4,4] oxadiazole-5- il.} - pyridin-2-yl) -acetamide, l-. { (R) -2- [5- (6-Chloro-3-hydroxy-pyridazin-4-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 6-. { 3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl} -1,4-dihydro-quinoxaline-2,3-dione, l-. { (R) -2- [5- (6-hydroxy-pyridin-3-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 7-. { 3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl} -3,4-dihydro-lH-quinoxalin-2-one, 1-. { (R) -2- [5- (6-Amino-pyridin-2-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 6- { 3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl} -nicotinonitrile, 5-. { 3 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-5-yl} -pyridine-2-carbonitrile, 4-. { 3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl} -l, 2-dihydro-indazol-3-one, l-. { (R) -2- [5- (2-Amino-pyridin-4-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (6-hydroxy-pyrimidin-4-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 4- (3- { 3 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazole-5- il.}. phenyl) -2,4-dihydro- [1,2,4] triazol-3-one, 1- (3. {3. 3 [(R) -1- (2-phenoxy-acetyl ) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl.} - phenyl) -imidazolidine-2,4-dione, 1- ((R) -2-. [3- (1, l-dioxo-l6-isothiazolidin-2-yl) -phenyl] - [1,2,4] oxadiazol-3-yl.} - piperidin-1-yl) -2-phenoxy -etanone, l- (3- { 3 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl}. phenyl) -pyrrolidin-2-one, l- (3- { 3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazole -5-yl.}.-Phenyl) -l, 3-dihydro-imidazol-2-one, 3- (3- (3 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2- il] - [1, 2,4] oxadiazol-5-yl.} - phenyl) -imidazolidine-2,4-dione, l- { (R) -2- [5- (l-methyl-lH -pyrazol-3-yl) - [1,2,4] oxadiazole- 3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1-. { (R) -2- [5- (lH-pyrazol-3-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1-yl} -etanona, 1-. { (R) -2- [5- (5-Methyl-isoxazol-3-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (2,5-Dimethyl-2H-pyrazol-3-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (5-Methyl-2H-pyrazol-3-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone and l-. { (R) -2- [5- (3-Methyl-isoxazol-5-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, and the pharmaceutically acceptable salts and esters thereof. Other especially preferred compounds of the formula (I) are those selected from the group consisting of: 2-methyl-5. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -3H-pyrimidin-4-one, 1-. { (R) -2- [3- (5-Methyl-isoxazol-3-yl) - [1, 2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1-. { (R) -2- [3- (1H-pyrazol-3-yl) - [1, 2, 4] oxadiazol-5-yl] -piperidin-1-yl} -etanona, 1-. { (R) -2- [3- (6-Amino-pyridin-3-yl) - [1,4,2] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 5-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl} -l, 3-dihydro-indol-2-one, l-. { (R) -2- [5- (2-Amino-pyridin-4-yl) -2 H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 6-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl} -4H-benzo [1,4] oxazin-3-one, l-. { (R) -2- [5- (6-Amino-pyridin-3-yl) -2 H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-f enoxi-ethanone, l-. { (R) -2- [5- (lH-benzoimidazol-5-yl) -2 H- [1, 2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, N- (2-fluoro-5- (5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1,2,4] triazol-3-yl.}. phenyl) -acetamide and l- { (R) -2- [5- (2-hydroxy-pyridin-4-yl) - [1,2,4] oxadiazole-3 -yl] -piperidin-1-yl.} -2-phenoxy-ethanone, and pharmaceutically acceptable salts and esters thereof It will be appreciated that the compounds of the general formula (I) of this invention can be derivatized in their groups The invention also relates to a process for the preparation of compounds of the formula (I) defined above, the compound consists of the reaction of a compound of the formula (II) with a compound of the formula (III ' wherein R1, R2, R3, R4, R5, R6, R7 and X have the meanings defined in any one of claims 1-22 and L is halogen. The reaction of a compound of the formula (II) with a compound of the formula (III) can be carried out under conditions well known to those skilled in the art. Such reactions can be carried out, for example, by mixing a compound of the formula (II), for example, with an acid chloride of the formula (III) or alternatively with an activated ester thereof., a compound of the formula (III) in a solvent, eg DMF, at appropriate temperatures, between 25 ° C and 120 ° C, optionally in the presence of diisopropylethylamine. Preferably, L is Cl. Alternatively, L can be an active ester. The active esters as well as their use to form amide bonds are well known to those skilled in the art. The present invention also relates to compounds of the formula (I) defined above, when they are obtained by the process just described. The compounds of the formulas (I), (II) and (III) can - 5 - obtained by methods known in the art or by methods described below or by similar methods. Unless otherwise indicated, R1, R2, R3, R4, R5, R6, R7 and X have the meanings defined above. The compounds of the formula (I) can be obtained according to the following general methods. Reaction scheme 1 The compounds of the general formula 1 are preferably dissolved in DMF and 1 equivalent of activating reagent is added, for example TBTU. The reaction mixture was stirred at room temperature for 10 min and the corresponding hydroxyamidine (compound 2) was added to obtain the compounds of the general formula 3. heat the reaction mixture to 80 ° C and stir overnight or treat in a microwave at 120 ° C for 15-30 minutes to obtain compound 4. After evaporating the solvent and extracting with ethyl acetate / water it is treated the crude material with trifluoroacetic acid alone or 4N HCl in dioxane, to obtain the compounds of the general formula 5. The final product is obtained by treating these intermediate compounds with phenoxy chloride or derivatives thereof or with the corresponding active esters. The corresponding N-methylpiperazine derivatives are generated from the piperazines in the manner indicated in reaction scheme 2. Reaction scheme 2 1 The type 1 compounds are dissolved, preferably in DMF and are treated with an excess of formaldehyde and a catalytically sufficient amount of acetic acid. The reaction mixture was stirred at room temperature for 30 minutes and 1 equivalent of NaBH 3 CN was added. The mixture is stirred The reaction was carried out at room temperature for 16 h and the product was isolated by chromatography. The carboxylic acid analogues are generated from the corresponding esters by conventional saponification with NaOH or LiOH or by catalytic debenzylation processes, in which the starting material is dissolved for example in methanol and an aqueous solution is added thereto. of NaOH or LiOH. The reaction mixture is stirred, preferably at room temperature for 2 h, and the product is extracted with ethyl acetate / water after the reaction mixture has been acidified. The carboxyamide analogs are generated from the corresponding carboxylates by preactivation with reagents, such as TBTU, in DMF. Normally, the reaction mixture is stirred at room temperature overnight. The primary carboxyamide analogues are generated from the corresponding carboxylates by addition to a Rink resin and subsequent cleavage with TFA by preactivation of the starting material with reagents of the TBTU type. The reaction mixture is usually stirred at room temperature overnight. After washing the resin excessively with solvents of the type DMF, methanol and methylene chloride, the solid phase is treated with TFA at room temperature for 2 h. After concentrating by evaporation, the product is isolated by chromatography.

The amino derivatives are generated from the corresponding nitro analogues by a zinc-mediated reduction, in which the starting material is preferably dissolved in ethanol and saturated aqueous ammonium chloride solution. An excess of zinc powder is added, the reaction mixture is heated under reflux for a short time and then it is stirred at room temperature for 16 h. The product is isolated by extraction with ethyl acetate / water and final chromatography. The following N-amides, -sulfonamides, -carbamates and -ureas are all generated from the corresponding amino derivatives, for which the amino derivatives are preferably dissolved in DMF and the corresponding acetyl chlorides or activated esters, chlorides are added of sulfonyl or isocyanates. The reactions are carried out at room temperature. The products are isolated by chromatography. Benzonitriles are generated from the corresponding primary benzamides by treatment of the latter with trifluoroacetic anhydride as such at room temperature, preferably 16 h. The amino acids, which are not commercial products, are generated from piperazine-1,2-dicarboxylic acid 1-tert-butyl and 2-methyl by addition of acetyl chloride or methylsulfonyl chloride in THF at room temperature and subsequent saponification described before. Hydroxyamidines, which are not commercial products, are generated from the corresponding nitriles by addition of 5 equivalents of hydroxylamine monohydrochloride and 2.5 equivalents of sodium carbonate in an ethanol / water mixture (7: 3). The reaction mixture is heated at 80 ° C normally for 2 h. The product is isolated by extraction with ethyl acetate / water. Sulfonamido-hydroxyamidines which are not commercial products are obtained by the addition of 4-cyanobenzene-1-sulfonyl chloride with 2 equivalents of the corresponding amine in THF at room temperature for 16 h. After evaporation of the solvent, the product is extracted with ethyl acetate / water. The crude nitrile is treated with hydrazine in the manner described above. The 2-aminopyridino-hydroxyamidines which are not commercial products are obtained from the corresponding nitriles, in the manner described above. The nitriles are obtained from the corresponding chlorocyanopyridines after dissolving them in DMF and adding 2 equivalents of the amine. The reaction mixture is heated at 120 ° C in a microwave, usually for 30 min. The product is isolated by extraction in ethyl acetate / water after evaporating the reaction solvent. The aminoamidines are obtained from the corresponding imidoethers by the addition of 1 equivalent of hydrazine monohydrate in methanol. The product is isolated by precipitation by adding 1.25 M HCl in methanol. The imino ethers are obtained from the corresponding nitriles after having been suspended in methylene chloride and saturated with HCl gas at 0 ° C for 30 min. The reaction mixture was stirred at room temperature for 16 h, add diethyl ether and filter the product. The nitriles which are not commercial products are obtained from the corresponding primary amides by addition of the trifluoroacetic anhydride as such at room temperature, preferably for 16 h. Reaction scheme 3 1 4 X = CH2, O, N In addition, as described in reaction scheme 3, the compounds of the general formula 1 can be preferably dissolved in DMF and then 1 equivalent of activating reagent, for example the TBTU, and 1 equivalent of a base are added. , for example, DIPELA. The reaction mixture is cooled to 0 ° C and an excess of hydrazine is added. The reaction mixture was heated and stirred at room temperature to obtain compound 2. After evaporation of the solvent and extraction with ethyl acetate / water, the crude material was treated with 1 equivalent of the corresponding amidine in DMF. HE add a catalytic amount of acetic acid and heat the reaction mixture at 120 ° C overnight to obtain the compounds of the general formula 4. After evaporation of the solvent and extraction with ethyl acetate / water, trifluoroacetic acid is added. or 4N HCl in dioxane, obtaining the compounds of the general formula 5. The final product is obtained by treating these intermediate compounds with phenoxyacetyl chloride or derivatives thereof or with their corresponding active esters. Reaction scheme 4 On the other hand, as described in reaction scheme 4, compound 1 can be dissolved preferably in aqueous ethanol and treated with an excess of hydrazine hydrochloride and a base of the sodium carbonate type to obtain compound 2. This intermediate compound can be reacted with 1 equivalent of preactivated carboxylate or its corresponding acetyl chloride in solvents of the DMF type to obtain the compounds of the general formula 3. The cyclization to obtain the corresponding oxadiazole is carried out at elevated temperature, either by conventional heating, or in a microwave. The removal of the Boc protecting group is usually carried out with TFA as such or with 4N HCl in dioxane, obtaining the compounds of the general formula 5. The final product is obtained by treatment of these intermediates with phenoxyacetyl chloride or derivatives thereof or its derivatives. corresponding active esters. The corresponding salts can be obtained by standard methods, already known to those skilled in the art, for example by dissolving the compound of the formula (I) in an appropriate solvent, for example dioxane or THF, and adding the appropriate amount of the corresponding acid. The products can usually be isolated by filtration or by chromatography. The conversion of the compounds of the formula (I) to pharmaceutically acceptable esters can be effected, for example, by treatment of a carboxy group present in the molecule with a suitable alcohol, using, for example, a condensation reagent of the benzotriazole hexafluorophosphate type. -1-Ixyloxy (dimethylamino) phosphonium (BOP), N, N-dicyclohexylcarbodiimide (DCC), N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (EDCI) or O- (1,2-dihydro) tetrafluoroborate -2-oxo-l-pyridyl) -N, N, N, N- tetra-methyluronium (TPTU). The pharmaceutically acceptable esters can be further obtained by treatment of a suitable hydroxy group, present in the molecule, with an appropriate acid, optionally or if necessary in the presence of a condensing agent as mentioned above. Assuming that their preparation is not described in the examples, the compounds of the formula (I) as well as all the intermediates can be obtained according to similar methods or according to methods already described above. The starting materials are commercial products, are known compounds of the art or compounds that can be obtained by methods already known in the art or similar to them. As described above, it has been observed that the compounds of the present invention inhibit the carnitine-palmitoyl-transferase 1 activity of the liver (L-CPT1). The compounds of the present invention can therefore be used in the treatment and / or prophylaxis of diseases modulated by inhibitors of L-CPTl, in particular diseases related to hypergiukaemia and / or glucose tolerance disorders. Such diseases include, for example, diabetes and associated pathologies, diabetes mellitus not dependent on insulin, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, disease - Fatty liver, atherosclerosis, congestive heart failure and renal failure. Accordingly, the invention also relates to pharmaceutical compositions containing a compound defined above and a pharmaceutically acceptable carrier and / or adjuvant. The invention also encompasses compounds described above for use as therapeutically active substances, especially as therapeutically active substances for the treatment and / or prophylaxis of diseases modulated by inhibitors of L-CPTl, in particular as therapeutically active substances for the treatment and / or prophylaxis of hyperglycemia, glucose tolerance disorders, diabetes and associated pathologies, diabetes mellitus not dependent on insulin, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure. In another preferred embodiment, the invention relates to a method for the therapeutic and / or prophylactic treatment of diseases modulated by inhibitors of L-CPTl, in particular to the therapeutic and / or prophylactic treatment of hypergiukaemia, glucose tolerance disorders. , diabetes and associated pathologies, diabetes mellitus not Insulin dependent, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure, the method consists in administering a compound defined before to a human being or to an animal. The invention also encompasses the use of compounds defined above for the therapeutic and / or prophylactic treatment of diseases modulated by inhibitors of L-CPTl, in particular to the therapeutic and / or prophylactic treatment of hypergiukaemia, glucose tolerance disorders, diabetes and associated pathologies, diabetes mellitus not dependent on insulin, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure. The invention also relates to the use of compounds described above for the manufacture of medicaments for the therapeutic and / or prophylactic treatment of diseases modulated by inhibitors of L-CPTl, in particular to the therapeutic and / or prophylactic treatment of hypergiukaemia, disorders of tolerance of glucose, diabetes and associated pathologies, diabetes mellitus not dependent on insulin, obesity, hypertension, syndrome of insulin resistance, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure. The medicines contain compound already described in previous pages. The preferred indication is the prevention and / or treatment of hyperglycemia and diabetes mellitus not dependent on insulin. The following tests are carried out in order to determine the activity of the compounds of the present invention. Information regarding the tests performed can be found in: Jackson et al., Biochem. J. 341, 483-489, 1999 and Jackson et al., J. Biol. Chem. 27J3, 19560-19566, 2000. The human liver and muscle CPT1 cDNAs and the rat CPT2 cDNAs are subcloned pGAPZB and pGAPZA, respectively. These plasmids are used to transform P. pastoris strain X-33 by electroporation after obtaining electrocompetent cells. Clones of very high number of copies are selected, if necessary using 0.5 or 1 mg / ml zeocin. Cultures are induced for activity measurements for 16 h in YPD medium (1% yeast extract, 2% peptone, 2% glucose). The crude cell extracts are prepared by breaking the cells with glass spherules or with the French press, depending on the sizes of the fermenter. After centrifugation they are suspended from new cell-free extracts in a cell disruption buffer (50 mM Tris, pH = 7.4, 100 mM KCl, 1 mM EDTA) in the presence of a cocktail of protease inhibitors, then divided into aliquots and frozen to - 20 ° C. The activity of the CPT is measured by a spectrophotometric assay using 5,5 '-dithio-bis- (2-nitrobenzoic acid) (DTNB), also called Ellman's reagent. HS-CoA released during the formation of acylcarnitine from carnitine (500 μM) and palmitoyl-CoA (80 μM) reduces DTNB (300 μM) by forming the 5-mercapto- (2-nitrobenzoic acid) that absorbs 410 nm with a molar extinction coefficient of 13600 M ^ .cpf1. The assay buffer contains 120 mM KCl, 25 mM Tris, pH = 7.4, 1 mM EDTA. This test is carried out for the identification of selective inhibitors of the isoform of the CPT1 of the liver against the isoforms of the CPT1 and CPT2 of the muscle. The compounds of the formula (I) preferably have an IC50 value of less than 10 μM, preferably from 10 nM to 10 μM, more preferably from 10 nM to 5 μM. The following table shows the data corresponding to the compounds of some examples.

The compounds of the formula I and / or their salts Pharmaceutically acceptable substances can be used as medicaments, eg in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, eg in the form of tablets, coated tablets, dragees, hard or soft gelatine capsules, solutions, emulsions or suspensions, rectally, eg in the form of suppositories, parenterally, P-ex. in the form of injectable solutions or suspensions or solutions for infusion, or topically, eg in the form of ointments, creams or oils. Oral administration is preferred. The production of the pharmaceutical preparations can be carried out in a manner that will be familiar to any person skilled in the art, which consists in incorporating the described compounds of the formula I and / or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a form of galenic administration together with solid or liquid carrier materials, suitable, non-toxic, inert, therapeutically compatible, and, if desired, with the usual pharmaceutical adjuvants. The ideal carrier materials are not only the inorganic carrier materials, but also the organic carrier materials. For example, they can be used as carrier materials for tablets, tablets Coated, coated and hard gelatine capsules lactose, corn starch and its derivatives, talc, stearic acid and its salts. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semisolid and liquid polyols (however, depending on the nature of the active ingredient, the use of carriers may not be necessary. in the case of soft gelatine capsules). The suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. The suitable carrier materials for the injectable solutions are, for example, water, alcohols, polyols, glycerin and vegetable oils. The suitable carrier materials for suppositories are, for example, natural or hydrogenated oils, waxes, fats and semi-liquid and liquid polyols. The suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives. As pharmaceutical adjuvants, the usual stabilizers, preservatives, wetting agents and emulsifiers, the agents that improve the Or - consistency, aroma, salts to vary the osmotic pressure, buffer substances, solubilizers, dyes and masking agents as well as antioxidants. The dosage of the compounds of the formula I can vary within wide limits depending on the disease to be controlled, the age and individual state of health of the patient and the mode of administration and will obviously have to be adjusted to the individual requirements in each particular case . For adult patients, a daily dosage of 1 to 2000 mg, especially 1 to 500 mg, is taken into consideration. Depending on the dosage it is convenient to administer the daily dose divided into several dosage units, eg in 1-3 sub-doses. The pharmaceutical preparations conveniently contain from 1 to 500 mg, preferably from 1 to 200 mg, of a compound of the formula I. The following illustrative examples serve to describe the present invention in greater detail. However, in no way is intended to limit the scope of the same. Ex emplos Example 1 (R) -l-. { 2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone Step 1: (R) -2-. { [hydroxyimino- (4-methoxy-phenyl) -methyl] -carbamoyl} -piperidine-1-tert-butyl carboxylate 23 mg (0.1 mmol) of Boc-D-pipecolic acid are treated for 10 min with 0.1 mmoles of [dimethylamino- ([1, 2, 3] triazolo hexafluorophosphate [4,5] -b] pyridin-3-yloxy) -methylene] -dimethyl-ammonium (HATU) and diisopropylamine (DIPEA) in 1 ml of dimethylformamide (DMF). 17 mg (0.1 mmol) of N-hydroxy-4-methoxy-benzamidine are added and the reaction mixture is stirred at room temperature for 20 min. The product is not characterized more. Step 2: (R) -2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidine-1-carboxylic acid tert-butyl ester The crude material of the step 1 at 80 ° C for 16 h or it is heated at 120 ° C in a microwave for a short time (10 min). The DMF is evaporated and the product extracted with ethyl acetate / water. The product is not characterized more. Step 3: (R) -2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidine trifluoroacetate The crude material from step 2 is treated with trifluoroacetic acid ( TFA) as such at room temperature for 1 h. The TFA is evaporated. The crude product is not characterized more. Step 4: 2 - (R) -1-. { 2- [3- (4-methoxy-phenyl) - [1,2,] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone The crude material from step 3 is dissolved in 1 ml of DMF and 0.1 mmol of DIPEA. 0.1 mmol phenoxyacetyl chloride is added and the reaction mixture is stirred at room temperature for 30 min, or the corresponding derivatives of the phenoxyacetic acid derivatives are preactivated with HATU / DIPEA in DMF for 10 min and added to the raw material from step 3 The product is isolated by preparative high performance liquid chromatography (HPLC). MS (ISO) = 394.4 (MH +). In a similar manner, the following compounds are obtained. Table 1 - - - - Example 164 4-. { 5- [4-methi 1-1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzamide 0.1 mmoles of 4- are dissolved. { 5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -benzamide in 1 ml of DMF and 1 eq. of DIPEA and Na2C03. To this suspension is added 1 eq. of Mel and the reaction mixture was stirred at room temperature overnight. The product is isolated by preparative HPLC. MS (ISO) = 422.4 (MH +) The following compounds are similarly obtained.

Table 2 Example 179 (R) -4- acid. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzoic. 4 mmoles of (R) -4- are dissolved. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -benzyl benzoate in MeOH, treated with Pd / C and subjected to hydrogen pressure (3 bar) and stir for 30 min. The catalyst is removed by filtration and the solvent is evaporated. After extraction with ethyl acetate / water, the resulting oil is purified by preparative HPLC. The corresponding alkyl esters are treated with a 2N aqueous solution of NaOH or LiOH in methanol at room temperature. The allyl ester can be decomposed using Pd (Ph3) 4 as a catalyst and morpholine as the nucleophile. MS (ISO) = 408.5 (MH +). In a similar manner, the following compounds are obtained. Table 3 Example 194 (R) -l- (2- { 3- [4- (morpholine-4-carbonyl) -phenyl] - [', 2,4] oxadiazol-5-yl}. -piperidin-1 -yl) -2-phenoxy-ethanone 10 mM 0.07 mmoles of (R) -4- (5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2, 4] oxadiazol-3-yl] .benzoic acid with 1 eq of TBTU / DIPEA in 1 ml of DMF and 2 eq of morpholine are added, then the reaction mixture is stirred at room temperature overnight and isolated the product by preparative HPLC, MS (ISO) = 477.6 (MH +). The following compounds are similarly obtained.

Example 231 (R) -4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzamide 34 mg of (R) - - acid are treated. { 5- [1 - (2-f-enoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -benzoic with 1 eq. of HATU / DIPEA in DMF and are added on 1 eq. of Rink resin. The reaction mixture was stirred at room temperature overnight. The resin is washed with DMF, MeOH, DCM (3 times each) and then treated with TFA / DCM (1: 1) for 2 h. The resulting yellow oil is purified by preparative HPLC. MS (ISO) = 407.5 (MH +). In a similar manner, the following compounds are obtained.

Table 5 Example 239 (R) -l-. { 2- [3- (3-Amino-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone The (R) -1- is dissolved. { 2- [3- (3-nitro-phenyl) - [1,4,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone in 100 ml of MeOH. 50 ml of sat solution is added. of NH4C1 and Zn powder. The suspension is heated under reflux for a short time and stirred for 30 min. After filtration, the MeOH is evaporated and the product is isolated by extraction with ethyl acetate / water. MS (ISO) = 379.5 (MH +) Example 240 (R) -l-. { 2- [3- (4-Amino-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone The (R) -1- (2- [3- (4-nitro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl is dissolved. -2-phenoxy-ethanone in 100 ml of MeOH, 50 ml of saturated NH4C1 and Zn sat solution are added, the suspension is heated under reflux for a short time and stirred for 30 min. evaporate the MeOH and isolate the product by extraction with ethyl acetate / water MS (ISO) = 379.5 (MH +) .Example 241 (R) -l- { 2- [5- (3-amino-phenyl) -2H- [1,2, 4] triazol-3-yl] -piperidin-1-yl.} -2-phenoxy-ethanone The (R) -1- is dissolved. { 2- [5- (3-nitro-phenyl) -2 H- [1, 2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone in 100 ml of MeOH. 50 ml of sat solution is added. of NH4C1 and Zn powder. The suspension is heated under reflux for a short time and stirred for 30 min. After filtration, the MeOH is evaporated and the product is isolated by extraction with ethyl acetate / water. MS (ISO) = 378.5 (MH +).

Example 242 (R) -N- (3-. {5- [l- (2-f-enoxy-acetyl) -piper-idin-2-yl] - [1,2,4] oxadiazol-3-yl}. .-phenyl) -acetamide 1 mmol of (R) -1 - is dissolved. { 2 - [3 - (3-amino-phenyl) - [1, 2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone in THF. 2 eq. of DIPEA. The reaction mixture was cooled to 0 ° C. 1 eq. Is added dropwise. of acetyl chloride in THF and the reaction mixture was stirred for 30 min. The product is isolated by extraction with ethyl acetate / water and subsequent purification by preparative HPLC. MS (ISO) = 421.5 (MH +). The following compounds are obtained by a similar method using as reagents acetyl chloride, mesyl chloride, allyl chloroformate or ethyl isocyanate.

Table 6 Example 252 (R) -3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2,4] triazol-3-yl} -benzonitrile 1.3 min. of the (R) -3- are treated at room temperature overnight. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1 H- [1, 2, 4] triazol-3-yl} -benzamide with trifluoroacetic anhydride alone. The reaction is quenched with aqueous NaHC03 and the product is extracted twice with ethyl acetate. The organic phases are washed with water / NaCl, combined, dried over Na 2 SO 4 and the solvent is evaporated. The product is purified by preparative HPLC. MS (ISO) = 388.5 (MH +).

Example 253 (R) -5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -nicotinonitrile Treat 0.15 mmoles of 5- (5- [1- (2-f-enoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazole-3 at room temperature overnight. Fig. 4-nicotinamide with trifluoroacetic anhydride The reaction is quenched with aqueous NaHC03 and the product is extracted twice with ethyl acetate, the organic phases are washed with water / NaCl, combined, dried over Na2SO4 and evaporated. The product is purified by preparative HPLC: MS (ISO) = 390.4 (MH +) Example 254 4-Acetyl-piperazine-1,2-dicarboxylic acid 1-tert-butyl 10 mmoles of piper az ina-1 are dissolved, 2-Dicarboxylate of 1 - 1 er t-butyl and 2-methyl in 20 ml of methylene chloride: 1.05 eq of DIPEA and acetyl chloride are added.The reaction mixture is stirred at room temperature for 30 min. The product is extracted with ethyl acetate / water, the crude material is dissolved again in methanol and treated with 2N NaOH. The reaction mixture was stirred at room temperature for 2 h. The mixture is neutralized with HCl and the product is isolated by extraction with ethyl acetate / water.

MS (ISO) = 271.3 (M-H +). EXAMPLE 255 4-Methanesulfonyl-piperazine-1,2-dicarboxylic acid 1-tert-butyl 10 mmoles of piper-azine-1, 2-di carboxylate of 1-1 ert-butyl and 2-methyl are dissolved in 20 ml of methylene chloride. They are added 1.05 eq. of DIPEA and mesyl chloride. The reaction mixture was stirred at room temperature for 30 min. The product is extracted with ethyl acetate / water. The crude material is dissolved again in methanol and treated with 2N NaOH. The reaction mixture was stirred at room temperature for 2 h. The mixture is neutralized with HCl and the product is isolated by extraction with ethyl acetate / water. MS (ISO) = 307.4 (M-H +). Example 256 N-hydroxy-4-sui famoyl-benzamidine 1 mmol of 4-cyano-benzenesulfonamide is dissolved in an ethanol / water mixture (7: 3) and 5 eq. of hydroxylamine hydrochloride and 2.5 eq. of Na2C03. The suspension is heated at 80 ° C for 2 h. After evaporation of the solvent mixture, the resulting material is extracted with ethyl acetate / water. The product is not characterized more. MS (ISO) = 216.3 (MH +).

All the following falls are obtained by a similar method. Table 7 Example 297 N-Hydroxy-4-methyl-sulphamoyl-1-benzamidine 5 mmoles of 4-cyano-benzenesulfonyl chloride in 10 ml of THF are dissolved. 10 ml of a 2M solution of methylamine in THF are added dropwise. The reaction mixture was stirred at room temperature overnight. The solvent is evaporated and the product extracted with ethyl acetate / water. The resulting nitrile is treated in a manner similar to that described in Example 231. MS (ISO) = 230.5 (MH +). All the following compounds are obtained in a similar manner. Table 8 EXAMPLE 303 6- (1,1-dioxo-thiomorpholin-4-yl) -N-hydroxy-nicotinamidine 10 mmoles of 6-Cl-4-CN-pyridine are dissolved in 10 ml of DMF. 20 mmoles of morpholine are added and the reaction mixture is heated at 120 ° C in a microwave for 20 min. The DMF is evaporated and the crude material is extracted into ethyl acetate / water. After evaporation, the resulting solid is treated with 30 mmol of meta-chloroperbenzoic acid in DCM at room temperature overnight, the resulting precipitate is filtered and recrystallized from MeOH. The resulting nitrile is treated in a manner similar to that described in Example 231. MS (ISO) = 271.5 (MH +). In a similar manner, the following compounds are obtained. Table 9 - Example 312 4-Fluoro-N-amino-benzamidine hydrochloride 82 mmoles of methyl 3-cyanobenzoate are dissolved in 50 ml of a saturated solution of HCl in methylene chloride and 50 ml of methanol. Cooling with an ice bath, gaseous HCl is bubbled through the solution to keep the temperature below 20 ° C. The reaction mixture was stirred overnight at room temperature. 100 ml of diethyl ether are added, the resulting solid is filtered, washed with diethyl ether and dried with vacuum. The resulting imidoether is extracted with ethyl acetate / aqueous sodium bicarbonate solution, forming an oily residue. This is taken up in 25 ml of methanol and treat with 1 ml of hydrazine monohydrate at room temperature overnight. The solution is poured slowly onto a cold solution of 4N HCl in dioxane. 80 ml of diethyl ether are added and the suspension is stirred at room temperature for 30 min. The solid is filtered, washed with diethyl ether and dried with vacuum. The product is confirmed by EM. MS (ISO) = 194.4 (MH +). In a similar way, the following compounds are obtained: Table 10 - - Example 327 Allyl 6-cyano-nicotinate 4 mmoles of 6-cyanonicotinic acid are dissolved in THF. 1.5 eq. of Cs2C03 and the reaction mixture was stirred for 10 min. 1.5 eq. allyl bromide and a catalytically sufficient amount of Kl and the reaction mixture is heated at 100 ° C for 4 h. The product is isolated by extraction with ethyl acetate / water. MS (ISO) = 222.5 (MH +). EXAMPLE 328 lH-benzotriazole-5-carbonitrile 10 mmoles of 3,4-diamino-benzonitrile in water / acetic acid (4: 1) are suspended and cooled to 0 ° C. Dissolve 1.05 eq. of NaN02 in water and added in 30 min. The reaction mixture was stirred at room temperature overnight. The precipitate is filtered, washed with ether and dried with vacuum. The intermediate compound is not further characterized. Example 329 6-benzyloxy-nicotinonitrile 20 mmoles of 6-chloro-nicotinonitrile are dissolved in - - THF They are added 1.1 eq. of benzyl alcohol. The reaction mixture was cooled to 0 ° C and maintained under an argon atmosphere. Slowly add 4 eq. of NaH. After 15 min the product is isolated by extraction with ethyl acetate / water. MS (ISO) = 211.5 (MH +). Example 330 N- (5-Cyano-pyridin-2-yl) -acetamide 8 mmoles of 6-amino-nicotinonitrile are dissolved in THF. 2 eq. of DIPEA. The reaction mixture was cooled to 0 ° C, 1.0 eq. of acetyl chloride in THF and the reaction mixture was stirred for 2 h. The product is isolated by extraction with ethyl acetate / water. MS (ISO) = 162.2 (MH +). Example 331 N- (4-Cyano-pyridin-2-yl) -acetamide 8 mmoles of 2-amino-isonicotinonitrile are dissolved in THF. They are added 2 eq. of DIPEA. The reaction mixture was cooled to 0 ° C, 1.0 eq. of acetyl chloride in THF and the reaction mixture was stirred for 2 h. The product is isolated by extraction with ethyl acetate / water. MS (ISO) = 162.2 (MH +). The following compounds are obtained by a method similar to that described in example 1. - 1 8 - - 1 0 - Boc-D-pipecolic acid, 3-. { 5- [1- (2-phenoxy-acetyl) • N-amino-3-piperidin-2-yl] -1H-367 carbamidoyl-407.5 [1,2,4] triazol-3-yl acid} - phenylboronic and phenylboronic acid phenoxyacetic acid Example 368 6-. { 5 - [(R) -l- (2-phenoxy-acetyl) -piper? Din-2-yl] -1H- [l, 2,4] triazol-3-yl} -4H-benzo [1,4] oxazin-3-one Step 1: tert-butyl-1-hydrazinocarbonyl-piperidine-l-carboxylate 3 g of (R) -piperidine-1,2-dicarboxylate of 1-tert are dissolved -butyl in 30 ml of DMF. 5 g of HATU and 2.2 ml of DIPEA are added and the reaction mixture is cooled to 0 ° C. 4 eq. of hydrazine monohydrate in 30 ml of DMF, the reaction was heated to t. amb and it is stirred for 1 h. The crude product is extracted with ethyl acetate / aqueous NaHCO 3 solution. MS (ISO) = 244, 3 (MH +). Step 2: 6- (5-piperidin-2-yl-lH- [1,2,4] triazol-3-yl) -4-libenzo [1,4] oxazin-3-one 1.5 mmoles of 2-hydrazinocarbonyl- are dissolved tert-butyl piperidine-1-carboxylate in 3 ml of DMF. 1 eq. of 3-oxo-3,4-dihydro-2H-benzo [1,4] oxazine-6- carboxamidine and 90 μl of acetic acid and the reaction mixture is heated at 120 ° C overnight. The solvent is evaporated and the crude product is extracted with ethyl acetate / water. The resulting oil is taken up in 15 ml of DCM and treated with 3 ml of TFA. The resulting mixture is concentrated to dryness. Step 3: 6- (5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2,4] triazol-3-yl.} -4H- benzo [1,4] oxazin-3-one The crude product from step 3 is taken up in DMF and cooled to 0 ° C. 4 eq of DIPEA and 1 eq of phenoxyacetyl chloride are added dropwise. Heat the reaction mixture to RT and stir for an additional 30 min.The product is isolated by preparative HPLC.The following compounds are obtained by a method similar to that described in Example 368.

The following compounds are obtained by a method similar to that described in example 1.

Example 391 (3- {5- [(R) -l- (2-f-enoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl}. phenoxy) -acetic The title compound is obtained in a manner similar to that described in example 180 from (3- {5 - [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl) ] - [1, 2, 4] oxadia zol -3-i 1.} - f-enoxy) -acetic acid or methyl. MS = 436.5 (M-H +). The following compounds are obtained by a method similar to that described in example 194.

The following compounds are obtained according to the method of Example 231.

The following compounds are obtained according to the method of Example 242.

The following compounds are obtained according to the method of example 1.

Example 424 N- (4- (5 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl}. pyridin-2-yl) -acetamide The title compound is obtained in a manner similar to that described in Example 242 from 1- (2- [5- (2-amino-pyridin-4-yl) -2H- [ 1,2,4-triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone and acetyl chloride, EM = 421.5 (MH +). EXAMPLE 425 l- (3- (5- [ (R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl.} - phenyl) -zetidin-2-one Dissolve 75 mg of 1- { 2- [5- (3-Amino-phenyl) -2 H- [1, 2,4] triazol-3-yl] -piperidin-1-yl.} -2-phenoxy-ethanone in DMF and add 40 μl of DIPEA, add 34 mg of 3-bromo-propionyl chloride at 0 ° C, warm the reaction mixture at room temperature and stir for a further 30 min. at 120 ° C using a microwave and the product is isolated by preparative HPLC: MS (ISO) = 432.5 (MH +) Example 426 l- (3-. {5- [l- (2-phenoxy-acetyl) -piperidine) -2-il] -1H- [l, 2,4] tri azol-3-il} -phenyl) -pyrrolidine-2, 5-dione 0.1 mmol of 1- are dissolved. { 2- [5- (3-Amino-phenyl) -2 H- [1, 2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone in 1 ml of DMF and 1 eq. of succinic anhydride. The reaction mixture was stirred overnight and the intermediate was isolated (N- (3. {5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2.4 Oxadiazol-3-yl.}. phenyl) -succinnamic acid) by preparative HPLC. The isolated material is dissolved again in DMF and 1 eq. of HATU. The reaction mixture is heated at 120 ° C in a microwave. The product is isolated by preparative HPLC. MS (ISO) = 460.5 (MH +). Example 427 2-phenoxy-l- [(R) -2- (5-pyridazin-4-yl- [1, 2,4] Oxadiazol-3-yl) -piperidin-1-yl] -ethanone Step 1: (R) -2- (N-hydroxycarbamidoyl) -piperidine-1-tert-butyl carboxylate 3 g of ( R) -N-Boc-2-cyanopiperidine (14 mmoles) with 70 mmoles of hydrazine hydrochloride and 35 mmoles sodium carbonate in an ethanol / water mixture (7: 3) and heated at 50 ° C overnight. The solvent is evaporated and the crude material is extracted with ethyl acetate / water. The organic phase is dried with sodium sulfate. After evaporation a white solid is obtained in a quantitative yield.

- MS (ISO) = 244.5 (MH +). Step 2: (R) -2- (5-pyridazin-4-yl- [1,2,4] oxadiazol-3-yl) -piperidine-1-tert-butyl carboxylate 0.2 mmoles of pyridazine-4 are dissolved -carboxylic acid, HATU and diisopropylethylamine in 1 ml of DMF and stirred for 15 min. 0.2 mmoles of (R) -2- (N-hydroxycarbamidoyl) -piperidine-1-carboxylic acid tert-butyl ester are added. The reaction mixture was heated to 80 ° C and stirred overnight. The DMF is evaporated and the crude material is extracted with ethyl acetate / water. The crude product is not characterized more. Step 3: (R) 4- (3-piperidin-2-yl- [1,2,4] oxadiazol-5-yl) -pyridazine trifluoroacetate The crude material from step 2 is treated at room temperature for 1 hr. TFA only. The solvent is evaporated. The crude product is not characterized more. Step 4: 2-phenoxy-l- [(R) -2- (5-pyridazin-4-yl- [1,2,4] oxadiazol-3-yl) -piperidin-1-yl] -ethanone Dissolve the raw material from step 3 in 1 mi of DMF and 0.1 mmol DIPEA. 0.1 mmoles of phenoxyacetyl chloride are added and the reaction mixture is stirred at room temperature for 30 min, or the preactivated corresponding derivatives of phenoxyacetic acid with HATU / DIPEA in DMF for 10 min. and added to the crude material from step 3. The product is isolated by preparative high performance liquid chromatography (HPLC). MS (ISO) = 366.5 (MH +). The following compounds are obtained by a method similar to that described in example 427. - 14! The following intermediates are obtained in a manner similar to that described in Example 256.

The following compounds are obtained according to the method of Example 312.

Example 535 N- (5-cyano-2-fluoro-phenyl) -acetamide 10 mmoles of 3-amino-4-fluoro-benzonitrile are dissolved in 30 ml of THF. They are added 1.5 eq. of DIPEA and the reaction mixture was cooled to 0 ° C. 1.2 eq. Are added dropwise. of acetyl chloride, the reaction mixture was warmed to t.amb. and stir for 30 more minutes. The solvent is evaporated and the product is isolated by extraction with ethyl acetate and a saturated solution of NaHCO 3. MS (ISO) = 179.2 (MH +). Example 536 N- (3-cyano-5-fluoro-phenyl) -acetamide The title compound is obtained in a manner similar to that described in Example 535 from 3-amino-5-fluoro-benzonitrile. MS (ISO) = 179.2 (MH +). Example 537 N- (3-cyano-4-fluoro-phenyl) -acetamide The title compound is obtained in a manner similar to that described in Example 535 from 5-amino-2-fluoro-benzonitrile. MS (ISO) = 179.2 (MH +). Example 538 3-Oxo-3,4-dihydro-2H-benzo [1,4] oxazine-6-carbonitrile 24 mmoles of 4-hydroxy-3-nitrobenzonitrile are dissolved in DMF. 1.1 eq. of Cs2C03 and the reaction mixture was stirred at t.amb. for 15 min. 1.5 eq. from ethyl bromoacetate and the reaction mixture was heated at 50 ° C for 2 h. The intermediate was isolated by extraction with ethyl acetate / water. The organic phase is separated and dried with Na 2 SO 4. After evaporation the resulting solid is dissolved again in MeOH and a sat. of NH4C1 (1: 1). 8 g of powdered Zn are added and the suspension is stirred at RT. for 2 h. The solid is separated by filtration and the organic phase is concentrated. Ethyl acetate is added and the organic phase is washed with a sat. of NaHCO3. The organic phase is separated again, dried with Na 2 SO 4 and concentrated to obtain a slightly brown solid. MS (ISO) = 175.2 (MH +). Example 539 2-Oxo-l, 4-dihydro-2H-benzo [d] [1,3] oxazine-6-carbonitrile 20 mmoles of 4-amino-3-hydroxymethyl-benzonitrile are dissolved in THF. 1.2 eq. of DIPEA and the reaction mixture was cooled to 0 ° C. 3.5 eq. Are added dropwise. of ethyl chloroformate, the reaction mixture was warmed to t.amb. and it is stirred for 15 more minutes. The crude material is extracted with ethyl acetate and a sat. of NaHCO3. After separation and drying of the organic phase, the solvent is evaporated and the residue is taken up in toluene. 2.5 ml of DBU are added and the reaction mixture is refluxed for 4 h. The organic phase is extracted with water, the organic phase is separated and concentrated, obtaining a yellow oil The raw material is not characterized more. Example 540 2-Oxo-l, 2,3,4-tetrahydro-quinazoline-7-carbonitrile 24 mmoles of the hydrochloride of 2-nitro-4-chloro-benzylamine are dissolved in THF. They are added 2.2 eq. of DIPEA and the reaction mixture was cooled to 0 ° C. 3.5 eq. Are added dropwise. of ethyl chloroformate and the reaction mixture was stirred for 15 min. After extraction with ethyl acetate / sat. NaHCO 3 and concentration of the organic phase gives a slightly brown solid. This is taken up in MeOH / sat. of NH4C1 (1: 1). 6 g of Zn are added and the suspension is stirred at t.amb. for 4 h. The solid is separated by filtration, the methanol is evaporated and the product is isolated by extraction with ethyl acetate. After evaporation a light yellow solid is obtained. MS (ISO) = 174.2 (MH +). Example 541 3- (5-Oxo-l, 5-dihydro- [1, 2, 4] triazol-4-yl) -benzonitrile 2 g of 3-aminobenzonitrile are dissolved in 20 ml of MeOH. 1.8 ml of trimethyl orthoformate, methyl hydrazinecarboxylate and para-toluenesulfonic acid cat. The reaction mixture was heated at 65 ° C for 3 h.

The suspension is cooled to RT, 9 ml of a NaOMe solution are added and the reaction mixture is stirred at RT. for 2 h. Water is added and the pH is adjusted to 1 adding Aqueous HCl (25%). The resulting suspension is filtered and dried under vacuum. MS (ISO) = 187.2 (MH +). Example 542 3- (2,4-dioxo-imidazolidin-1-yl) -benzonitrile 1 g of 3-aminobenzonitrile is dissolved in 60 ml of dioxane and 0.8 ml of chloroacetyl isocyanate are added. The reaction mixture was stirred at rt. for 2 h. 2.5 ml of DBU are added and the reaction mixture is stirred at t.amb. for 40 h. The product is extracted with DCM. MS (ISO) = 202.2 (MH +). Example 543 3- (1, l-dioxo-l6-isothiazolidin-2-yl) -benzonitrile 1 g of 3-aminobenzonitrile is dissolved in 10 ml of DCM and 2.2 ml of DIPEA. 1.3 ml of 3-chloro-propane-1-sulfonyl chloride are added and the reaction mixture is stirred at RT. during one night. The organic phase is concentrated, the residue is taken up in DMF and 1.5 ml of DBU are added. The reaction mixture was stirred at rt. during one night. DCM is added and the organic phase is washed with water. The organic phase is separated, dried with Na 2 SO 4 and concentrated. MS (ISO) = 232.2 (MH +). Example 544 3- (2-Oxo-pyrrolidin-1-yl) -benzonitrile 2 g of 3-aminobenzonitrile are dissolved in 20 ml of DMF and 4.4 ml of DIPEA. The reaction mixture was cooled to 0 ° C and 2 ml of 4-chloro-butyryl chloride are added. The reaction mixture was stirred at rt. for 1 h. 5 ml of DBU are added and the reaction mixture is stirred at t.amb. during one night. DCM is added and the organic phase is washed with IN HCl and water. The organic phase is separated, dried with Na 2 SO 4 and concentrated. MS (ISO) = 187.2 (MH +). Example 545 6-Chloro-3-hydroxy-oxy-4-carboxylic acid-2-carboxylic acid 2 mmoles of 3,6-dichloropyridazine-4-carboxylic acid are treated with 8 ml of 2N aqueous NaOH and kept under reflux for 1 h . The reaction mixture is acidified to pH = 1. The resulting white solid is filtered and dried under vacuum. MS (ISO) = 173.2 (M-H +). Example 546 3- (5-Oxo-l, 5-dihydro- [1, 2, 4] triazol-4-yl) -benzoic acid 13 mmoles of 3-aminobenzoa or methyl are dissolved in 20 ml of MeOH. 12 mmoles of trimethyl orthoformate, 12 mmoles hydrocarboxylate methyl and 50 mg of p-t oluenosulphonic acid are added. The suspension is heated at 65 ° C for 48 h. 37 mmol of sodium methanolate are added and the mixture is stirred for a further 2 h. The organic phase is concentrated and water is added. The solution is acidified to pH = 1 and the resulting solid is filtered, obtaining 5.7 mmoles of product. MS (ISO) = 204.2 (M-H +). Example 547 3- (2, -dioxo-imidazolidin-1-yl) -benzoic acid 12 mmoles of ethyl 3-aminobenzoate are dissolved in 120 ml of dioxane. 1 eq. of chloroacetyl isocyanate. The reaction mixture was stirred at rt. for 1 h and then heated at 120 ° C for 2 h more. The reaction mixture was cooled to RT, then 2 eq. from DBU and shake back to t.amb. during one night. The solvent is evaporated and the residue extracted with DCM. The raw material is dissolved in 20 ml of MeOH and added 4 ml of 4N NaOH. The reaction mixture was stirred at rt. for 20h. After concentration of the organic phase, the aqueous phase is acidified to pH = 1, the resulting white solid is filtered and dried under vacuum. MS (ISO) = 219.2 (M-H +). Example 548 3- (1, l-Dioxo-l6- [1, 2,5] thiadiazolidin-2-yl) -benzoic acid 13 mmoles of methyl 3-aminobenzoate are dissolved in 20 ml of DCM and added 3 mi from TEA. 1.6 ml of 3-chloropropanesulfonyl chloride are slowly added under an argon atmosphere. The reaction mixture was stirred at rt. overnight and washed with IN HCl. The organic phase is separated, dried with Na 2 SO 4 and reduced with vacuum. HE collect the resulting residue in 16 ml of DMF and add 2.4 ml of DBU. The reaction mixture was stirred at rt. for 2 h and washed with IN HCl. The crude material is dissolved in 20 ml of MeOH and 4 ml of 2N NaOH are added. The reaction mixture was stirred at rt. for 72 h and acidified with HCl to pH = 1. The resulting white solid is filtered and dried with vacuum. MS (ISO) = 241.3 (M-H +). Example 549 3- (2-Oxo-2,3-dihydro-imidazol-1-yl) -benzoic acid 12 mmoles of ethyl 3-aminobenzoate are dissolved in 20 ml of DCM and 2 ml of TEA are added. The reaction mixture is cooled to ° C and 1.5 ml of diphosgene are added slowly. The reaction mixture was warmed to t.amb. and it is stirred for an additional 1 h under an argon atmosphere. The reaction mixture was poured onto ice, the organic phase was separated, dried over Na 2 SO 4 and concentrated in vacuo. The crude residue is taken up in 30 ml of DCM and 1.3 ml of dimethylacetal of the aminoacetaldehyde are added. The reaction mixture was stirred at rt. for 3 h. The organic phase is washed with a sat. of NaHCO 3, separated and dried with Na 2 SO 4. After evaporation of the solvent, the resulting crude material is purified by chromatography through silica gel. 200 mg of the product are dissolved in 5 ml of MeOH and 2 ml of 2N NaOH are added. The reaction mixture was stirred at rt. for 2 h, it is acidified with HCl to pH = 1 and the resulting white solid is filtered. MS (ISO) = 203.2 (M-H +). Example 550 3- (2,5-dioxo-imidazolidin-1-yl) -benzoic acid 13 mmoles of methyl 3-aminobenzoate are dissolved in ml of DCM and 1.7 ml of ethyl isocyanatoacetate are added. The reaction mixture was stirred at rt. for 1 h. The solvent is evaporated and the residue is taken up in 50 ml of acetone. 50 ml of aqueous HCl (25%) are added and heated to reflux for 8 h. After concentration of the organic phase the resulting solid is filtered, washed with water and dried with vacuum. MS (ISO) = 219.2 (M-H +). Example 551 3-Oxo-3,4-dihydro-2H-benzo [1,] oxazine-6-carboxamidine 8.7 mmol of N-hydroxy-3-oxo-3,4-dihydro-2H-benzo [1, ] oxazine-6-carboxamidine in ml of acetic acid. 5 eq. of ammonium formate and 0.05 eq. of 10% Pd on C and the reaction mixture was heated to reflux overnight. The reaction mixture was concentrated, cooled to 0 ° C and the pH was adjusted to 8 with an aqueous solution of NaOH (28% strength). The resulting solid is filtered and washed with water. MS (ISO) = 192.2 (M-H +). The following intermediate compounds are obtained in a manner similar to that described in example 551.

- - Example A Films coated with a film, containing the following ingredients, can be manufactured in conventional manner: - - Ingredients per core tablet: compound of the formula (I) 10.0 mg 200.0 mg microcrystalline cellulose 23.5 mg 43.5 mg lactose hydrated 60.0 mg 70.0 mg Povidone K30 12.5 mg 15.0 mg sodium starch glycolate 12.5 mg 17.0 mg magnesium stearate 1.5 mg 4.5 mg (core weight) 120.0 mg 350.0 mg coating film: hydroxypropyl methyl cellulose 3.5 mg 7.0 mg polyethylene glycol 6000 0.8 mg 1.6 mg talc 1.3 mg 2.6 mg iron oxide (yellow) 0.8 mg 1.6 mg titanium dioxide 0.8 mg 1.6 mg The active ingredient is screened and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water. The granulate is mixed with sodium starch glycolate and magnesium stearate and compressed to obtain cores of 120 and 350 mg, respectively. The cores are varnished with an aqueous solution / suspension of the aforementioned film. Example B In a conventional manner, capsules can be manufactured which contain the following ingredients: Ingredients per capsule compound of formula (I) 25.0 mg lactose 150.0 mg corn starch 20.0 mg talc 5.0 mg The components are sieved, mixed and packed in size 2 capsules. Example C The injectable solutions can have the following composition: compound of the formula (I) 3.0 mg polyethylene glycol 400 150.0 mg acetic acid, sufficient amount for pH 5.0 water for injectable solutions up to 1.0 mi The active ingredient is dissolved in a mixture of polyethylene glycol 400 and water for injection (one part). The pH is adjusted to 5.0 with acetic acid. The volume is adjusted to 1. 0 ml by addition of the remaining amount of water. The solution is filtered, packaged in vials using an appropriate excess and sterilized. Example D Capsules can be manufactured in conventional manner - soft gelatin containing the following ingredients: content of the capsule compound of the formula (I) 5.0 mg yellow wax 8.0 mg hydrogenated soybean oil 8.0 mg vegetable oils partialm. Hydrogen 34.0 mg soybean oil 110.0 mg capsule content: 165.0 mg gelatin capsule gelatin 75.0 mg glycerin 85% 32. 0 mg Karion 83 8. 0 mg (dry matter titanium dioxide 0.4 mg yellow iron oxide 0.1 mg) The active ingredient is dissolved in a melt of the other ingredients and the mixture is filled into soft gelatin capsules of the appropriate size. The soft gelatin capsules and their contents are treated according to the usual procedures. Example E In a conventional manner, bags containing the following ingredients can be manufactured: compound of the formula (I) 50. 0 mg lactose, powder 1015. 0 mg microcrystalline cellulose (AVICEL PH 102) 1400.0 mg sodium carboxymethyl cellulose 14.0 mg polyvinylpyrrolidone K 30 10.0 mg magnesium stearate 10.0 mg flavoring additives 1.0 mg The active ingredient is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone and water. The granulate is mixed with magnesium stearate and the flavoring additives and packaged in sachets. It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention.

Claims (7)

Claims The invention having been described as antrecede, the content of the following claims is claimed as property: 1. Compounds of the formula (I) characterized in that X is C (R8R9), NR10, O, S, S (O), S (02); R1 is phenyl optionally substituted by 1 to 3 substituents selected from the group consisting of halogen, hydroxy, lower alkyl, hydroxyalkyl, fluoralkyl, lower alkoxy and CN; R2 is hydrogen or lower alkyl; R3 and R4 independently of each other are hydrogen, halogen, lower alkyl or lower alkoxy, or R3 and R4 together are = 0 to form a carbonyl group together with the carbon atom to which they are attached; R5 and R6 independently of each other are hydrogen, halogen, lower alkyl or lower alkoxy, or R5 and R6 together are = 0 to form a carbonyl group together with the carbon atom. carbon to which they are attached; R7 is an oxadiazolyl or triazolyl, the oxadiazolyl or triazolyl are substituted by R11 and optionally substituted by R12; R8 and R9 independently of each other are hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy; or R8 and R9 are linked together and -R8-R9- is - (CH2) 2_7-to form a ring together with the carbon atom to which they are attached; R10 is hydrogen, lower alkyl, (lower alkyl) -carbonyl or lower alkylsulfonyl; R11 is aryl or heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl, pyridinyl-2-one, oxadiazolyl, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one , benzotriazolyl, imidazopyridinyl, triazolopyridinyl, tetrazolpyridinyl, benzimidazolyl, 2-oxo-2,3-dihydro-lH-indol-5-yl, pyrimidin-4-one, furanyl, thiadiazolyl, pyrazolyl, isoxazolyl, pyrimidine-2,4-dione , benzooxazin-3-one, 1,4-dihydro-benzooxazin-2-one, indolyl, thiophenyl, oxazolyl, benzooxazin-2-one, 3,4-dihydro-quinazolin-2-one, pyridazinyl, quinoxalinyl, benzothiazolyl, benzothiadiazolyl , naphthyridinyl, cinolinyl, 1,4-dihydro-quinoxaline-2,3-dione and 1,2-dihydro-indazol-3-one, the aryl or heteroaryl is optionally substituted by from 1 to 3 substituents chosen from the group consisting of lower alkyl, hydroxy, B (OH) 2, carboxy-lower alkoxy, carbamoyl-lower alkoxy, cyano, hydroxyalkyl, lower fluoroalkyl, lower alkoxy, halogen, S (02) R13, C (0) ) R14, N02, NR15R16, imidazolyl, pyrazolyl, tetrazolyl, pyrrolyl, phenyl-lower alkoxy, [1, 3, 4] oxadiazol-2-one, oxadiazolyl, triazolyl and isoxazolyl, imidazolyl is optionally substituted by lower alkyl and phenyl - lower alkoxy is optionally substituted by hydroxy, halogen, lower alkyl, lower alkoxy or fluoroalkyl lower and the pyrazolyl is optionally substituted by lower alkyl and the isoxazolyl is optionally substituted by lower alkyl; R 12 is hydrogen or lower alkyl; R 13 is lower alkyl, NR 17 R 18 or lower fluoroalkyl; R14 is OH, NR19R20, lower alkoxy, lower alkenyloxy or lower alkyl; R15 and R16 independently of each other are hydrogen, lower alkyl, (lower alkyl) -carbonyl, lower alkyl-S02, (lower alkenyloxy) -carbonyl, NH2-carbonyl, (lower alkyl) -NH-carbonyl, (lower alkyl) 2N -carbonyl or phenyl-lower alkyl, the phenyl-lower alkyl is optionally substituted by hydroxy, halogen, lower alkyl, lower alkoxy or fluoralkyl lower; or NR15R16 is a heterocyclyl selected from the group consisting of morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, 8-oxa-3-aza-bicyclo [3.2.1] octyl, piperazinyl, pyrrolidinyl, 1,1-dioxo-isothiazolidinyl, pyrrolidin-2-one, imidazolidine-2,4-dione, 2,4-dihydro [l, 2,4] triazol-3-one, pyrrolidine-2, 5-dione, azetidin-2-one and 1,3-dihydro-imidazol-2-one, the heterocyclyl is optionally substituted by lower hydroxyalkyl or (lower alkyl) -carbonyl; R17 and R18 independently of each other are hydrogen, lower alkyl, lower hydroxyalkyl, lower alkoxy-lower alkyl; or NR17R18 is morpholinyl; R19 and R20 independently of each other are hydrogen, lower alkyl, cycloalkyl, lower hydroxyalkyl, lower alkoxy-lower alkyl, (lower alkyl) 2N-lower alkyl, pyridinyl-lower alkyl or cyano-lower alkyl; or NR19R20 is a heterocyclyl selected from the group consisting of morpholinyl, pyrrolidinyl, 8-oxa-3-aza-bicyclo [3.2.1] octyl, piperidinyl, piperazinyl, piperazin-2-one, thiazolidinyl, thiomorpholinyl, 1, 3, 8 -triaza-spiro [4, 5] decane-2,4-dione and spiro (1-phthalane) -piperidin-4-yl, the heterocyclyl is optionally substituted by hydroxy, (lower alkyl) -S (02), lower alkyl , (I rent lower) -carbonyl, carboxy, carbamoyl, lower alkoxycarbonyl, cyano, phenyl, pyridinyl or lower alkoxy; and the pharmaceutically acceptable salts and esters thereof. 2. Compounds according to claim 1, characterized in that X is C (R8R9), NR10, 0, S, S (0), S (02); R1 is phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, hydroxy, lower alkyl, hydroxyalkyl, fluoralkyl, lower alkoxy and CN; R2 is hydrogen or lower alkyl; R3 and R4 independently of each other are hydrogen, halogen, lower alkyl or lower alkoxy, or R3 and R4 together are = 0 to form a carbonyl group together with the carbon atom to which they are attached; R5 and R6 independently of each other are hydrogen, halogen, lower alkyl or lower alkoxy, or R5 and R6 together are = 0 to form a carbonyl group together with the carbon atom to which they are attached; R7 is an oxadiazolyl or triazolyl, the oxadiazolyl or triazolyl is substituted with R11 and optionally substituted with R12; R8 and R9 independently of each other are hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy; or - R8 and R9 are linked together and -R8-R9- is - (CH2) 2_ - to form a ring together with the carbon atom to which they are attached; R10 is hydrogen, lower alkyl, (lower alkyl) -carbonyl or lower alkylsulfonyl; R11 is aryl or heteyl selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl, pyridinyl-2-one, oxadiazolyl, indazolyl, 1, 3-dihydro-benzimidazol-2-one, 1, 3-dihydro-indol-2- one, benztriazolyl, imidazopyridinyl, triazolepyridinyl, tetrazolepyridinyl and benzimidazolyl, the aryl or heteyl is optionally substituted with 1 to 3 substituents selected from the group consisting of lower alkyl, lower hydroxyalkyl, lower fluokyl, lower alkoxy, halogen, S (02) R13 , C (0) R14, N02, NR15R16, imidazolyl, pyrazolyl, tetrazolyl, pyrrolyl, and phenyl-lower alkoxy, imidazolyl is optionally substituted with lower and phenyl-lower alkoxy is optionally substituted with hydroxy, halogen, lower alkyl, alkoxy lower or lower fluokyl; R 12 is hydrogen or lower alkyl; R 13 is lower alkyl, NR 17 R 18 or lower fluokyl; R 14 is OH, NR 19 R 20, lower alkoxy or lower alkenyloxy; R15 and R16 independently of each other are hydrogen, lower alkyl, (lower alkyl) -carbonyl, lower alkyl S02, (lower alkenyloxy) -carbonyl, NH2-carbonyl, (lower alkyl) -NH-carbonyl , (lower alkyl) 2N-ca rbonyl or phenyl-lower alkyl, phenyl-lower alkyl is optionally substituted by hydroxy, halogen, lower alkyl, lower alkoxy or fluoro-lower alkyl; or NR15R16 is a heterocyclyl selected from the group consisting of morpholinyl, thiomorpholinyl, 1,1-dioxo iomor fol t ini it, piperidinyl, piper Idyn-2-one, piperazin-2-one, 8-oxa-3-aza- bicyclo [3.2.1] octyl, piperazinyl and pyrrolidinyl, the heterocyclyl is optionally substituted with lower hydroxyalkyl or (lower alkyl) -carbonyl; R17 and R18 independently of each other are hydrogen, lower alkyl, lower hydroxyalkyl, lower alkoxy-lower alkyl; or NR17R18 is morpholinyl; R19 and R20 independently of each other are hydrogen, lower alkyl, cycloalkyl, hydroxy-lower alkyl or lower alkoxy-lower alkyl; or NR19R20 is a heterocyclyl selected from the group consisting of morpholinyl, pyrrolidinyl and 8-oxa- 3 - . 3-aza-bicyclo [3.2.1] oct i lo, the heterocyclyl is optionally substituted by hydroxy or (lower alkyl) -S (02); and the pharmaceutically acceptable salts and esters thereof. 3. Compounds according to any of claims 1 - 2, characterized in that R1 is phenyl optionally substituted with halogen, hydroxy, hydroxyalkyl or CN. 4. Compounds according to any of claims 1 - 3, characterized in that R1 is phenyl. 5. Compounds according to any of claims 1-4, characterized in that R2 is hydrogen. 6. Compounds according to any of claims 1-5, characterized in that R3 is hydrogen. 7. Compounds according to any of claims 1-6, characterized in that R 4 is hydrogen. 8. Compounds according to any of claims 1-7, characterized in that R5 is hydrogen. 9. Compounds according to any of claims 1-8, characterized in that R6 is hydrogen. 10. Compounds according to any of claims 1-9, characterized in that R7 is - 17! wherein R11 and R12 have the meanings defined in claim 1. 11. Compounds according to any of claims 1-10, characterized in that R7 is wherein R11 and R12 have the meanings defined in claim 1. 12. Compounds according to any of claims 1-10, characterized in that R7 is wherein R11 has the meaning defined in claim 1. 13. Compounds according to any of claims 1-12, characterized in that X is C (R 8nR9) ,, NR10, O or S, in which R, R and R have the meanings defined in claim 1. 14. Compounds according to any of claims 1-13, characterized in that X is C (R8R9) or NR10, in the that R8, R9 and R10 have the meanings defined in claim 1. 15. Compounds according to any of claims 1-14, characterized in that R8 is hydrogen. 16. Compounds according to any of claims 1-15, characterized in that R9 is hydrogen. 17. Compounds according to any of claims 1-16, characterized in that R 10 is hydrogen. 18. Compounds according to any of claims 1-17, characterized in that R 11 is phenyl or a heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyridinyl-2-one, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one, benzotriazolyl and benzimidazolyl, the phenyl or heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of lower alkyl, lower hydroxyalkyl, lower fluoroalkyl, lower alkoxy, halogen, S ( 02) R13, C (0) R14, N02, NR15R16, imidazolyl, pyrazolyl, tetrazolyl, pyrrolyl and phenyl-lower alkoxy, the imidazolyl is optionally substituted with lower alkyl, characterized in that R13, R14, R15 and R16 have the meanings defined in - claim 1. 19. Compounds according to any of claims 1-18, characterized in that R11 is phenyl or a heteroaryl selected from the group consisting of pyridinyl, pyridinyl-2-one, indazolyl, 1,3-dihydro-benzimidazole. -2-one, 1,3-dihydro-indol-2-one, benzotriazolyl and benzimidazolyl, the phenyl or heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of fluoro-lower alkyl, halogen, C (0) R 14 and NR15R16, wherein R14, R15 and R16 have the meanings defined in claim 1. 20. Compounds according to any of claims 1-19, characterized in that R11 is 1H-indazol-5-yl, lH-indazol-6 -yl, 1,3-dihydro-indol-2-on-6-yl, 1,3-dihydro-benzoimidazol-2-on-5-yl, 1,3-dihydro-indol-2-on-5-yl , lH-benzotriazol-5-yl, lH-benzoimidazol-5-yl, lH-pyridin-2-on-4-yl, 4-fluoro-phenyl, 3-trifluoromethyl-phenyl, lH-benzoimidazol-5-yl, -benzamide, 5-nicotinamide, 3- (N-acetamide) -phenyl or 3- (N-methanesulfonamide) -phenyl. 21. Compounds according to any of claims 1-17, characterized in that R11 is phenyl or a heteroaryl selected from the group consisting of 2-oxo-2,3-dihydro-lH-indol-5-yl, pyrimidin-4- Ona, furanyl, thiadiazolyl, pyrazolyl, isoxazolyl, pyrimidine-2,4-dione, benzooxazin-3-one, 1,4-dihydro-benzooxazin-2-one, indolyl, thiophenyl, oxazolyl, benzooxazin-2-one, 3,4-dihydro-quinazolin-2-one, pyridazinyl, quinoxalinyl, benzothiazolyl, benzothiadiazolyl, naphthyridinyl, cinolinyl, 1,4-dihydro-quinoxaline-2,3-dione and 1, 2-dihydro-indazol-3-one, the phenyl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of hydroxy, B (OH) 2, carboxy-lower alkoxy, carbamoyl-lower alkoxy, cyano, [ 1, 3, 4] oxadiazol-2-one, oxadiazolyl, triazolyl and isoxazolyl, pyrazolyl is optionally substituted with lower alkyl and the isoxazolyl is optionally substituted with lower alkyl. 22. Compounds according to any of claims 1-17, characterized in that R11 is phenyl or a heteroaryl selected from the group consisting of pyridinyl, 1,3-dihydro-indol-2-one, lH-benzimidazolyl, 3H-pyrimidin- 4-one, lH-pyrazolyl, isoxazolyl and 4H-benzo [1,4] oxazin-3-one, the phenyl or heteroaryl is optionally substituted with from 1 to 3 substituents selected from the group consisting of lower alkyl, hydroxy, halogen and NR15R16, wherein R14 and R15 have the meanings defined in claim 1. 23. Compounds according to any of claims 1-17, characterized in that R11 is 2-methyl-3H-pyrimidin-4-one, 5-methyl-isoxazol-3-yl, lH-pyrazol-3-yl, 6-amino- pyridin-3-yl, 1,3-dihydro-indol-2-one, 2-amino-pyridin-4-yl, 4H-benzo [1,4] oxazin-3-one, lH-benzimidazole-5- ilo, 3- (N-acetamide) -4-fluoro-phenyl or 2-hydroxy-pyridin-4-yl. 24. Compounds according to any of claims 1-23, characterized in that R12 is hydrogen. 25. Compounds according to any of claims 1-24, characterized in that R13 is lower alkyl. 26. Compounds according to any of claims 1-25, characterized in that R14 is NR19R20, wherein R19 and R20 have the meanings defined in claim 1. 27. Compounds according to any of claims 1-25, characterized because R14 is lower alkyl. 28. Compounds according to any one of claims 1-27, characterized in that R15 and R16 independently of each other are hydrogen, lower alkyl, (lower alkyl) -carbonyl, lower alkyl-SO2, lower (alkanyl) -oxycarbonyl or (lower alkyl) -NH-carbonyl; or NR15R16 is a heterocyclyl selected from the group consisting of morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, piperazinyl and pyrrolidinyl, the heterocyclyl is optionally substituted with lower hydroxyalkyl or (lower alkyl) -carbonyl. 29. Compounds according to any one of claims 1-28, characterized in that R15 and R16 independently of each other are hydrogen, (lower alkyl) -carbonyl or lower alkyl-S02. 30. Compounds according to any one of claims 1-27, characterized in that NR15R16 is a heterocyclyl selected from the group consisting of 1,1-dioxo-isothiazolidinyl, pyrrolidin-2-one, imidazolidine-2,4-dione, 2,4-dihydro [1,2,4] triazol-3-one, pyrrolidine-2, 5-dione, azetidin-2-one and 1,3-dihydroimidazol-2-one, the heterocyclyl is optionally substituted with lower hydroxyalkyl or (lower alkyl) -carbonyl. 31. Compounds according to any of claims 1-30, characterized in that R17 and R18 independently of each other are hydrogen or lower alkyl; or NR17R18 is morpholinyl. 32. Compounds according to any of claims 1-31, characterized in that R19 and R20 independently of each other are hydrogen, lower alkyl, cycloalkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl; or NR19R20 is a heterocyclyl selected from the group consisting of morpholinyl or pyrrolidinyl, the heterocyclyl is optionally substituted with hydroxy or (lower alkyl) -S (02). 33. Compounds in accordance with any of the claims 1-32, characterized in that R19 and R20 are hydrogen. 34. Compounds according to any of claims 1-31, characterized in that R19 and R20 independently of each other are (lower alkyl) 2N-lower alkyl, pyridinyl-lower alkyl or cyano-lower alkyl; or NR19R20 is a heterocyclyl selected from the group consisting of piperidinyl, piperazinyl, piperazin-2-one, thiazolidinyl, thiomorpholinyl, 1, 3, 8-triaza-spiro [4, 5] decane-2, 4-dione and spiro (1 -phthalane) -piperidin-4-yl, the heterocyclyl is optionally substituted with hydroxy, (lower alkyl) -S (02), lower alkyl, (lower alkyl) -carbonyl, carboxy, carbamoyl, lower alkoxycarbonyl, cyano, phenyl , pyridinyl or lower alkoxy. 35. Compounds according to any of claims 1-34, characterized in that they are R isomers and have the formula (la) wherein R1, R2, R3, R4, R5, R6, R7 and X have the meanings defined in any one of claims 1-34. 36. Compounds according to any of claims 1-35, characterized in that they are chosen from the group consisting of: (R) -l-. { 2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -3- (2- { 2- [3- (4-methoxy-phenyl) [1, 2, 4] oxadiazol-5-yl] -piperidin-l-yl .} -2-oxo-ethoxy) benzonitrile, (R) -l-. { 2- [3- (4-methoxy-phenyl) - [1,4,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-propan-1-one, (R) -l-. { 2- [3- (4-bromo-phenyl) [1, 2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -2- (4-hydroxy-phenoxy) -l-. { 2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -etanone, (R) -2- (4-chloro-phenoxy) -l-. { 2- [3- (-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -etanone, (R) -2- (4-hydroxymethyl-phenoxy) -1-. { 2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -etanone, (R) -2- (3-chloro-phenoxy) -l-. { 2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -etanone, (R) -2- (4-fluoro-phenoxy) -l-. { 2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -etanone, (R) -l-. { 2- [3- (4-Fluoro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-methano-sulfonyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzenesulfonamide, (R) -2- (4-fluoro-phenoxy) -1- [2- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl ] -ethanone, (R) -3- (5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,4,2] oxadiazol-3-yl.} - methyl-benzoate , (R) -l- { 2- [3- (3-nitro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy- ethanone, (R) -l- { 2- [3- (4-nitro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy -etanone, (R) -3- { 5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl}. -benzenesulfonamide, (R) -2-phenoxy-l- [2- (3-pyrazin-2-yl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -ethanone, (R) -l - (2- { 3- [4- (morpholine-4-sulfonyl) -phenyl] - [1,2,4] oxadiazol-5-yl.} - piperidin-1-yl) -2-phenoxy ethanone, (R) -l- { 2- [3- (6-methoxy-pyridin-3-yl) - [1, 2, 4] oxadiazol-5-yl] -piperidin-1-yl}. -2-phenoxy-ethanone, (R) -l- { 2- [3- (3-hydroxymethyl-phenyl) - [1,2, 4] oxadiazol-5-yl] -piperidin-1-yl}. -2-phenoxy-ethanone, (R) -6- (5- [1- (2-phenoxy-acetyl) -pi peridin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -allylnicnicinate, (R) -l-. { 2- [3- (4-imidazol-1-yl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -N-methyl-4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -benzenesulfonamide, (R) -l-. { 2- [3- (6-morpholin-4-yl-pyridin-3-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -2-phenoxy-1- (2- [3- (4-trifluoromethanesulfonyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl .} - ethanone, (R) -2-phenoxy-l- { 2- [3- (4-trifluoromethyl-phenyl) - [1,2, 4] oxadiazol-5-yl] -piperidin-1- il.) .etane, (R) -l- { 2- [3- (4-chloro-phenyl) - [1,4,2-oxadiazol-5-yl] -piperidin-1-yl}. -2-phenoxy-ethanone, (R) -N- (4- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.} -2 -trifluoromethyl-phenyl) -acetamide, (R) -l-. { 2- [3- (3-methanesulfonyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-methyl-3-nitro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l- (2- [3- (4-methoxy-3-nitro-phenyl) - [1,2, 4] oxadiazol-5-yl] -piperidin-l-yl .} -2-phenoxy-ethanone, (R) -N- (2-hydroxy-ethyl) -4- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [ 1, 2, 4] oxadiazol-3-yl.}. -benzenesulfonamide, (R) -N- (2-methoxy-ethyl) -N-methyl-4- (5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.}. -benzenesulfonamide, (R) -N, N-dimethyl-4-. {5- [1- (2-phenoxy) -acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl.}. -benzenesulfonamide, (R) -N, N-diethyl-4-. {5- [1- ( 2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.} - benzenesulfonamide, (R) -l-. { 2- [3- (2-morpholin-4-yl-pyridin-4-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -2-phenoxy-1-. { 2- [3- (3,4,5,6-tetrahydro-2 H- [1,2 '] bipyridinyl-4'-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1- il} -etanone, (R) -2-phenoxy-l- (2- [3- (2-thiomorpholin-4-yl-pyridin-4-yl) - [1,2, 4] oxadiazol-5-yl] -piperidine -l-il.}.-ethanone, (R) -l- { 2- [3- (2-diethylamino-pyridin-4-yl) - [1,4,2-oxadiazol-5-yl] - piperidin-l-yl.} -2-phenoxy-ethanone, (R) -4-. {5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2,] Oxadiazol-3-yl.} - pyridine-2-carboxylic acid ethyl ester, (R) -1- (2- (3- [6- (4-acetyl-piperazin-1-yl) -pyridin-3-yl] - [1, 2,4] oxadiazol-5-yl}. -piperidin-1-yl) -2-phenoxy-ethanone, (R) -l- { 2- [3- (2-imidazole-1 -yl-pyridin-4-yl) - [1, 2,4] oxadiazol-5-yl] -piperidin-1-yl.} -2-phenoxy-ethanone, (R) -1- (3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2, 4] oxadiazol-3-yl.} - phenyl) -piperidin-2-one, (R) - 1- (2- (3- [4- (3H-imidazol-4-yl) -phenyl] - [1,2,4] oxadiazol-5-yl}. -piperidin-1-yl) -2-phenoxy -etanone, (R) -l- (2- { 3- [4- (2-methyl-imidazol-1-yl) -phenyl] - [1,2,4] oxadiazol-5-yl}. -piperidin-l-yl) -2-phenoxy-ethanone, (R) -2-phenoxy-l- { 2- [3- (2-pyrazol-l-yl-pyridin-4-yl) - [1 , 2,4] oxadiazol-5-yl] -piperidin-1-yl} -ethanone, (R) -4- (5- (5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl}. -pyridin -2-il) -piperazin-2-one, (R) -2-phenoxy-1- (2- { 3- [4- (lH-tetrazol-5-yl) -phenyl] - [1,2,4] oxadiazol-5-yl}. piperidin-1-yl) -ethanone, (R) -l-. { 2- [3- (lH-indazol-5-yl) - [1, 2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (lH-indazol-6-yl) - [1,2, 4] oxadiazol-5-yl] -piperidin-l-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-Fluoro-3-trifluoromethyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -6-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -l, 3-dihydro-indol-2-one, (R) -5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -l, 3-dihydro-benzoimidazol-2-one, (R) -5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -1, 3-dihydro-indol-2-one, (R) -l-. { 2- [3- (1H-benzotriazol-5-yl) - [1,2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (lH-benzoimidazol-5-yl) - [1,2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l- (2- { 3- [6- (l, l-dioxo-thiomorpholin-4-yl) -pyridin-3-yl] - [1, 2, 4] oxadiazol-5-yl.}. -piperidin-1-yl) -2-phenoxy-ethanone, (R) -N- (4-. {5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl}. -pyridin- 2-yl) -acetamide, (R) -l-. { 2- [3- (6-benzyloxy-pyridin-3-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -5-. { 5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2,] oxadiazol-3-yl} -nicotinate of ethyl, (R) -4-. { 5- [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1,2,4] oxadiazol-3-yl} -lH-pyridin-2-one, (R) -5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -lH-pyridin-2-one, (R) -2-phenoxy-1- [2- (5-phenyl-2H- [1, 2, 4] triazol-3-yl) -piperidin-1-yl] - ethanone, (R) -l- (2- [5- (4-methanesulfonyl-1-phenyl) -2H- [1, 2,4] triazol-3-yl] -piperidin-1-yl.} -2-phenoxy -etanone, (R) -l- { 2- [5- (3, 4-dimethoxy-phenyl) -2H- [1, 2,4] triazol-3-yl] -piperidin-1-yl}. -2-phenoxy-ethanone, (R) -l- { 2- [5- (3,4-dichloro-phenyl) -2H- [1, 2, 4] triazol-3-yl; piperidin-1 -yl.} -2-phenoxyethanone, (R) -l-. {2- 2- [5- (4-fluoro-phenyl) -2H- [1,2,4] triazol-3-yl] -piperidine- l-yl.) -2-phenoxy-ethanone, (R) -2-phenoxy-l-. {2- [5- (3-trifluoromethyl-phenyl) -2H- [1,2,4] triazole- 3-yl] -piperidin-1-yl.}.-Ethanone, (R) -l- { 2- [5- (4-methoxy-phenyl) -2H- [1,2,4] triazole-3 -yl] -piperidin-1-yl.} -2-phenoxy-ethanone, (R) -l- (2- [5- (3-nitro-phenyl) -2H- [1,2,4] triazole- 3-yl] -piperidin-1-yl.} -2-phenoxy-ethanone, (R) -3- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -lH - tl, 2, 4] triazol-3-yl.}. -methylbenzoate, (R) -l- (2- [5- (4-fluoro-3-trifluoromethyl-f enyl) -2H- [1,2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, - (R) -6-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2,4] triazol-3-yl} -l, 3-dihydro-indol-2-one, l-. { 3- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -morpholin-4-yl} -2-phenoxy-ethanone1- (3- [3- (4-methanesulfonyl-phenyl) - [1,2,4] oxadiazol-5-id morpholin-4-yl.} -2-phenoxy-ethanone, 4-. {5 - [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1,2,4] oxadiazol-3-yl.} - benzenesulfonamide, 1- (3-. {3- [6-] (1, 1-dioxo-thiomorpholin-4-yl) -pyridin-3-yl] - [1, 2,4] oxadiazol-5-yl.} - -morpholin-4-yl) -2-phenoxy-ethanone, N- (4-. {5- [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1,2,4-oxadiazol-3-yl] - pyridin-2-yl) -acetamide, l- { 3- [5- (4-methanesulfonyl-1-phenyl) -2H- [1, 2,4] triazol-3-yl] -morpholin-4-yl.} -2-phenoxy- ethanone, 2-phenoxy-l-. {3- [5- (3-trifluoromethyl-phenyl) -2H- [1, 2,4] triazol-3-yl] -morpholin-4-yl} -ethanone (R) -4- { 5- [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1,2,4] oxadiazol-3-yl.} - L-pyridine- 2-one, l- { 3- [3- (4-methoxy-phenyl) - [1, 2, 4] oxadiazol-5-yl] -thiomorpholin-4-yl.} -2-phenoxy-ethanone , 1- (3- [3- (4-methanesulfonyl-phenyl) - [1,4,4] oxadiazol-5-id thiomorpholin-4-i1.} -2-phenoxy-ethanone, 4-. {5 - [4- (2-phenoxy-acetyl ) -thiomorpholin-3-i1] - [1,2,4] oxadiazol-3-yl} -benzenesulfonamide, 2-phenoxy-l- [3- (3-pyridin-4-yl- [1, 2,4] oxadiazol-5-yl) - thiomorpholin-4-yl] -ethanone, l-. { 2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, N- (5-. {5- [l- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl}. -pyridin-2-yl) -acetamide, 1-. { 2- [3- (2-imidazol-1-yl-pyridin-4-yl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, N, N-diethyl-4-. { 5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,4,2] oxadiazol-3-yl} -benzenesulfonamide, N, N-dimethyl-4- (5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1, 2, 4] oxadiazol-3-yl.} - -benzenesulfonamide, 4- (5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl} - benzenesulfonamide, 1-. {2- [3 - (4-methanesulfonyl-phenyl) - [1, 2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1- [2- (3- pyridin-4-yl- [1,2,4] oxadiazol-5-yl) -piperazin-1-yl] -ethanone, 1- (2- [3- (2,4-dichloro-phenyl) - [1, 2,4] oxadiazol-5-yl] -piperazin-1-yl.} -2-phenoxy-ethanone, 2-phenoxy-l- [2- (3-pyridin-2-yl- [1,2,4] ] oxadiazol-5-yl) -piperazin-1-yl] -ethanone, 2-phenoxy-1- [2- (3-pyridin-2-yl- [l, 2,4] oxadiazol-5-yl) -piperazine -2-yl] -etanone, l- { 2- [3- (4-nitro-phenyl) - [1, 2, 4] oxadiazol-5-yl] -piperazin-1-yl.} -2 -phenoxy-ethanone, 1- . { 2- [3- (6-methoxy-pyridin-3-yl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 1-. { 2- [3- (6-morpholin-4-yl-pyridin-3-yl) - [1,2, 4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 1-. { 2- [3- (6-morpholin-4-yl-pyridin-3-yl) - [1, 2, 4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 1-. { 2- [3- (3-hydroxymethyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 1-. { 2- [3- (4-diethylamino-phenyl) - [1,4,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 1- (2 { 3- [4- (morpholine-4-sulfonyl) -phenyl] - [1,2,4] oxadiazol-5-yl}. -piperazin-1 -yl) -2-phenoxy-ethanone, N-methyl-4- (5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzenesulfonamide, N- (2-methoxy-ethyl) -N-methyl-4-. {5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1, 2.4 ] oxadiazol-3-yl.} - benzenesulfonamide, l-. {2- [3- (4-chloro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, N- (4-. {5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl} -2-trifluoromethyl-phenyl) -acetamide, 4-. {5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1, 2, 4] oxadiazol-3-yl} - allylbenzoate, l- { 2- [3- (4-methyl-3-nitro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl}. -2-phenoxy-ethanone, l- { 2- [3- (4-methoxy-3-nitro-phenyl) - [1,2,4] oxadiazol-5-yl] - piperazin-l-il} -2-phenoxy-ethanone, 1-. { 2- [3- (4-chloro-3-nitro-phenyl) - [1,2,] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 3-fluoro-4- (5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1, 2, 4] oxadiazol-3-yl.} - methyl benzoate, 4-. {5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,4,4] oxadiazol-3-yl} - pyridine-2-carboxylate ethyl, 2-phenoxy-l-. {2- [3- (4-piperidin-1-yl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl}. .-ethanone, l- { 2- [3- (4-morpholin-4-yl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2 -phenoxy-ethanone, 1- (2- (3- [4- (2-methyl-imidazol-1-yl) -phenyl] - [1,2,4] oxadiazol-5-yl}. -piperazin-1 -yl) -2-phenoxy-ethanone, 1- (2 { 3- [4- (3H-imidazol-4-yl) -phenyl] - [1,2, 4] oxadiazol-5-yl}. .-piperazin-l-yl) -2-phenoxy-ethanone, 4- (5-. {5- [l- (2-phenoxy-acetyl) -piperazin-2-y1] - [1,2,4] Oxadiazol-3-yl.} - pyridin-2-yl) -piperazin-2-one, 1- (2- [3- (6-imidazol-1-yl-pyridin-3-yl) - [1,2 , 4] oxadiazol-5-yl] -piperazin-1-yl.} -2-phenoxy-ethanone, 1- (2. {3- [6- (4-acetyl-piperazin-1-yl) - pyridin-3-yl] - [1,2,4] oxadiazol-5-yl.}. -piper azin-1-yl) -2-phenoxy-ethanone, 2-phenoxy-1-. { 2- [3- (4-pyrrol-1-yl-phenyl) - [1,4,4] oxadiazol-5-yl] -piperazin-1-yl} -etanone, 2-phenoxy-1-. { 2- [3- (4-trifluoromethanesulfonyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -etanone, l-. { 2- [3- (2-morpholin-4-yl-pyridin-4-yl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1-. { 2- [3- (2-thiomorpholin-4-yl-pyridin-4-yl) - [1,2, 4] oxadiazol-5-yl] -piperazin-1-yl} -etanone, l- (2- (3- [6- (3-hydroxymethyl-pyrrolidin-1-yl) -pyridin-3-yl] - [1, 2,4] oxadiazol-5-yl}. -piperazin -l-il) -2-phenoxy-ethanone, (R) -1-. { 2- [3- (6-methoxy-pyridin-3-yl) - [1,4,2] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (6-morpholin-4-yl-pyridin-3-yl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -N- (4-. {5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazole-3- il.} -2-trifluoromethyl-phenyl) -acetamide, (R) -l-. { 2- [3- (4-methyl-3-nitro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-methyl-3-nitro-phenyl) - [1, 2, 4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-morpholin-4-yl-phenyl) - [1,4,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l- (2- { 3- [4- (3H-imidazol-4-yl) -phenyl] - [1,2,4] oxadiazol-5-yl} -piperazin-1-yl) -2-phenoxy-ethanone, (R) -l- (2 { 3- [6- (3-hydroxymethyl-pyrrolidin-1-yl) -pyridin-3-yl) ] - [1, 2,4] oxadiazol-5-yl.} - piperazin-1-yl) -2-phenoxy-ethanone, (R) -l- (2-. {3- [6- (4 -acetyl-piperazin-1-yl) -pyridin-3-yl] - [1,2, 4] oxadiazol-5-yl.} - piperazin-1-yl) -2-phenoxy-ethanone, (R) -N- (3- (5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [l, 2,4] oxadiazol-3-yl}. -phenyl) -acetamide , hydrochloride, (R) -l- { 2- [3- (1H-benzoimidazol-5-yl) - [1, 2, 4] oxadiazol-5-yl] -piperazin-1-yl}. 2-phenoxy-ethanone, (R) -l-. {2- [3- (lH-benzotriazol-5-yl) - [1,2, 4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. {2- [3- (lH-indazol-5-yl) - [1,2,4] oxadiazol-5-yl] -piperazine-1 -yl.} -2-phenoxy-ethanone, hydrochloride, (R) -5- (5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazole- 3-yl.}., -1,3-dihydro-benzoimidazol-2-one, (R) -l- (2- { 3- [6- (1, 1-dioxo-thiomorpholin-4-yl) - pyridin-3-yl] - [1, 2, 4] oxadiazol-5-yl.} - piperazin-1-yl) -2-phenoxy-ethanone, hydrochloride, (R) -l-. {2- [2- 3- (3-nitro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. {2- [3- (4-fluoro-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -4-. {5 - [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl.}. -lH-py idin-2-one, l- (4-acetyl-2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, l-. { 4-Acetyl-2- [3- (4-methanesulfonyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 4-. { 5- [4-acetyl-l- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzenesulfonamide, l- [4-Acetyl-2- (3-pyridin-4-yl- [1, 2, 4] oxadiazol-5-yl) -piperazin-1-yl] -2-phenoxy-ethanone, 1-. { 4-methanesulfonyl-2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [5- (4-Fluoro-phenyl) -2H- [1,2,4] triazol-3-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) -2-phenoxy-1-. { 2- [5- (3-trifluoromethyl-phenyl) -2H- [1, 2,4] triazol-3-yl] -piperazin-1-yl} -etanona, l-. { 2- [5- (4-Fluoro-3-trifluoromethyl-phenyl) -2H- [1, 2,4] triazol-3-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 1- (2- [5- (4-methanesulfonyl-phenyl) -2H- [1,2, 4] triazol-3-yl] -piperazin-1-yl.} -2- phenoxy-ethanone, 2-phenoxy-1 -. {2- [5- (3-trifluoromethyl-phenyl) -2H- [1,2, 4] triazol-3-yl] -piperazin-1-yl}. -ethanone, 2-phenoxy-l- [2- (5-p-tolyl-2H- [1, 2, 4] triazol-3-yl) -piperazin-1-yl] -ethanone, 2-phenoxy-l- {.2- [5- (4-trifluoromethyl-phenyl) -2H- [1,2, 4] triazol-3-yl] -piperazin-1-yl}.-Ethanone, l-. {2- [5- (4-methoxy-phenyl) -2H- [1, 2, 4] triazol-3-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 1- (2- [5- (4-fluoro-phenyl) -2H- [1,2, 4] triazol-3-yl] -piperazin-1-yl.} -2-phenoxy-ethanone, 1- (2- [5- (4- fluor-phenyl) -2H- [1,2,4] triazol-3-yl] -piperazin-1-yl} -2-phenoxy-ethanone, l-. {2- [5- (3, 4 -dimethoxy-phenyl) -2H- [1,2, 4] triazol-3-yl] - 19Í piperazin-l-il} -2-phenoxy-ethanone, 1-. { 2- [5- (3, 4-dichloro-phenyl) -2 H- [1,2, 4] triazol-3-yl] -piperazin-1-yl} -2-phenoxy-ethanone, l-. { 2- [5- (2-Fluoro-phenyl) -2 H- [1, 2,4] triazol-3-yl] -piperazin-1-yl} -2-phenoxy-ethanone, l-. { 2- [5- (2-Fluoro-phenyl) -2H- [1,2,4] triazol-3-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 4- (5- [4-methyl-1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl}. benzamide, (R) -l-. {2- [3- (lH-indazol-5-yl) - [1,2, 4] oxadiazol-5-yl] -4-methyl-piperazin-1-yl}. -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-Fluoro-phenyl) - [1,2,4] oxadiazol-5-yl] -4-methyl-piperazin-1-yl} -2-phenoxy-ethanone, (R) -5- (5- [4-methyl-1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl .}.-l, 3-dihydro-indol-2-one, (R) -5- { 5- [4-methyl-l- (2-phenoxy-acetyl) -piperazin-2-yl] - [ 1, 2, 4] oxadiazol-3-yl.} - l, 3-dihydro-benzoimidazol-2-one, (R) -l- { 2- [3- (lH-benzoimidazol-5-yl) - [1,2,4] oxadiazol-5-yl] -4-methi1-piperazin-1-yl} -2-phenoxy-ethanone, (R) -l- (2- [3- (lH-benzotriazole -5-yl) - [1,2,4] oxadiazol-5-yl] -4-methyl-piperazin-1-yl.} -2-phenoxy-ethanone, (R) -l-. {4- methyl-2- [5- (3-trifluoromethyl-phenyl) -2H- [1, 2,4] triazol-3-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (R) - l-. {2- [5- (4-methoxy-phenyl) -2H- [1,2,4] triazol-3-yl] -4-methyl-piperazin-1-yl} -2-phenoxy -etanone, (R) -l-. { 2- [5- (4-fluoro-phenyl) -2H- [1,2,4] triazol-3-yl] -4-methyl-piperazin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [5- (4-methanesulfonyl-phenyl) -2H- [1,2,4] triazol-3-yl] -4-methyl-piperazin-1-yl} -2-phenoxy-ethanone, (R) -4-. { 5- [4-methyl-1- (2-phenoxy-acetyl) -piperazin-2-yl] -1H- [1, 2, 4] triazol-3-yl} methyl-benzoate, (R) -N- (3-. {5- [4-methyl-1- (2-phenoxy-acetyl) -piperazin-2-yl] -lH- [l, 2,4] triazol-3-yl.} - phenyl) -acetamide, (R) -N- (3-. {5- [4-methyl-1- (2-phenoxy-acetyl) -piperazin-2-yl] - 1 H- [1,2, 4] triazol-3-yl.}. Phenyl) -methanesulfonamide, (R) -4-. { 5- [4-methyl-1- (2-phenoxy-acetyl) -piperazin-2-yl] -1H- [1, 2, 4] triazol-3-yl} -benzamide, (R) -4- (5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [l, 2,4] oxadiazol-3-yl}. -benzoic acid, acid (R) -3- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [l, 2,4] oxadiazol-3-yl}. -benzoic acid (R ) -6- (5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl}. -nicotinic acid (R) -2- fluor-4- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,4,4] oxadiazol-3-yl}. -benzoic acid (R) - 5- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [l, 2,4] oxadiazol-3-yl.} - pyridine-2-carboxylic acid (R ) -4- { 5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.} - pyridine-2-carboxylic acid (R) -3- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2,4] triazol-3-yl} -benzoic, acid 3-. { 5- [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1,2, 4] oxadiazol-3-yl} -benzoic, acid 3-. { 5- [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1,2,4] oxadiazol-3-yl} -benzoic, 4-. { 5- [4- (2-phenoxy-acetyl) -thiomorpholin-3-yl] - [1,2,4] oxadiazol-3-yl} -benzamide, 4- (5- [4- (2-phenoxy-acetyl) -thiomorpholin-3-yl] - [1,2,4] oxadiazol-4-yl}. -benzamide, 3-. 5- [4-acetyl-1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl}. -benzoic acid, 4-. {5- [4-acetyl-l- (2-phenoxy-acetyl) -piperazin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -benzoic acid, (R) -4-. 5- [4-methyl-1- (2-phenoxy-acetyl) -piperazin-2-yl] -1H- [1,2, 4] triazol-3-yl}. -benzoic acid, (R) -5 acid - { 5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2, 4] oxadiazol-3-yl.} - -nicotinic, 1- (2- { 3- [4- (morpholine-4-carbonyl) -phenyl] - [1,2,4] oxadiazol-5-yl}. -piperidin-1-yl) -2-phenoxy-ethanone, (R) -l - (2- { 3- [4- (3-hydroxy-pyrrolidine-1-carbonyl) -phenyl] - [1,2,4] oxadiazol-5-yl}. -piperidin-1-yl) - 2-phenoxy-ethanone, (R) -N, N-diethyl-4- (5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazole-3 il.}. -benzamide, (R) -N-methyl-4- (5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzamide, (R) -N, N-dimethyl-4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzamide, (R) -N-ethyl-4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzamide, (R) -N-cyclopropyl-4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2, 4] oxadiazol-3-yl} -benzamide, (R) -N- (2-hydroxy-ethyl) -4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzamide, (R) -N- (2-methoxy-ethyl) -N-methyl-4- (5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4 ] oxadiazol-3-yl.}. -benzamide, (R) -N-methy1-3-. {5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2, 4] oxadiazol-3-yl.}. -benzamide, (R) -N, N-dimethyl-3- (5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2] ,] oxadiazol-3-yl.}. -benzamide, (R) -N-ethyl-3-. {5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2] , 4] oxadiazol-3-yl.}. -benzamide, (R) -N-cyclopropyl-3 { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2,4] oxadiazol-3-yl.} - benzamide, (R) -N- (2-hydroxy-ethyl) -3-. {5- [l- (2-phenoxy-acetyl) -piperidin-2] -yl] - [1, 2,4] oxadiazol-3-yl.}. -benzamide, (R) -N- (2-methoxy-ethyl) -N-methyl-3- { 5- [1- (2-phenoxy-acetyl) • piperidin-2-yl] - [1, 2,4] oxadiazol-3-yl.}. -benzamide, (R) -l- (2- { 3- [3- (morpholine-4-carbonyl) -phenyl] - [1, 2,4] oxadiazol-5-yl.}. -piperidin-1-yl) -2-phenoxy-ethanone, (R) -l- (2- { 3- [3- (3-hydroxy-pyrrolidine-1-carbonyl) -phenyl] - [1,2,4] oxadiazol-5-yl}. -piperidin- 1-yl) -2-phenoxy-ethanone, (R) -N, N-diethyl-3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -benzamide, (R) -4- (5- [1- (2-phenoxy-acetyl) piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -pyridine-2-methylamide carboxylic acid, (R) -4-. {5- [1- (2-phenoxy-acetyl) piperidin-2-yl] - [l, 2,4] oxadiazol-3-yl} -pyridine dimethylamide -2-carboxylic acid, (R) -4-. {5- [1- (2-phenoxy-acetyl) piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} ethylamide. .-pyridine-2-carboxylic acid, (R) -4-. {5- [1- (2-phenoxy-acetyl) piperidin-2-yl] - [1,2,4] oxadiazole-3-diethylamide il.} - pyridine-2-carboxylic, (R) -1- (2- { 3- [2- (morpholine-4-carbonyl) -pyridin-4-yl] - [1,2,4] oxadiazol-5-yl.}. -piperidin-1-yl) -2-phenoxy-ethanone, (R) -l- (2- (3- [2- (3-methanesulfonyl-pyrrolidine-1-carbonyl) -pyridin -4-yl] - [1,2,4] oxadiazol-5-yl.}. -piperidin-1-yl) -2-phenoxy-ethanone, (R) -5- (5-) -acetic acid methylamide. 1- (2-phenoxy-acetyl) piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.} - pyridine-2-carboxylic acid, (R) -N-meti1-3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1 H- [1, 2, 4] triazol-3-yl} -benzamide, lN, N-diethyl-4-. { 5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzamide, l- (2- { 3- [4- (morpholine -carbonyl) -phenyl] - [1,2,4] oxadiazol-5-yl}. -piperazin-1-yl) -2 -phenoxy-ethanone, N-methyl-4-. { 5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2, 4] oxadiazol-3-yl} -benzamide, (R) -N-meti1-5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -nicotinami a, (R) -N-etil-5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -nicotinamide, (R) -N-diethyl-5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -nicotinamide, (R) -N-diethyl-5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -nicotinamide, (R) -N- (2-hydroxy-ethyl) -5- (5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazole-3 -yl.}. -nicotinamide, (R) -N- (2-methoxy-ethyl) -N-methy1-5- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [l, 2,4] oxadiazol-3-yl.}. -nicotinamide, (R) -N-cyclopropyl-5- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl ] - [1, 2,4] oxadiazol-3-yl.}. -nicotinamide, (R) -1- (2- { 3- [5- (3-hydroxy-pyrrolidine-l-carbonyl) -pyridin -3-yl] - [l, 2,4] oxadiazol-5-yl.}. -piperidin-l-yl) -2-phenoxy-ethanone, (R) -4-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzamide, (R) -3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzamide, amide of (R) -4- acid. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,] oxadiazol-3-yl} -pyridine-2-carboxylic, (R) -3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2,4] triazol-3-yl} -benzamide, 4-. { 5- [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1,2,4] oxadiazol-3-yl} -benzamide, 4-. { 5- [4- (2-phenoxy-acetyl) -thiomorpholin-3-yl] - [1,2, 4] oxadiazol-3-yl} -benzamide, 4-. { 5- [1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl} -benzamide, 5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2, 4] oxadiazol-3-yl} -nicotinamide, (R) -l-. { 2- [3- (3-Amino-phenyl) - [1,4,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (4-Amino-phenyl) - [1,4,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [5- (3-Amino-phenyl) -2 H- [1,2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -N- (3- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazole-3- il.}. phenyl) -acetamide, (R) -N- (4- (5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} phenyl) -acetamide, (R) -N- (5- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl .}. -pyridin-2-yl) -acetamide, (R) -N- (3- { 5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl.} - phenyl) -acetamide, (R) -N- (3-. {5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2,4] oxadiazol-3-yl.} - phenyl) -methanesulfonamide, (R) -N- (4- (5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2,4] oxadiazol-3-yl.} - phenyl) -methane-sulfonamide, (R) - (3. {5 - [l- (2-phenoxy-acetyl) -piperidin-2 -yl] - [1, 2, 4] oxadiazol-3-yl.} - phenyl) -alicylcarbamate, (R) - (4-. {5- [l- (2-phenoxy-acetyl) - allyl piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl.}. phenyl) -carbamic acid, (R) -N- (3-. {5- [1- (2- phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl.} - phenyl) -methanesulfonamide, (R) -l-ethyl-3- (3- (5 - [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1,2, 4] triazol-3-yl.}. -phenyl) -urea, (R) -3-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2,4] triazo. l-3-il} -benzonitrile and (R) -5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -nicotinonitrile, and pharmaceutically acceptable salts and esters thereof. 37. Compounds according to any of claims 1-36, characterized in that they are chosen between the group consisting of: (R) -l- (2- [3- (lH-indazol-5-yl) - [1,2, 4] oxadiazol-5-yl] -piperidin-l-yl.}. -2-phenoxy-ethanone, (R) -l- { 2- [3- (lH-indazol-6-yl) - [1,4,2-oxadiazol-5-yl] -piperidin-l-yl .} -2-phenoxy-ethanone, (R) -6- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazole-3 il.}. -l, 3-dihydro-indol-2-one, (R) -5-. { 5- [L- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2, 4] oxadiazol-3-yl} -1, 3-dihydro-benzoimidazol-2-one, (R) -5-. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -l, 3-dihydro-indol-2-one, (R) -l-. { 2- [3- (1H-benzotriazol-5-yl) - [1,2, 4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -l-. { 2- [3- (1H-benzoimidazol-5-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, (R) -4-. { 5- [4- (2-phenoxy-acetyl) -morpholin-3-yl] - [1,2,4] oxadiazol-3-yl} -lH-pyridin-2-one, (R) -l- (2- [5- (4-fluorophenyl) -2H- [1,2, 4] triazol-3-yl] -piperidin-l-yl .} -2-phenoxy-ethanone, (R) -2-phenoxy-l- { 2- [5- (3-trifluoromethyl-phenyl) -2H- [l, 2,4] triazol-3-yl. ] -piperidin-1-yl.}. -etanone, (R) -1- { 2- [3- (lH-benzoimidazol-5-yl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl.} -2-phenoxy-ethanone, (R) -3- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2, 4] oxadiazol-3-yl.}. -benzamide, 5- . { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -nicotinamide, (R) -N- (3- { 5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1,2, 4] triazol-3-yl}-phenyl) -acetamide and (R) -N- (3- { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1,2,4] triazole -3-yl.}.-Phenyl) -methanesulfonamide, and the pharmaceutically acceptable salts and esters thereof. 38. Compounds according to any of claims 1-35, characterized in that they are chosen from the group consisting of: l-. { (R) -2- [3- (2-Methyl-lH-benzoimidazol-5-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 1-. { (R) -2- [3- (2-Amino-pyridin-4-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [3- (3-hydroxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 4- (5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl}. lH-pyridin-2-one, l- { (R) -2- [3- (4-hydroxy-phenyl) - [1,2,] oxadiazol-5-yl] -piperidin-l-yl.} -2-phenoxy-ethanone, 3- {5- [l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl}. phenylboronic, 4- (2-oxo-2- { (R) -2- [3- (2-oxo-2,3-dihydro-lH-indol-5-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl.}. -ethoxy) -benzonitrile, 4- (2- { (R) -2- [3- (4-methoxy-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl.} -2- oxo-ethoxy) -benzonitrile, 2-methy1-5-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -3H-pyrimidin-4-one, 1- [(R) -2- (3-furan-2-yl- [1, 2,4] oxadiazol-5-yl) -piperidin-1-yl] -2- phenoxy-ethanone, 1- [(R) -2- (3-imidazo [1,2- a] pyridin-2-yl- [1, 2, 4] oxadiazol-5-yl) -piperidin-1-yl] -2-phenoxy-ethanone, l-. { (R) -2- [3- (4-methyl- [1,2,3] thiadiazol-5-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [3- (2,5-Dimethyl-2H-pyrazol-3-yl) - [1,2,4-oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1-. { (R) -2- [3- (1H-pyrazol-4-yl) - [1,2, 4] oxadiazol-5-yl] -piperidin-1-yl} -etanona, l-. { (R) -2- [3- (5-Methyl-isoxazol-3-yl) - [1, 2,] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1-. { (R) -2- [3- (1H-pyrazol-3-yl) - [1,2, 4] oxadiazol-5-yl] -piperidin-1-yl} -etanona, 5-. { 5 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -lH-pyrimidine-2,4-dione, l-. { (R) -2- [3- (6-Amino-pyridin-3-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 1- [(R) -2- (3-imidazo [l, 2-a] pyridin-6-yl- [1,2, 4] oxadiazol-5-yl) -piperidin-1 -yl] -2-phenoxy-ethanone, 6-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -4H-benzo [1,4] oxazin-3-one, 6-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -l, 4-dihydro-benzo [d] [l, 3] oxazin-2-one, l - ((R) -2- { 3- [3- (l, l-dioxo-l? 6- isothiazolidin-2-yl) -phenyl] - [l, 2,4] oxadiazol-5-yl}. -piperidin-1-yl) -2-phenoxy-ethanone, 1- (3- {5- [5- (R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.} - phenyl) -pyrrolidin-2-one, 1- (3 - (5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.} - phenyl) -imidazolidine-2, - dione, 4- (3- { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl}. phenyl) -2,4-dihydro- [1, 2, 4] triazol-3-one, l- (3-fluor-5-. {5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1, 2,] oxadiazol-3-yl.} - phenyl) -pyrrolidine-2,5-dione, 5- (5- [(R) -1- (2-phenoxy) -acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl.} - l, 3-dihydro-indol-2-one, l- { (R) - 2- [5- (lH-indazol-5-yl) -2H- [1,2,4] triazol-3-yl] -piperidin-1-yl.} -2-phenoxy-ethanone, l-. { (R) -2- [5- (lH-indol-5-yl) -2H- [l, 2,4] triazol-3-yl] -piperidin-1-yl.} -2-phenoxy-ethanone , l- ((R) -2- [5- (3 H -benzotriazol-5-yl) -2 H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 5-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl} -l, 3-dihydro-benzoimidazol-2-one, - l-. { (R) -2- [5- (2-Methyl-lH-benzoimidazol-5-yl) -2H- [l, 2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (2-Amino-pyridin-4-yl) -2 H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 5- (3-. {5 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1,2, 4] triazol-3-yl}. -phenyl) -3H- [1, 3, 4] oxadiazol-2-one, l-. { (R) -2- [5- (3- [1, 3,4] oxadiazol-2-yl-phenyl) -2 H- [1, 2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 3- acid. { 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1,2, 4] triazol-3-yl} -phenylboronic, 6-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl} -4H-benzo [1,4] oxazin-3-one, 1- [(R) -2- (5-imidazo [1,2- a] pyridin-6-yl-2H- [1, 2, 4] triazol-3-yl) -piperidin-1-yl] -2-phenoxy-ethanone, l-. { (R) -2- [5- (6-Amino-pyridin-3-yl) -2 H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (lH-benzoimidazol-5-yl) -2H- [l, 2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1 - [(R) -2- (5-pyridin-3-yl-2H- [1, 2, 4] triazol-3-yl) -piperidin-1-yl ] -etanona, l-. { (R) -2- [5- (3, 5-dimethyl-isoxazol-4-yl) -2 H- [1, 2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1- [(R) -2- (5-thiophen-2-yl-2H- [1, 2,4] triazol-3-yl) -piperidin-1-yl ] -etanone, 2-phenoxy-l- [(R) -2- (5-pyrimidin-2-yl-2H- [1, 2, 4] triazole-3- - il) -piperidin-1-yl] -ethanone, l-. { (R) -2- [5- (4-Methyl-oxazol-5-yl) -2 H- [1,2, 4] tria zol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1- [(R) -2- (5-pyrazin-2-yl-2H- [1,2, 4] triazol-3-yl) -piperidin-1-yl ] -etanona, l-. { (R) -2- [5- (2-Fluoro-phenyl) -2 H- [1, 2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (3, 5-difluor-phenyl) -2 H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (2-Methyl-pyridin-4-yl) -2 H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (3-Fluoro-phenyl) -2 H- [1, 2,4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (3,4-difluoro-phenyl) -2H- [1,2, 4] triazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 6-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl} -l, 4-dihydro-benzo [d] [l, 3] oxazin-2-one, 7-. { 5 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2,4] triazol-3-yl} -3,4-dihydro-lH-quinazolin-2-one, l- (3-. {5 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [ 1, 2, 4] triazol-3-yl.}. Phenyl) -imidazolidine-2,4-dione, 1-. { (R) -3- [3- (2-Amino-pyridin-4-yl) - [1,2, 4] oxadiazol-5-yl] -morpholin-4-yl} -2-phenoxy-ethanone, l-. { (R) -3- [3- (lH-benzoimidazol-5-yl) - [1,2, 4] oxadiazol-5-yl] -morpholin-4-yl} -2-phenoxy-ethanone,
1. l-. { (R) -2- [3- (1H-benzoimidazol-5-yl) - [1,2,4] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, 5-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperazin-2-yl] - [1,2,4] oxadiazol-3-yl} -1, 3-dihydro-indol-2-one, l-. { (R) -2- [3- (2-Amino-pyridin-4-yl) - [1, 2,] oxadiazol-5-yl] -piperazin-1-yl} -2-phenoxy-ethanone, (3- {5 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] [1, 2, 4] oxadiazol-3-yl}-phenoxy) -acetic, 2-phenoxy-1 - ((R) -2- { 5- [3- (piperidine-1-carbonyl) -phenyl] -2H- [1, 2, 4] triazole -3-yl.}. -piperidin-1-yl) -ethanone, l - ((R) -2- { 5- [3- (morpholine -carbonyl) -phenyl] -2H- [l, 2 , 4] triazol-3-yl.}. -piperidin-1-yl) -2-phenoxy-ethanone, 1 - ((R) -2- { 5- [3- (4-methyl-piperazine-1 -carbonyl) -phenyl] -2H- [l, 2,4] triazol-3-yl.}. -piperidin-1-yl) -2-phenoxy-ethanone, 4- (3. {5 - [( R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1,2, 4] triazol-3-yl.}. -benzoyl) -piperazin-2-one, N- ( 2-methoxy-ethyl) -N-meth1-3-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1 H- [1, 2, 4] triazol-3-yl} -benzamide, 1- ((R) -2- (5- [3- (4-acetyl-piperazine-1-carbonyl) -phenyl] -2H- [1, 2,4] triazol-3-yl}. -piperidin-1-yl) -2-phenoxy-ethanone, 1- (3. {5 - [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] lH- [l , 2,4] triazol-3-yl.}. -benzoyl) -piperidine-4-carboxylic acid, 1- (3- (5- [(R) -1- (2-phenoxy-acetyl) piperidine-) 2-yl] -1 H- [1, 2, 4] triazol-3-yl.} - benzoyl) -piperidine-4-carboxylic acid,
2. 2-phenoxy-1- ((R) -2- { 5- [
3. 3- (thiazolidine-3-carbonyl) -phenyl] -2H- [1, 2,4] triazol-3-yl}. piperidin-1-yl) -ethanone, N- (2-dimethylamino-ethyl) -N-meth1-3-. { 5- [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2,] triazol-3-yl} -benzamide, 2-phenoxy-1 - ((R) -2-. {5- [3- (thiomorpholine-
4. 4-carbonyl) -phenyl] -2H- [1,2,4] triazol-3-yl} -piperidin-1-yl) -ethanone, 4- (3. {
5. 5 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2 , 4] triazol-3-yl.}. Benzoyl) -piperazine-1-carboxylic acid ethyl ester, N- (2-hydroxy-ethyl) -3-. { 5 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -lH- [l, 2,4] triazol-3-yl} -benzamide, N-methyl-3-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1 H- [1, 2, 4] triazol-3-yl} -N- (2-pyridin-2-yl-ethyl) -benzamide, N- (2-cyano-ethyl) -N-cyclopropyl-3. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1 H- [1, 2, 4] triazol-3-yl} -benzamide, 1- (3. {5 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1,2, 4] triazol-3-yl} -benzoyl) -4-phenyl-piperidine-4-carbonitrile, l - ((R) -2- { 5- [3- (4-hydroxy-piperidine-l-carbonyl) -phenyl] -2H- [1, 2,4] triazol-3-yl.}. -piperidin-1-yl) -2-phenoxy-ethanone, 8- (3. {5 - [(R) -l- (2-phenoxy) -acetyl) -piperidin-2-yl] -1H- [1,2,4] triazol-3-yl}. -benzoyl) -1,3,8-triaza-spiro [4.5] decane-2, 4-dione, 1- (2- { 5- [3- (spiro (1-phthalane) -piperidine-4-carbonyl) -phenyl] -2H- [1, 2,4] triazol-3-yl} -piperidin-l-il) -2-phenoxy- ethanone, 2-phenoxy-l- ((R) -2- { 5- [3- (3-pyridin-4-yl-pyrrolidine-1-carbonyl) -phenyl] -2H- [1, 2, 4 ] triazol-3-yl.}. -piperidin-1-yl) -ethanone, l - ((R) -2- { 5- [3- (3-methanesulfonyl-1-pyrrolidine-1-carbonyl) -phenyl] -2H- [1,2,4] triazol-3-yl.}. -piperidin-1-yl) -2-phenoxy-ethanone, 1- ((R) -2- { 5- [3- ( (S) -3-ethoxy-pyrrolidine-1-carbonyl) -phenyl] -2H- [l, 2,4] triazol-3-yl}. -piperidin-1-yl) -2-phenoxy-ethanone, - ((R) -2-. {5- [3- ((S) -3-hydroxy-pyrrolidine-1-carbonyl) -phenyl] -2H- [1, 2, 4] triazol-3-yl} -piperidin-l-yl) -2-phenoxy-ethanone, 5-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-y1] -1H- [l, 2,4] triazol-3-yl} -nicotinamide, 2- (3- (5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.} - phenoxy) -acetamide, N- (3-fluoro-5- { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.} .-phenyl) -acetamide, N- (2-fluoro-5- { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl.}. phenyl) -acetamide, N- (3-. {5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -lH- [l , 2,4] triazol-3-yl.} - phenyl) -propionamide, N- (3- (5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H - [1, 2,4] triazol-3-yl.} - phenyl) -isobutyramide, N- (4-fluoro-3- { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2, 4] triazol-3-yl .}.-phenyl) -acetamide, N- (3-fluoro-5- { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -lH- [l, 2,4] triazol-3-yl.} - phenyl) -acetamide, N- (2-fluoro-5-. {5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2) -yl] -1 H- [1, 2, 4] triazol-3-yl.} - phenyl) -acetamide, N- (4-. {5 - [(R) -l- (2-phenoxy-acetyl ) -piperidin-2-yl] -1H- [1, 2,4] triazol-3-yl.} - pyridin-2-yl) -acetamide, 1- (3-. {5- [(R)] -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [l, 2,4] triazol-3-yl.} - phenyl) -azetidin-2-one, 1- (3- {. 5- [1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1, 2, 4] triazol-3-yl.} - phenyl) -pyrrolidine-2, 5- dione, 2-phenoxy-l- [(R) -2- (5-pyridazin-4-yl- [1,2,4] oxadiazol-3-yl) -piperidin-1-yl] -ethanone, 4-. { 3 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl} -benzonitrile, l-. { (R) -2- [5- (3-Amino-pyrazin-2-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 3- (3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl}. benzonitrile, l- { (R) -2- [5- (2-hydroxy-pyridin-3-yl) - [1, 2, 4] oxadiazol-3-yl] -piperidin-1-yl}. -2-phenoxy-ethanone, l- { (R) -2- [5- (5-amino-pyridin-3-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-l -yl.} -2-phenoxy-ethanone, l- { (R) -2- [5- (2-hydroxy-pyridin-4-yl) - [1,2,4] oxadiazole-3 - - il] -piperidin-l-il} -2-phenoxy-ethanone, l-. { (R) -2- [5- (2-Hydroxy-
6. 6-methyl-pyridin-4-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (4-hydroxy-pyridin-2-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (2-amino-5-chloro-pyrimidin-4-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1- [(R) -2- (5-pyrazin-2-yl- [1,2,4] oxadiazol-3-yl) -piperidin-1-yl] - ethanone, 2-phenoxy-l- ((R) -2- [5- (4- [1, 2,4] triazol-1-yl-phenyl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl.} -etanone, 2-phenoxy-1 - ((R) -2- [5- (4-tetrazol-1-yl-phenyl) - [1,2,4] oxadiazole-3 -yl] -piperidin-l-yl.}. -etanone, l- { (R) -2- [5- (lH-benzoimidazol-4-yl) - [1,2,4] oxadiazole-3 il] -piperidin-1-yl.} -2-phenoxy-ethanone, l- { (R) -2- [5- (4-acetyl-phenyl) - [1,4,4] oxadiazole-3 -yl] -piperidin-1-yl.} -2-phenoxy-ethanone, l- ((R) -2- [5- (6-hydroxy-pyridin-2-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl.} -2-phenoxy-ethanone, l- { (R) -2- [5- (5-methyl-pyrazin-2-yl) - [1 , 2,4] oxadiazol-3-yl] -piperidin-1-yl.} -2-phenoxy-ethanone, 2-phenoxy-l- [(R) -2- (5-quinoxalin-2-yl- [ 1,2,4] oxadiazol-3-yl) -piperidin-1-yl] -ethanone, l- { (R) -2- [5- (3-methanesulfonyl-phenyl) - [1,2,4 ] oxadiazol-3-yl] -piperidin-1-yl.} -2-phenoxy-ethanone, l-. { (R) -2- [5- (6-chloro-pyridin-3-yl) - [1, 2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 1- [(R) -2- (5-benzothiazol-6-yl- [1, 2, 4] oxadiazol-3-yl) -piperidin-1-yl] -2-phenoxy- ethanone, 2-phenoxy-l- ((R) -2- [5- (2, 4, 5-trifluor-phenyl) - [1, 2,4] oxadiazol-3-yl] -piperidin-1-yl} -etanone, 2-phenoxy-1-. { (R) -2- [5- (6-trifluoromethyl-pyridin-3-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1-yl} -etanone, l- [(R) -2- (5-benzo [l, 2,3] thiadiazol-5-yl- [1, 2, 4] oxadiazol-3-yl) -piperidin-1-yl] - 2-phenoxy-ethanone, l- [(R) -2- (5- [1, 8] naphthyridin-2-yl- [1, 2, 4] oxadiazol-3-yl) -piperidin-1-yl] - 2-phenoxy-ethanone, l- [(R) -2- (5- [1, 6] naphthyridin-2-yl- [1,2,4] oxadiazol-3-yl) -piperidin-1-yl] - 2-phenoxy-ethanone, 1- [(R) -2- (5-cinolin-4-yl- [1,2,4] oxadiazol-3-yl) -piperidin-1-yl] -2-phenoxy-ethanone , l-. { (R) -2- [5- (lH-benzotriazol-5-yl) - [1,2,] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (lH-benzoimidazol-5-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (3,6-Dichloro-pyridazin-4-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 6-. { 3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl} -4H-benzo [1,4] oxazin-3-one, l-. { (R) -2- [5- (3H-imidazo [4, 5-b] pyridin-6-yl) - [1, 2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, N- (4- { 3- [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazole-5- il.} - pyridin-2-yl) -acetamide, 1-. { (R) -2- [5- (6-Chloro-3-hydroxy-pyridazin-4-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 6-. { 3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl} -l, 4-dihydro-quinoxaline-2,3-dione, 1-. { (R) -2- [5- (6-hydroxy-pyridin-3-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone,
7. 7-. { 3 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl} -3,4-dihydro-lH-quinoxalin-2-one, 1-. { (R) -2- [5- (6-Amino-pyridin-2-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 6-. { 3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl} -nicotinonitrile, 5- (3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl.} - pyridine-2- carbonitrile, 4- { 3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [l, 2,4] oxadiazol-5-yl}. -l, 2 -dihydro-indazol-3-one, l- { (R) -2- [5- (2-amino-pyridin-4-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin -l-yl.} -2-phenoxy-ethanone, l - ((R) -2- [5- (6-hydroxy-pyrimidin-4-yl) - [1,2,4] oxadiazol-3-yl ] -piperidin-1-yl.} -2-phenoxy-ethanone, 4- (3. {3 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] - [ 1,2,4] oxadiazol-5-yl.} - phenyl) -2,4-dihydro- [1,2,4] triazole-3- ona, 1- (3- { 3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2, 4] oxadiazol-5-yl.} - phenyl) -imidazolidine-2,4-dione, 1- ((R) -2-. {5- [3- (1, l-dioxo-l6-isothiazolidin-2-yl) -phenyl] - [ 1, 2, 4] oxadiazol-3-yl.}. -piperidin-1-yl) -2-phenoxy-ethanone, 1- (3. {3- [(R) -1- (2-phenoxy) acetyl) -piperidin-2-yl] - [l, 2,4] oxadiazol-5-yl.} - phenyl) -pyrrolidin-2-one, l- (3-. {3 - [(R) - l- (2-phenoxy-acetyl) -piperidin-2-yl] - [l, 2,4] oxadiazol-5-yl.} - phenyl) -1,3-dihydro-imidazol-2-one, 3- (3- { 3- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-5-yl.} - phenyl) -imidazolidine -2, 4 -diona, l-. { (R) -2- [5- (1-methyl-1H-pyrazol-3-yl) - [1, 2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1-. { (R) -2- [5- (1H-pyrazol-3-yl) - [1, 2, 4] oxadiazol-3-yl] -piperidin-1-yl} -etanona, 1-. { (R) -2- [5- (5-Methyl-isoxazol-3-yl) - [1,4,2] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (2, 5-dimethyl-2H-pyrazol-3-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, l-. { (R) -2- [5- (5-Methyl-2H-pyrazol-3-yl) - [1,2, 4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone and 1-. { (R) -2- [5- (3-Methyl-isoxazol-5-yl) - [1,2,4] oxadiazol-3-yl] -piperidin-1-yl} -2-phenoxy-ethanone, and the pharmaceutically acceptable salts and esters of the same. 39. Compounds according to any of claims 1 - 35, characterized in that they are chosen from the group consisting of: 2-methyl-5-. { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] - [1,2,4] oxadiazol-3-yl} -3H-pyrimidin-4-one, l-. { (R) -2- [3- (5-Methyl-isoxazol-3-yl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -2-phenoxy-ethanone, 2-phenoxy-1 - ((R) -2- [3- (1H-pyrazol-3-yl) - [1, 2, 4] oxadiazol-5-yl] -piperidin-1 -yl.}.-ethanone, l- { (R) -2- [3- (6-amino-pyridin-3-yl) - [1,2, 4] oxadiazol-5-yl] -piperidin- 1-yl.) -2-phenoxy-ethanone, 5- (5 - [(R) -l- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1,2,4] triazole -3-yl.} .l, 3-dihydro-indol-2-one, l- { (R) -2- [5- (2-amino-pyridin-4-yl) -2H- [1 , 2,4] triazol-3-yl] -piperidin-1-yl.} -2-phenoxy-ethanone, 6-. {5- [(R) -1- (2-phenoxy-acetyl) -piperidine] -2-yl] -1 H- [1, 2,4] triazol-3-yl.} -4 H -benzo [1,4] oxazin-3-one, l- { (R) -2- [ 5- (6-amino-pyridin-3-yl) -2H- [1, 2, 4] triazol-3-yl] -piperidin-1-yl.} -2-phenoxy-ethanone, l- { (R) -2- [5- (lH-benzoimidazol-5-yl) -2H- [l, 2,4] triazol-3-yl] -piperidin-1-yl.} -2-phenoxy-ethanone, N- (2-fluoro-5- { 5- [(R) -1- (2-phenoxy-acetyl) -piperidin-2-yl] -1H- [1,2, 4] triazol-3-yl .}.-phenyl) -acetamide and l- { (R) -2- [5- (2-hydroxy-pyridin-4-yl) - [1,2,4] oxadiazole-3- il] -piperidin-l-il} -2-phenoxy-ethanone, and the pharmaceutically acceptable salts and esters thereof. 40. Process for obtaining compounds of the formula (I) defined in any one of claims 1-39, characterized in that it consists in the reaction of a compound of the formula (II) with a compound of the formula (III wherein R1, R2, R3, R4, R5, R5, R7 and X have the meanings defined in any one of claims 1-39 and L is halogen. 41. Compounds according to any of claims 1-39, characterized in that they are obtained by a process of confounding with claim 40. 42. Pharmaceutical compositions characterized in that they contain a compound according to any of claims 1-39 and a carrier and / or adjuvant pharmaceutically acceptable. 43. Compounds according to any of claims 1-39, characterized in that they are for use as therapeutically active substances. 44. Compounds according to any of claims 1-39, characterized in that they are for use as therapeutically active substances intended for the treatment and / or prophylaxis of diseases modulated by inhibitors of L-CPTl. 45. Method for the therapeutic and / or prophylactic treatment of diseases modulated by inhibitors of L-CPTl, in particular for the therapeutic and / or prophylactic treatment of hypergiukaemia, glucose tolerance disorders, diabetes and associated pathologies, diabetes mellitus not dependent on insulin, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure, characterized in that it consists of administering a compound according to any one of the claims 1-39 to a human being or an animal. 46. Use of the compounds according to any of claims 1-39 for the therapeutic and / or prophylactic treatment of diseases modulated by inhibitors of L-CPT1. 47. Use of the compounds according to any of claims 1-39 for the therapeutic and / or prophylactic treatment of hypergiukaemia, glucose tolerance disorders, diabetes and associated pathologies, diabetes mellitus not dependent on insulin, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure. 48. Use of the compounds according to any of claims 1-39 for the manufacture of medicaments for the therapeutic and / or prophylactic treatment of diseases modulated by inhibitors of L-CPTl. 49. Use of the compounds according to any of claims 1-39 for the manufacture of medicaments for the therapeutic and / or prophylactic treatment of hypergiukaemia, glucose tolerance disorders, diabetes and associated pathologies, diabetes mellitus not dependent on insulin, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure.